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General introduction and outline of the thesis 
 Cystic fibrosis (CF) is a life-threatening autosomal recessive monogenic disease that 
affects all racial and ethnic groups but is most common among Caucasians, with a carrier 
frequency of 1:25 (affecting 1 in 2500–4500 newborns) [2, 3]. The major CF pathology is the 
accumulation of viscous mucus at the epithelial surfaces of affected organs [4, 5]. A major organ 
affected by CF is the respiratory system, in which accretion of viscous mucus leads to impaired 
mucociliary clearance, recurrent pulmonary infection, and chronic lung and sinus disease [6]. 
This pulmonary pathology is the major cause of morbidity and mortality in CF patients [7].  
 The gastrointestinal pathology of CF includes inflammation of the gut wall, pancreatic 
insufficiency, malabsorption and malnutrition, bacterial overgrowth and obstruction of the small 
intestine, and liver disease (focal biliary cirrhosis) [8, 9]. Replacement of pancreatic enzymes 
and intensive symptomatic pulmonary therapy have improved the treatment of CF, resulting in a 
progressive increase in the median survival age (currently ~37 years) [10].  
CFTR Structure 
 CF is caused by mutations in the CF gene (also referred to as ABCC7) that encodes a 
chloride (Cl-)/bicarbonate (HCO3-) conducting channel called the cystic fibrosis transmembrane 
conductance regulator (CFTR) [11, 12]. CFTR is composed of 1480 amino acid residues 
arranged in a single polypeptide chain. CFTR is structurally akin to the family of ABC 
transporters, consisting of 2 transmembrane domains (TMDs), 2 nucleotide-binding domains 
(NBDs) and a regulatory domain (RD). The presence of the RD makes CFTR unique when 
compared to other ABC transporters. CFTR contains an N-terminal extension of about 80 
residues and a C-terminal extension of about 30 residues. Both extensions are cytoplasmic 
oriented (Figure 1) [13, 14].  
 The 2 TMDs, each consisting of 6 membrane-spanning α-helices, are predicted to form a 
pore that allows the passage of Cl- and other anions, including HCO3- [15, 16]. Phosphorylation 
of the RD is a prerequisite for CFTR channel gating (opening and closing).  
CF disease variability 
 Presently, over 2000 different mutations have been discovered of which more than 1100 
are disease-associated [10] (http://www.genet.sickkids.on.ca/cftr/). CFTR mutations are 
clustered into six different classes, based on their phenotypic consequences [17-19]. CF-causing 
mutations can interfere with the biogenesis, transport, activity, and/or stability at the cell surface 
of CFTR [20]. The most common mutation, F508del, occurring on at least one allele in nearly 
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90% of all CF patients, has several separate functional defects, i.e. in protein folding (class II), 
channel gating (class III) and membrane stability (class V). This markedly complicates its 
pharmacological repair at the protein level. To some extent, these mutation classes also define 
disease severity. However, although CF is considered a monogenic disease, phenotypic variation 
among patients, even among those with the same CFTR genotype, is considerable. This variation 
is a consequence of genetic modifiers and, to a lesser extent, environmental factors [2].   
 Disease severity and complications also vary considerably among affected organ systems 
[21], and among individuals carrying different CFTR mutations [22]. For example, patients 
carrying the G551D mutation rarely suffer from meconium ileus, in contrast to those carrying the 
F508del or G542X mutation, although all these mutations are associated with pancreatic 
insufficiency [23-26].  
CF gastrointestinal disease  
Organization of the intestinal epithelium 
 The intestinal lumen is lined by a continuous monolayer of columnar epithelial cells [27], 
that are structured into proliferative crypts and differentiated villi (small intestine) or surface 
epithelium (colon). The crypts invaginate into the underlying mesenchyme and the villi project 
into the intestinal lumen [28]. The crypt-based columnar (CBC) stem cells give rise to rapidly 
dividing transit-amplifying cells (TACs) which differentiate into 5 different cell types (Figure 2). 
The absorptive cells, also known as enterocytes, comprise ~90% of the villus cell population. 
All differentiated cells migrate towards the top of the villi, except for the Paneth cells that 
are retained at the base of the crypts. In the crypts, Paneth cells reside interspaced between the 
CBC stem cells during their life span of ~1 month [29]. These cells protect the epithelium 
against bacterial infection by secreting lysozyme and other antimicrobial proteins, such as the α-
Figure 1 Schematic model of 
CFTR structure, showing the 
CFTR domains organized from the 
N- to the C-terminus TMD1-NBD1-
RD-TMD2-NBD2. 
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defensins [30]. In addition, Paneth cells have been shown to express the luminocrinic peptides 
guanylin (GUCA2A) and uroguanylin (GUCA2B) which fulfill an essential role in intestinal fluid 
homeostasis [31]. Other cells of the secretory lineage, including enteroendocrine cells and Tuft 
cells, secrete different classes of peptide hormone such as glucagon-like peptide 1 and 2 (GLP-1, 
-2), cholecystokinin (CCK), glucose-dependent insulinotropic peptide (GIP), and somatostatin 
(SST) [28, 31-34]. 
 The colonic epithelium mainly consists of crypts that, like the small intestinal crypts, 
contain CBC-like proliferative stem cells. These cells produce TACs which differentiate into 
columnar-, goblet- and enteroendocrine cells. The colonic crypts also contain Paneth-like cells 
that, however, do not produce anti-microbial peptides [35, 36]. In the human small intestine, cell 
migration from the base of the crypts to the tip of the villi takes 3-5 days, after which the cells 
become apoptotic and are shedded. The continuous and rapid renewal of the epithelium from 
CBC stem cells and TACs is a unique property of the intestine and requires a delicate balance 
between locally produced growth and differentiation factors.  
 The intestinal epithelium is structurally and functionally polarized, with segregation of 
specific plasma membrane (transport) proteins to either the apical or basolateral pole of the cell. 
Paracellular transport of electrolytes and solutes (e.g. glucose, amino acids, peptides, bile salts) 
is restricted through cation-selective tight junctional complexes consisting of multiple 
transmembrane proteins including claudins, occludins and paracellin [37-41]. Many other 
proteins associate with the tight junction at its cytoplasmic side, thereby changing its selectivity 
and turning it into a dynamic rather than a static structure [41].  
Figure 2 Schematic diagram of 
the monolayered intestinal 
epithelium showing the columnar 
epithelial cells forming the crypts 
and villi. 
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Fluid homeostasis, electrolyte absorption and secretion, and water flow 
In the gastrointestinal tract, water and electrolyte secretion are central to its physiological 
function. The gastrointestinal tract drains about 8 liters of fluid per day [42]. The main pathway 
for apical chloride secretion into the intestinal lumen is CFTR. CFTR is expressed 
predominantly in the apical membrane of the crypt cells, although a small number of cells with 
very high expression of CFTR is found scattered throughout the villus epithelium in humans 
(and rats), but not in mice (Figure 3) [1, 42-44].  
 Chloride is the predominant electrolyte that contributes to fluid secretion. Chloride 
secretion initiates paracellular sodium secretion in response to electrical hyperpolarization. This 
salt secretion triggers eventual osmotic water flow to the lumen. Concurrent with activation of 
CFTR, sodium absorption via the sodium/proton exchanger NHE3, the major sodium importer in 
mammalian intestine is inhibited (discussed in more details below) [45]. This combination of 
chloride secretion and inhibition of NHE3-mediated sodium absorption drives net fluid secretion 
into the intestinal lumen. Disruption of this process, through yet incompletely resolved 
mechanisms, results in the many secondary intestinal disease manifestations of CF, e.g. defective 
mucin expansion and clearance, impaired bacterial clearance and bacterial overgrowth, 
inflammation, fecal wasting of bile salts, and intestinal obstruction. 
 In CF, hyperabsorption of sodium through ENaC channels in the airways or through 
NHE3 in the intestine may contribute to the imbalance of luminal fluid volume and composition 
[46-51]. NHE3 is responsible for the majority of sodium absorption in the gastrointestinal tract 
and kidney [45, 52]. In the small intestine, NHE3 activity also provides the acidic micro-climate 
that drives proton-coupled nutrient absorption mechanisms [53-55]. NHE3 is in a partially 
activated state under basal conditions, and it is thought to be inhibited in the early digestive 
period [56]. This inhibition stimulates retention of water in the lumen, which serves to spread 
Figure 3 CFTR immunostaining in mouse ileum using two distinct antibody titers. CFTR is localized 
predominantly at the apical pole of epithelial cells in the crypts, but expression extends to the villi 
[1]. 
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digestive enzymes over the intestinal surface, enhancing enzymatic digestion of nutrients. NHE3 
activity is tightly regulated by multiple signaling pathways, leading to rapid cell surface insertion 
or retrieval of the protein [45, 57]. Inactivation of NHE3 is triggered by protein kinase-mediated, 
phosphorylation of NHE3 [57, 58]. The importance of NHE3 in intestinal fluid and acid-base 
homeostasis is underlined by the fact that genetic ablation of NHE3 results in mild diarrhea and 
systemic acidosis [59, 60]. 
Mucus production 
 The mucus that lines the surface of the intestinal epithelium is principally produced by 
goblet cells, which secrete its major component, MUC2. The mucus layer lubricates the 
epithelial surface, aids digestion, and helps to preserve the intestinal architecture. In addition, the 
mucus layer forms a barrier between luminal pathogens and epithelial cells. In the healthy 
intestine, this mucus layer appears to act as a size exclusion filter that prevents bacteria from 
entering the crypts [61]. 
 Recent studies in CF animal models (mouse [62-64], pig [65], rat [66]) indicate that 
normal mucus release in the intestine and trachea requires concurrent bicarbonate secretion. 
Bicarbonate serves to chelate calcium and hydrogen ions that prevent expansion of MUC2, 
released by the goblet cells. The subsequent detachment of MUC2 from the goblet cells is 
catalyzed by a metalloprotease, meprin β, which is shedded from neighboring enterocytes in 
response to bacterial contact or microbial signaling [67]. Thus, a major function of the mucus 
layer is to entrap pathogens and prevent direct contact with the small intestinal epithelium by 
promoting their fast transit (“flushing”). 
 In CF, both CFTR mediated and regulated chloride and bicarbonate secretion is defective, 
causing the production of a hyper-viscous, immobile mucus layer. The accretion of this sticky 
mucus triggers small intestinal bacterial overgrowth (SIBO) and, together with luminal 
dehydration, may result in intestinal inflammation and obstruction [16, 46, 64, 68, 69]. In 
addition, defective bicarbonate production is suggested to lower epithelial surface pH and 
impede bacterial killing by pH-sensitive defensins. This, in conjunction with protracted nutrient 
digestion and absorption, further expedites SIBO [46, 68, 69]. 
Intestinal obstruction 
 Meconium ileus, which affects 10 – 20% of CF newborns, develops perinatally when 
inspissated secretions obstruct the gastrointestinal lumen of the distal small intestine [47, 48, 70-
72]. CF-associated meconium ileus typically presents within 48h after birth as a failure to pass 
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meconium. Because of the severe obstruction, this complication may be fatal if left untreated 
[73, 74]. Obstruction of the distal small intestine also affects CF patients in later stages of life. 
The so-called distal intestinal obstructive syndrome (DIOS) is caused by accumulation of 
viscous mucoid and faecal material that adheres strongly to the intestinal wall [75-77]. DIOS 
occurs mostly, but not exclusively, in patients with a history of meconium ileus and pancreatic 
insufficiency. Delayed gastric emptying and protracted ileal and colonic transit may also 
contribute to DIOS [78]. A defect in bile acid-induced, CFTR-mediated chloride and bicarbonate 
secretion may worsen luminal dehydration in the ileum and may account for the predominantly 
distal location of obstruction . At present, meconium ileus is treated by surgery and DIOS is 
treated by oral rehydration, using stool softeners [79]. 
Small intestinal bacterial overgrowth (SIBO) 
 There is an increasing awareness that the gut microbiota plays a key role in 
gastrointestinal disorders, thereby offering a novel therapeutic target to manage or prevent 
gastrointestinal conditions [80, 81]. The stagnant mucus in CF creates a niche for abnormal 
microbial colonization and development of SIBO [82, 83]. In mice, loss of CFTR function is 
associated with a significant decrease in gut bacterial community richness, and reduced 
abundance of putative protective species such as Acinetobacter iwoffii and a multitude of 
Lactobacilliales members [82-84]. Microorganisms associated with gastrointestinal infection and 
immunomodulation such as mycobacteria species and Bacteroides fragilis are significantly 
enriched in CF mice. The opportunistic pathogen B. fragilis is a frequent cause of 
gastrointestinal infection and diarrheal disease [85]. Use of antibiotics for CF management also 
influences the intestinal bacterial community, resulting in enrichment of Lactobacillaceae and 
Bifidobacteriaceae strains. Concomitantly, antibiotics, reduce abundance of Enterobacteriaceae 
and Clostridiaceae which are associated with SIBO and inflammatory bowel disease [83]. 
Enterobacteriaceae and Clostridiaceae may also suppress bacterial species required for 
maintaining motility and immune homeostasis. 
Intestinal (wall) inflammation 
 CF-related intestinal inflammation is already evident in children and young adults [86-
88]. Whether the pathogenesis of inflammation in CF–affected organs is of primary or secondary 
origin, or both, is still under debate [89]. Many factors may contribute to the pathogenesis of CF-
related intestinal inflammation, such as chronic pancreatic enzyme supplementation, dysmotility, 
and SIBO. CF-related intestinal inflammation, which is characterized by high plasma and fecal 
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levels of the “CF-antigen” calprotectin (MRP8/14), has been associated with a defective immune 
system [90-92], but may also occur secondary to bacterial infection [93]. Increased levels of 
inflammatory cytokines, immunoglobulins and other proteins have been found in the intestine of 
CF-patients with pancreatic-insufficiency [87]. 
 A recent report shows that knockdown of CFTR in intestinal epithelial cell lines induces 
changes in the inflammatory response system as is manifest by increases in gene expression of 
IL-6 and IL-8 as well as enhanced activation of the ERK1/2 MAPK, IkBα and NF-kB pathways 
[89]. This finding suggest that the CFTR defect itself may directly contribute to the propensity to 
inflammation in the CF intestine. 
Nutrient malabsorption and enhanced fecal bile salt excretion 
 Malabsorption of nutrients observed in CF patients is caused principally by pancreatic 
insufficiency, which results in malnutrition [94]. Nutrient malabsorption was shown to be 
accompanied by enhanced fecal bile salt excretion in CF patients and CF mice [95-98]. 
Enhanced fecal bile salt excretion may be attributed to interrupted enterohepatic cycling of bile 
salts. In CF mice, defective gallbladder emptying may reduce intraluminal bile salt levels and the 
activity of the farnesoid X receptor (FXR) in the intestine [99]. The FXR target FGF15 is an 
intestinal hormone that is released into the portal vein and regulates de novo bile acid synthesis 
in the liver by reducing the hepatic expression of CYP7a1 via the FGFR4-ERK-cJUN signal 
transduction pathway [100]. CYP7a1 is the rate limiting enzyme in the de novo synthesis 
pathway [101, 102]. However, at present it is not known how the FXR signaling pathway affects 
bile acid homeostasis in CF patients. 
CF Therapies 
Restoring CFTR function 
 Protein-repair therapy in CF aims at rescuing the function of the mutated CFTR protein 
by improving its expression, folding, trafficking, channel gating and/or membrane stability. 
Pharmacological targeting of CF disease will often require a combination of therapeutic 
molecules. This is because (i) one single mutation may interfere with several aspects of CFTR 
biogenesis and function; (ii) ~40% of all CF patients (“compound heterozygotes”) carry a 
different mutation on each of the CFTR alleles, and (iii) no single molecule is expected to correct 
the whole spectrum of mutation-induced abnormalities in CF. A clear exception to this rule is the 
rescue of class III mutant CFTR (G551D and 8 other CFTR gating mutations) by VX-770 
(Ivacaftor/Kalydeco®; Vertex), which was shown to be highly effective even in long-term 
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clinical trials [8, 103, 104]. However, efficient functional rescue of F508del-CFTR requires the 
combination of a small molecule “corrector” which is capable of improving the folding and 
trafficking of the F508del-CFTR protein to the cell surface, and a “potentiator” which corrects 
the opening/gating defect of F508del-CFTR. This is probably why clinical trials, assessing the 
efficacy of monotherapy with the corrector VX-809 (Lumacaftor) or with the potentiator VX-
770 failed to reach their primary endpoint [105, 106].  
 The combination of VX-809 and VX-770 (named Orkambi®) was shown to be 
moderately effective in improving CF lung function of homozygous F508del patients, and has 
recently been approved by the regulatory agencies (FDA and EMA) for this CF cohort [107-
110]. The search for small molecule CFTR rescue compounds is still on-going. New drugs may 
act additive or synergistically with an existing drug such as VX-809 [111-113]. In preclinical 
studies, synergy is especially prominent with a combination of F508del correctors, i.e. a so 
called class 1 corrector, acting as a NBD1 domain stabilizer, and a class II corrector, capable of 
stabilizing the NBD1-TMD2 interface [114]. New correctors may be discovered by high 
throughput screening (HTS) of new chemical libraries, by the synthesis of common 
pharmacophoric moieties present in known correctors [115], by the use of a genomic signature 
approach [116], or by HTS of potential CF drugs by molecular docking [117]. The recent 
breakthrough in our knowledge of the atomic structure of the full-length CFTR, achieved by 
single molecule electron cryo-microscopy [118], not only has provided new insights into the 
structural consequences of CF-causing mutations, but may also facilitate the rational design of 
novel and more efficient CF therapeutics by this virtual screening approach. In addition, testing 
of drugs (and drug combinations) on patient-derived cell models may allow the selection of the 
most effective therapeutic approach(es) for a specific patient i.e. personalized therapy [19]. For 
this purpose, human bronchial epithelial cells derived from lungs explants or intestinal organoids 
isolated from rectal biopsies are used in CFTR functional assays, to determine the optimal drug 
or combination of drugs for an individual patient [119, 120]. Current approaches to CFTR rescue 
therapies and personalized CF therapies are discussed in more detail in Chapter 2 of this thesis. 
CFTR independent strategies 
 Instead of restoring the function of CFTR itself by gene or protein therapy, the CF defect 
in chloride and bicarbonate secretion may also be bypassed by manipulating the abundance or 
activity of other ion transport mechanisms whose (in)activity may counteract the phenotypic 
consequences of CFTR dysfunction. Two approaches under consideration to regain ionic balance 
and restore luminal alkalinity are (1) activation of alternative chloride channels such as 
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anoctamins [121, 122] and SLC26A9 [123, 124] and (2) inhibition of sodium-coupled fluid 
absorption at the level of amiloride-sensitive epithelial sodium channels (ENaC) or the apical 
sodium/proton exchanger NHE3 [125-127]. The inhibition of NHE3, in contrast to ENaC 
inhibition, may not only improve luminal hydration, but may additionally promote luminal 
alkalinization. Therefore, both NHE3 and ENaC may serve as major therapeutic targets in CF 
[59, 128]. 
Improving the intestinal fluid balance by enhancing guanylyl cyclase C signaling 
 The luminocrinic peptides guanylin (GN, encoded by the GUCA2A) and uroguanylin 
(UGN, encoded by the GUCA2B) are involved in the regulation of salt and water transport across 
the intestinal epithelia [129]. The precursors of these peptides are secreted by epithelial cells and 
are extracellularly cleaved to generate the biologically active peptides. GN and UGN are similar 
in structure and consist of four conserved cysteine residues that form disulfide bonds which are 
essential for full activity of the peptides (Figure 4). 
 
 
 
 
 
 
 
 
 
GN is most active at a slightly alkaline pH while UGN is most active at a pH ~5.5 [130, 131]. 
The intestinal fluid present along the intestinal tract is of variable pH and this may have 
influenced the pattern of distribution observed for GN and UGN along the tract [31, 132, 133]. 
Intestinal secretion of GN and UGN is triggered by a high salt diet [134-136].  
 Upon luminal secretion and proteolytic cleavage, GN and UGN bind to the extracellular 
receptor domain of guanylyl cyclase C (GC-C), leading to the conversion of guanosine-5’-
triphosphate (GTP) to cyclic guanosine monophosphate (cGMP) [92, 137]. GC-C is also 
activated by the heat-stable enterotoxin (ST) produced by enterotoxigenic strains of Escherichia 
coli [138]. ST has an extra disulfide bond and this may account for its high potency (Figure 4). 
GN and UGN are less potent in stimulating chloride secretion than ST as their affinity for GC-C 
is lower than of ST [139, 140]. 
Figure 4 Amino acid sequence 
and disulfide bonds of guanylin, 
uroguanylin and ST. 
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 Cyclic GMP executes its function by interacting with cGMP-dependent protein kinase 
type II (PKG-II), cyclic nucleotide-gated channels (CNGs) and cGMP-regulated cyclic 
nucleotide phosphodiesterases (PDEs) [141-143]. The increase in cGMP production after GC-C 
activation by GN and UGN regulates intestinal ion and fluid transport [144] by protein kinase-
mediated activation of CFTR and inhibition of NHE3. The resultant increase in chloride and 
bicarbonate secretion and decrease in sodium absorption, stimulates osmotic water secretion and 
luminal alkalinization (Figure 5) [145, 146]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 GN and UGN were identified in serotonin-positive enterochromaffin cells of the small 
intestine [147]. However, there are indications that these peptides are also present in other 
intestinal cell types, including goblet cells [148]. In this thesis we investigated GN and UGN 
transcript levels in the various intestinal segments and cell types by a novel technique (RNA 
Scope) and also studied the expression at the protein level (Chapter 4 and 5).  
 
Aim and outline of the thesis 
 The hallmark of intestinal CF disease is dehydrated epithelial surfaces and mucus 
plugging emanating from defective CFTR-mediated chloride and bicarbonate secretion [45]. 
From this primary defect arises a plethora of secondary disease manifestations of which the exact 
etiology, and the relation to the primary defect is often uncertain. This thesis investigates several 
aspects of intestinal CF pathology, and aims to provide a rationale for novel therapeutic 
approaches. A potential alternative therapy proposed in this thesis aims to reduce NHE3-
Figure 5 Overview of GC-C/CFTR/NHE3 
signaling. GC-C activation leads to cGMP 
production which results in the 
modification of CFTR and NHE3. 
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mediated sodium and fluid absorption and to increase luminal fluidity by guanylin mimetic 
peptides. As a proof of principle, crossing CFTR- with NHE3-deficient mice has been shown to 
increase survival and decrease the incidence of intestinal obstruction in the CF mice [59]. 
 The guanylins, through their ability to trigger GC-C/cGMP signaling and NHE3 
inhibition may improve luminal hydration and alkalinization in the CF gut. Because the 
guanylins, in contrast to CFTR correctors and potentiators, act in a CFTR-mutation independent 
manner, their action could benefit all CF patients. In addition, guanylin/GC-C/cGMP signaling 
may also activate CFTR-mediated chloride and bicarbonate secretion in patients with residual 
CFTR activity, e.g. those carrying mutations belonging to class III-V. As discussed above, both 
chloride and bicarbonate secretion are required to restore the viscoelastic properties of mucus and 
ensure proper mucus unfolding and detachment. 
Thesis outline 
 Chapter 2 summarizes recent advances made toward personalized therapy in CF. We 
discuss the emergence and clinical efficacy of new CFTR-targeted drugs that act in a mutation-
specific manner. We also discuss developments in ex vivo drug testing modes using CF patient 
derived tissue samples which promise to transform the therapeutic land scape from a trial-and-
error prescription to personalized medicine.  
 In Chapter 3 we performed transcriptome analysis on intestinal epithelium of CF mice 
and controls to assess the impact of CF on the intestinal transcriptome. This analysis indicates 
that SIBO and inflammation are key determinants of the CF-typical intestinal transcriptome.  
 In chapter 4 the cellular localization of GN, UGN and GCC in the intestine was 
investigated, providing evidence for the role of GCC signaling in mucus production and innate 
immunity.  
 In chapter 5 we provide evidence for perturbed GCC signaling in the CF intestine, 
showing that CF leads to reduced GN and UGN expression. These findings provide a further 
incentive for exploitation of the guanylyl cyclase-C pathway for restoration of intestinal fluid 
balance.  
 In chapter 6 we investigate the effect of CF disease on FXR signaling and its impact on 
hepatic bile salt synthesis and fecal bile salt excretion. 
 Chapter 7 contains a general discussion of all parts and chapters and also describes the 
future perspectives. 
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Summary 
 Cystic fibrosis (CF), the most common, life-threatening monogenetic disease in 
Caucasians, is caused by mutations in the CFTR gene, encoding a cAMP-and cGMP-
regulated epithelial chloride channel. Symptomatic therapies treating end-organ 
manifestations have increased the life expectancy of CF patients towards a mean of 40 years. 
The recent development of CFTR-targeted drugs that emerged from high throughput 
screening and are capable of correcting the basic defect promises to transform the therapeutic 
landscape from a trial-and-error prescription to personalized medicine. This stratified 
approach is tailored to a specific functional class of mutations in CFTR, but can be refined 
further to an individual level by exploiting recent advances in ex vivo drug testing methods. 
These tests range from CFTR functional measurements in rectal biopsies donated by a CF 
patient to the use of patient-derived intestinal or pulmonary organoids. Such organoids may 
serve as an inexhaustible source of epithelial cells that can be stored in biobanks and allow 
medium- to high-throughput screening of CFTR activators, correctors and potentiators on the 
basis of a simple microscopic assay monitoring organoid swelling. Thus the recent 
breakthrough in stem cell biology allowing the culturing of mini-organs from individual 
patients is not only relevant for future stem cell therapy, but may also allow the preclinical 
testing of new drugs or combinations that are optimally suited for an individual patient. 
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Introduction 
 Cystic fibrosis (CF) is a life-threatening autosomal recessive monogenetic disease 
caused by mutations in the CFTR gene, encoding a cyclic AMP- and cyclic GMP-regulated 
and ATP-gated chloride channel [1]. The impact of a defect in CFTR function differs among 
tissues and cell types [2]. In sweat glands, the decreased reabsorption of sodium chloride by 
the water-impermeable ductal epithelium results in elevated sweat chloride, a hallmark of CF. 
In other epithelia, in particular the respiratory and intestinal epithelia as well as the biliary 
and pancreatic ducts, CFTR dysfunction causes a loss of chloride and bicarbonate secretion, 
resulting in cellular alkalinity and luminal acidification, impaired decondensation of 
discharged mucin granules by goblet cells, and defective mucus expansion [3, 4]. The 
ensuing acidification and dehydration of the mucus layer leads to impaired mucociliary 
clearance and bacterial killing by epithelial defensins [5]; this predisposes to recurrent 
infection, inflammation, mucus plugging and luminal obstruction. Loss of CFTR function in 
monocytes and macrophages, by impairing phagocytosis and intracellular killing of 
Pseudomonas aeruginosa, contributes to the enhanced susceptibility to infection in patients 
with CF [6-8].  
 When CF was first described in 1938, the predicted survival age of a CF patient was 
only 6 months. For patients born in the 1990’s median survival is now predicted to exceed 40 
years [9]. This impressive gain in life expectancy has resulted largely from advances in early 
diagnosis and symptomatic treatment of end-organ pathologies based on vast improvements 
in nutrition, control of airway infections, and physiotherapy (see Fig. 1 for an overview of CF 
symptomatic treatment).  Understandably the discovery of the disease-causing CFTR 
gene in 1989 created new hope for a curative treatment targeting the basic defect rather than 
treating CF disease manifestations [10]. The most obvious approach, viral or non-viral gene 
therapy, would potentially be of benefit to all patients with CF, independent of their 
genotype. So far however CFTR gene addition or gene replacement, despite promising 
advances, has not translated into clinical benefits despite more than 20 clinical trials, mainly 
due to a low expression of the CFTR transgene, inflammatory responses to viral proteins, the 
development of a humoral immune response preventing successful readministration, and the 
risk of insertional mutagenesis in case of integrating viral vectors. In contrast, considerable 
progress has been made in the development of tailored CFTR pharmacotherapy for specific 
CFTR mutations, and the design of better in vitro preclinical assays that allow the selection of 
the most effective therapeutic approaches on an individual basis, i.e. personalized medicine. 
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Mutation-specific therapies   
 Nearly 2000 mutations in the CFTR gene have been identified that can be subdivided 
in 6 different classes based on their phenotypic consequences (Fig. 2) [11, 12]. Class I 
mutations cause defects in full-length protein synthesis due to premature truncations or 
nonsense alleles, or to severe splicing defects; class II mutations cause folding defects and 
premature proteasomal degradation, class III shows normal trafficking to the plasma 
membrane but defective channel gating, class IV results in an impaired channel conductance, 
class V causes a reduced number of CFTR transcripts, and class VI is characterized by a 
reduced protein stability and increased turnover of CFTR at the cell surface. 
 The first three mutation classes are associated with a nearly complete loss of CFTR 
channel function and are considered severe mutations, whereas mutations in class IV-VI may 
allow residual CFTR function and are associated with a milder phenotype. F508del, the most 
common mutation with an allelic frequency of around 90% worldwide, has mixed properties 
of class II, III and VI and is therefore most difficult to repair at the protein level. Just four 
other mutations, notably G551D (class III), W1282X, G542X (class I), and N1303K (class II) 
Fig. 1: Overview of current symptomatic treatments of CF. Inset: CFTR domain structure. 
MSD, membrane spanning domain; NBD, nucleotide binding domain; R, regulatory domain.  
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have a worldwide prevalence of 1-3% each, whereas only 20 mutations have a frequency 
above 0.1%. 
 Before the introduction of high-throughput screening (HTS) as a new technique in 
CFTR drug discovery, proof of principle showing that mutation-specific repair of CFTR is 
feasible was reached at the DNA, RNA and protein level. A major advantage of this approach 
as compared to gene addition by cDNA vectors is that only those cells expressing CFTR 
endogenously are corrected. Potential deleterious consequences of ectopic expression of the 
CFTR transgene, such as supraphysiological expression of CFTR in the cells not normally 
expressing CFTR are avoided, and the need for CFTR promoter constructs or CFTR 
minigenes that are difficult to transfect and to integrate into viral vectors, is abolished.   
DNA repair 
 One promising approach to reach mutation-specific repair of CFTR at the DNA level 
is the application of recently developed genomic editing techniques, such as the Zinc-finger 
nuclease (ZFN), TAL effector nucleases (TALENs), or CRISPR/Cas9 system for genome 
engineering [13, 14]. Proof of concept for correction of the F508del mutation in exon 11 by 
Fig. 2: Overview of CFTR mutation classes. The functional consequences of the mutations 
are indicated in the flanking boxes. 
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homologous recombination with a donor plasmid encoding wild-type CFTR sequences using 
CRISPR/Cas9 has been reached recently in human intestinal stem cells [15]. In principle this 
approach is capable of correcting most if not all other “severe” class I-III mutations, by 
proper engineering of the 20 nucleotide guide sequence in the single guide RNA that targets 
the Cas9 nuclease to appropriate cleavage sites. However its direct therapeutic application in 
CF patients in vivo is hampered by the low efficacy of the repair and the mutagenic risk, 
requiring a time-consuming selection step of the repaired cells that is not feasible in vivo.     
RNA repair 
 Partial transcriptional repair of F508del-CFTR and functional restoration of chloride 
transport in human CF airway cells has been reached by spliceosome-mediated RNA trans-
splicing technology (SMaRT)  using recombinant adenovirus or adeno-associated virus 
(rAAV) as the delivery vector [16, 17]. Alternatively, insertion of the missing bases (TTT) by 
hybridization to a 2’-O-methyl RNA-unmodified RNA oligonucleotide duplex has been 
achieved in a F508del-CFTR expressing cell line [18]. Although RNA repair is transient and 
only modestly effective, studies of CFTR splicing polymorphisms suggest that 8% of normal 
CFTR message is sufficient for normal lung function, whereas 5% is associated with 
relatively mild CF lung disease [19, 20]. Genetic reprogramming of CFTR transcripts by 
SMaRT or oligonucleotides may in principle be applicable also to other severe CFTR 
mutations. In addition, the disease-causing effect of CFTR mutations affecting the pre-
mRNA splicing of the CFTR gene by disrupting or generating intronic splicing motifs 
(frequency ~13%), may be reduced in a mutation-specific fashion by bifunctional antisense 
oligonucleotides providing a trans-acting splicing enhancer, or by synthetic exon-specific 
activators or modified U1 small nuclear RNAs capable of correcting exon skipping [21, 22]. 
However the clinical utility of these techniques for ameliorating CF lung disease is not yet 
proven and awaits the development of suitable and safe in vivo delivery vectors, for example 
rAAV engineered to escape neutralizing antibodies, or methods to penetrate the mucus and 
periciliary layer in the CF lung more effectively [23]. Because oligonucleotide and viral 
repair techniques are less suitable for oral or systemic delivery, these therapies are likely to 
remain restricted to aerosolic treatment which targets only the lung compartment, in contrast 
to the orally applied CF therapeutics discussed hereafter.  
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CFTR protein therapy 
Repair of class I mutant CFTR 
 Of all CFTR mutations identified, ~10% are nonsense mutations (class I) that result in 
the creation of premature termination codons (PTCs) and rapid degradation of CFTR 
transcripts by a quality control mechanism known as nonsense-mediated mRNA decay 
(NMD) to prevent the synthesis of truncated proteins with potential dominant negative effects 
[9-11]. Aminoglycoside antibiotics, including tobramycin, gentamycin and amikacin, do not 
repair the RNA directly but bind to the ribosomes and cause the insertion of a near cognate 
amino-acyl tRNA into the ribosomal A site. This process suppresses translational fidelity and 
allows the ribosome to read through the PTC and to produce full-length protein.  
 Recently the non-aminoglycoside PTC suppressor ataluren (PTC 124; identified by 
HTS) which is orally bioavailable and non-toxic, has been assessed in a large phase III 
clinical trial. Despite some success in Phase II testing [24, 25], ataluren did not significantly 
improve the primary endpoint in Phase III [26].  Several recent  in vitro reporter assay studies 
likewise failed to confirm the read-through efficacy of PTC124, and the reliability of the 
original HTS has been questioned [27]. However encouraging results were obtained recently 
in preclinical studies using a second generation of synthetic aminoglycosides designed to 
provide higher readthrough activity with reduced mitochondrial toxicity [26].  
Repair of conformational defects in the CFTR protein 
 Defects in protein conformation, as occur in mutant CFTR, can be rescued by two 
different approaches: (1) through stabilizing the protein native state with pharmacological 
chaperones (PCs) that bind directly to the channel protein; and (2) through altering the 
activity of the transcriptional, folding, or membrane trafficking machinery or blocking the 
degradation of partially folded, but functional CFTR at the endoplasmic reticulum (ER) or the 
plasma membrane (PM) by so-called proteostasis regulators (PRs) [28, 29]. Most CFTR 
trafficking mutants, including F508del, with a few exceptions (e.g. G480C; N287Y), show 
additional defects in channel gating function, and most PCs and PRs identified thus far only 
partially normalize the channel conformational defect. Effective protein repair may therefore 
need the combined use of either PCs or PRs (collectively called ‘correctors’) which promote 
CFTR exit from the ER and accumulation in the PM, and ‘potentiators’ which improve 
channel gating [30].  
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Structural and functional repair of F508del-CFTR and other class II mutant CFTRs 
 It has recently been shown that F508del-CFTR actually contains two distinct folding 
defects. Studies on second site suppressor mutations and evolved sequences coupled to the 
F508del residue showed not only misfolding of NBD1 (containing residue 508), but also 
instability of the NBD1-MSD2 interface [31, 32]. This may explain the rather modest rescue 
effect of most CFTR correctors available to date, which target only a single defect. Thus 
multidrug therapy with a combination of a NBD1 domain stabilizer (now mechanistically 
classified as a “class I corrector”) and a NBD1-MSD2 interface stabilizer (“class II 
corrector”) may be required to overcome the previously observed “ceiling” in CFTR protein 
repair [33]. Conceivably, the parallel targeting of multiple conformational defects by separate 
small molecule correctors will allow wild-type folding of the mutant protein and obviate the 
need for a potentiator.  
 The current collection of preclinically active PCs and PRs is broad and rapidly 
expanding. It includes not only small molecules but also transcomplementing CFTR 
fragments [34] and RXR peptides [35].The most promising PC developed so far, VX-809 
(Lumacaftor; Vertex Pharmaceuticals) has emerged from HTS in a recombinant cell-based 
assay and is capable of restoring ~15% CFTR channel activity in primary respiratory 
epithelia expressing F508del-CFTR [36]. VX-809 is more selective for CFTR than most 
other folding correctors (for example VRT-325 and corr-4a) and acts early in CFTR 
biogenesis to interact directly with MSD1 and modulate its conformation [37, 38]. In this way 
it not only corrects disease-causing mutations in CFTR MSD1 with a high efficacy, but also 
allosterically suppresses the assembly  
 defects in CFTR caused by F508del and by several other remote folding mutations in the 
fourth intracellular loop (ICL4). Therefore VX-809 mono-or combination therapy, by 
promoting interdomain communication, may restore function to a large number of rare CFTR 
mutations, aside its main action as a class II F508del-CFTR corrector.  
 Results of a phase IIa clinical study of VX-809 showed a small but significant 
reduction of sweat chloride values, but no significant improvement in nasal potential 
difference (NPD), lung function or maturation of F508del-CFTR in rectal biopsies [39]. VX-
809 is reported to normalize the gating of corrected F508del-CFTR but has no direct 
potentiating action, explaining why acute addition of a potentiator further increased the 
activity of VX-809-corrected F508del-CFTR (as well as wild-type CFTR) by two-fold [36]. 
The therapeutic relevance of this gain in activity is presently explored in a phase III clinical 
study of homozygous F508del CF patients, encouraged by data from a phase II study 
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showing improved lung function in approximately 50% of the participants undergoing VX-
809/VX-770 combi-therapy (see http://www.cff.org).  
 Aside VX-809, several other small molecule F508del-CFTR correctors may qualify as 
candidate CF therapeutics, some of which are already in clinical use against other diseases. 
These include the psoralen-related compound and psoriasis drug trimethylangelicin (TMA), 
granted orphan designation by the EMA, and acting as a “dual” F508del-CFTR corrector and 
potentiator, and as a suppressor of IL-8 transcription [40]; the cyanoquinoline CoPo-22 
emerging from HTS, with dual corrector and potentiator activities albeit in the micromolar 
range [41]; in silico-selected disruptors of keratin8-F508del NBD1 interaction, functioning as 
potent correctors of CFTR maturation and trafficking [42]; inhibitors of F508del CFTR-CAL 
interaction, promoting the formation of a stable F508del CFTR-NHERF1 complex in the 
plasma membrane [43]; inhibitors of the Hsp90 co-chaperone Aha1 [44]; and sildenafil, a 
phosphodiesterase type V (PDE5) inhibitor used clinically against erectile dysfunction [45-
48].  Sildenafil may increase CFTR activity through cGMP-dependent phosphorylation or 
through direct cGMP-CFTR interaction, but is also functioning as a relatively weak F508del-
CFTR corrector, possibly due to its structural resemblance with the Vertex corrector VRT-
325 [49].  Although the rapid expansion of a broad collection of CFTR correctors is 
encouraging, in most cases additional mechanistic and/or toxicity studies remain to be done 
before clinical testing can be considered.  
Improvement of CFTR gating by potentiators 
 Most CFTR class III gating mutations, including the most common “Keltic” mutation, 
G551D (frequency ~3%) are localized in the ABC signature sequence or in the Walker A or 
B motif of the two ATP binding pockets (ABP1 and ABP2) of the NBDs (cf. Fig. 1, center), 
and cause a defect in ATP-dependent channel gating without abnormalities in synthesis, 
trafficking or CFTR phosphorylation [50]. Recent insights into the CFTR gating mechanism 
have revealed the existence of two distinct open states, O1 and O2, with different NBD 
configurations: a highly stable O1 state, in which with ATP occupies the ABP2 catalytic site, 
and the more transient O2 state, lacking ATP in ABP2 [51]. VX-770 (Ivacaftor), the first 
FDA-and EMA-approved CF medication forthcoming from HTS that directly targets CFTR, 
was found to stabilize the O2 state, thereby promoting ATP-independent gating. This 
nonconventional gating mechanism could be reproduced in purified G551D-CFTR inserted in 
planar lipid bilayers and proteoliposomes, confirming that VX-770 binds directly to the 
CFTR protein, most plausibly to  the MSDs rather than the NBDs [52]. Stabilizing O2 may 
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also promote reentry of the channel into the gating cycle and the transition to the O1 state, 
thereby increasing ATP-dependent gating of WT-CFTR. This new gating model may explain 
why VX-770 increases the open probability of both WT CFTR and all 10 class III gating 
mutants tested [53], as well as numerous other CFTR forms with missense mutations or 
deletions, including F508del and R117H [30, 54].  
 In several phase III trials oral VX-770 treatment of G551D patients led to rapid, 
dramatic and sustained improvements in FEV1 and body weight, and a strong reduction of 
sweat chloride and pulmonary exacerbations (reviewed in Rowe & Verkman). However a 4-
month placebo-controlled trial of Ivacaftor in F508del-CFTR homozygous patients only 
reduced sweat chloride by a small amount [55]. The relative failure of VX-770 monotherapy 
in F508del patients has been commonly attributed to the very low levels of F508del-CFTR at 
the cell surface. However recent studies on human bronchial cells suggest an alternative 
explanation: in these cells, chronic exposure to VX-770 resulted in a  dramatic increase in 
endocytosis and lysosomal degradation of WT- and F508del-CFTR, but not of G551D 
channels [56]. Whether this phenomenon is limited to VX-770 or is a property of other 
potentiators too, is not known and warrants further investigation. If occurring also in vivo, it 
may impact the outcome of the ongoing phase III combi-trial of VX-809 and VX-770.  
 The isoflavone genistein, a major component of soya-rich food, potentiates G551D- 
and F508del-CFTR channels by binding to the NBDs and promoting ATP-dependent gating 
[57, 58], but also enhances CFTR phosphorylation at basal cAMP levels [59] and inhibits 
CFTR endocytosis through an ill-defined mechanism [60]. In contrast, curcumin, another 
food component and CFTR potentiator, mimics the effect of VX-770 by binding to the MSDs 
and promoting ATP-independent channel gating [61]. As predicted from their distinct 
mechanism of action, the combined application of genistein and curcumin in a low 
concentration range (5-10 µM) synergistically restored the gating defect of G551D of up to 
~50% of the WT level [57]. Further clinical studies using combinations of both food 
components (or combinations of genistein and VX-770, likewise predicted to act 
synergistically) are needed to determine the therapeutic potential of the combination therapy 
relative to monotherapy.   
Towards individualized therapies 
 The success of VX-770 monotherapy in G551D patients and improved insights into 
the mechanism of action of CFTR potentiators and correctors have greatly boosted attempts 
to develop more potent and specific CFTR modulators targeting a specific class of mutant 
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CFTR. To define the optimal treatment for an individual patient, genotyping of CFTR is 
clearly the first step. Subsequently, in case of rare mutations with an unknown phenotype, 
one approach is to express the protein from a mutated cDNA in a model cell line, for example 
Fischer rat thyroid cells [54], followed by CFTR localization and functional assays in the 
absence and presence of CFTR modulators. This method however is unable to report possible 
differences in corrector and potentiator response among individuals belonging to the same 
CFTR mutation class, such as caused by polymorphisms in the CFTR gene and CF modifier 
genes, or by differences in the CFTR interactome. Moreover this technique may be prone to 
artefacts inherent to CFTR overexpression or to the heterologous cellular background, and is 
unsuitable for studying splice mutations or complex genotypes, e.g. CF compound 
heterozygotes. Such confounding factors may explain why some correctors potently act in 
transfected cell lines but fail in primary epithelial cell cultures [62] 
 Considering the limitations of heterologous expression systems, the use of native 
epithelium or primary cell cultures, obtained from CF patients, for CFTR corrector testing 
seems indicated. Evidently, access to such patient material is limited, and this has hampered 
its application for this purpose. However recent breakthroughs in the field of stem cell 
biology now allow large scale cell expansion of non-transformed cells, derived from single 
biopsies (skin, intestine, respiratory tissue) or blood samples, opening a new chapter for 
translational CF research.  
Testing CF therapeutics in rectal biopsies and rectal organoids  
 As illustrated in Fig. 3, one convenient and minimally invasive technique that is even 
applicable to CF neonates starts with the harvest of one or more rectal biopsy specimens by 
forceps or suction, followed by measurements of CFTR-mediated transepithelial chloride and 
bicarbonate currents (“ICM”) in Ussing chambers [63-65]. Both acute and chronic effects of 
CFTR modulators can be monitored using incubation conditions that maintain tissue viability 
for at least 20h. Uniquely this technique allows testing of CFTR modulators ex vivo in native, 
non-cultured epithelium, in which, auspiciously, non-CFTR chloride channels minimally 
contribute to the ICM response. It can also be used to monitor other CF-relevant pathologies, 
such as intracellular alkalinization and defects in mucin degranulation. Studies on biopsies 
from class V splice mutation patients indicate that the level of CFTR expression in colonic 
epithelium is such that only circa 20% of mature, normal CFTR protein in this two-
membrane assay (apical chloride exit; basolateral chloride import) suffices to normalize the 
ICM response (when CFTR is stimulated by saturating forskolin/cAMP levels). This implies 
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that ICM  can detect minute improvements in CFTR function. However, because ICM 
responses plateau at >20% of normal protein abundance, its dynamic range is rather narrow 
[64]. To some extent, this range can be expanded by using suboptimal stimulation (low 
forskolin). Such a strategy may be particularly important to identify corrector effects in 
biopsies carrying very mild mutations (e.g. R117H) that are associated with less than 80% 
loss of CFTR function.  
 A clear limitation of the ICM test is its low capacity (only 4-8 biopsies/patient) and 
lack of expandability and suitability for large-scale corrector screening.  However this 
problem can be overcome by converting the rectal biopsies into epithelial organoids (also 
named enteroids) using a 3-D culturing technique developed recently by the Clevers group 
[66-68]. This primary culture method enables intestinal stem cells to expand into closed and 
self-renewing organoids containing crypt-like structures and an internal lumen lined by 
differentiated cells, recapitulating the in vivo tissue architecture. Activation of CFTR by the 
cAMP agonist forskolin drives the secretion of electrolytes and fluid into the lumen of the 
organoid, resulting in forskolin-induced swelling (FIS) [69]. Luminal expansion is fully 
blocked by pharmacological CFTR inhibitors and completely absent from CFTR-null 
organoids, underscoring the validity of FIS as a CFTR-specific assay.  Quantification of FIS 
in calcein green-labeled organoids grown in 96-well plates (up to 80 organoids/well) using 
live-cell confocal microscopy and imaging software appeared highly reproducible and 
allowed  the testing of up to 32 conditions per experiment in triplicate. Normalized non-
corrected FIS rates differed greatly between different CFTR genotypes (non-CF ≈class IV 
(R117H)>class III>class II (F508del)>class I), and, perhaps less evident, between individuals 
carrying the same alleles (i.e. F508del/F508del). Similar to the ICM, FIS is a two-membrane 
assay reaching a “ceiling” at about 20% of “normal” CFTR activity, beyond which apical 
CFTR activity no longer limits the rate of water secretion. Submaximal stimulation by low 
forskolin is needed to measure differences in FIS between non-CF and a subgroup of mild 
mutations (i.e. R117H), and to quantitate rescue effects of CFTR correctors or potentiators 
above the 20% threshold. As in case of ICM, the assay is highly sensitive which explains why 
organoids derived from homozygous F508del/F508del patients, without prior corrector 
treatment, show a definite residual, albeit variable FIS activity (~5% of non-CF, 
corresponding with ~1% CFTR activity), which can be enhanced by potentiators, such as 
VX-770 [69].  
 The FIS assay readily reveals that organoids isolated from different CF patients, even 
when these carry the same or similar (i.e. same class) CF alleles, may respond differently to 
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(1) a single corrector or potentiator; (2) a combination of corrector and potentiator (e.g. VX-
809 +VX-770 in F508del homozygotes), and (3) a combination of two different correctors 
(e.g. VRT-325 and Corr-4a) [69]. Even larger individual differences are expected in case of a 
PR-type of CFTR corrector considering its stronger dependence on cellular background and 
CFTR interactome in comparison with a PC.  
 Obviously the FIS assay can only report intrinsic differences between CFTR 
modulator efficacies at the level of intestinal epithelial cells; it cannot account for individual 
differences in numerous other therapeutically relevant factors in vivo, such as 
pharmacokinetics, infection, inflammation, mesenchyme-epithelium and lymphocyte-
epithelium communication, and the frequency and intensity of physiological stimuli, in 
particular β-adrenergic and VIPergic cAMP agonists. Therefore additional studies designed 
to correlate drug responses in vivo with drug testing by FIS in organoids from the same 
patient are needed to gain more insight into the predictive value of the FIS assay.  Another 
favorable aspect of organoid cultures is their ability to maintain intact stem cell 
compartments and (epi)genetic stability even after >40 passages. Repetitive passaging will 
generate a large number of organoids from individual patients that can be stored in biobanks 
and used later for testing newly developed CF therapeutics. 
Organoids from airway epithelium as tools for testing CF therapeutics 
 Although the intestine and lungs both originate from endoderm during embryonic 
development, intestinal epithelium cannot be considered simply as a surrogate model  for the 
airways. In contrast to the intestine, the cell turnover in the lungs is very low but accelerates 
upon tissue injury, causing cryptic stem cells (presumably basal cells) to self-renew and 
generate luminal cells, including differentiated ciliated cells [70].  Similar to intestinal stem 
cells, these cells may form spheric structures in vitro.  More recent studies have shown that 
this process is reversible, and that fully differentiated epithelial cells, as present in tracheal or 
bronchial biopsies, can be reprogrammed to reach an adult stem cell-like, indefinite 
proliferative state [71, 72]. Induction of these karyotype-stable and nontumorigenic 
“conditionally reprogrammed” cells (CRCs) is reached by isolating cells from small biopsies 
or cryopreserved tissue by protease dissociation and growing the cells on a layer of fibroblast 
feeder cells in the presence of a Rho kinase (ROCK) inhibitor. Importantly, these cells 
maintain their epigenetic memory and, following expansion, shift back to their original 
differentiated phenotype, including ciliated cells and goblet cells, upon removal of the feeders 
and the inhibitor. By placing them into an appropriate 3D culture system, they are capable of 
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forming spheric lung organoids (grown in Matrigel) or monolayers of epithelial cells (grown 
as air-liquid interface cultures on filters). These can potentially be used to monitor CFTR 
activity in FIS assays or transepithelial current measurements, and to study the efficacy of 
CFTR modulators, in analogy to rectal biopsies and organoids (Fig. 3). Potential hurdles 
however are the relatively low expression levels of CFTR in human lung epithelial cells, 
possibly resulting in very low FIS rates and transepithelial currents, and the presence of 
compensatory non-CFTR channels, e.g. calcium-activated chloride channels, that are much 
less prominent in the intestine. Clearly further research is needed to evaluate the feasibility of 
CF drug testing in epithelial monolayers and organoids derived from nasal brushings or 
bronchial biopsies. If successful, this approach would offer the same advantages for 
individual drug testing as discussed for rectal organoids, but, considering the severe CF lung 
pathology, obtained in an even more CF-relevant cell type. 
 Another option to generate patient-specific airway epithelial cells for testing CF 
therapeutics starts with the creation of induced pluripotent stem cell (iPSC) lines from dermal 
fibroblasts donated by the CF patient, followed by an in vitro directed differentiation protocol 
Fig. 3: Flow diagram depicting the generation of epithelial organoids and monolayers that 
allow CFTR modulator screening on an individual basis. Green boxes: functional ex vivo CFTR 
assays used to select the most effective CFTR modulator (or combinations of modulators) for an 
individual patient.    
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using growth factors that mimic endoderm developmental pathways, and culturing the cells 
under Air-Liquid-Interface (ALI) conditions on permeable substrates [73]. However, 
although a subpopulation of cells did express CFTR and showed CFTR activity in an iodide 
efflux assay, the cell culturing procedure was highly time-consuming, and the assay was not 
robust enough to demonstrate clear effects of a VX-809 like corrector. 
Testing CF therapeutics in immune cells 
 The “personalized medicine” approaches discussed so far are restricted to epithelial 
cells and organoids; however, CFTR is also expressed at low but functionally important 
amounts in non-epithelial cells including myeloid cells [6], in particular monocytes [7, 8], 
macrophages [74] and lymphocytes [75]. CFTR defects in these cells may contribute to 
abnormalities in the innate immune defense of CF patients [76], implying that restoration of 
CFTR function by orally available CFTR correctors and potentiatiors may be of prime 
importance in preventing inflammation and infection. Though our present knowledge of 
CFTR biosynthesis, processing and function in immune cells is fairly limited [7], studying 
the effect of CFTR modulators in cells isolated from individual CF patients is clinically 
highly relevant. This can be done on a small scale using monocytes isolated freshly from 
blood samples of the patient, or following expansion of lymphocyte cell lines immortalized 
with Epstein-Barr virus, using fluorescent membrane potential sensing probes or other live 
assays to monitor CFTR activity (Fig. 3).  
Summary and future prospects and challenges 
 The development of mutation-specific and personalized therapies for CF is 
progressing rapidly, spurred by major technical advances at various levels. Firstly, the 
introduction of reliable newborn screening methods allows early evaluation of the efficacy of 
CFTR-restoring drugs, and optimization of treatment at the personal level, before overt 
disease progression sets in. Secondly, the advent of new generation DNA sequencing 
techniques, which allow the rapid detection of mutations within the full length of the CFTR 
gene, including introns and the promoter region. Thirdly, the development by HTS and other 
approaches, of an ever-expanding collection of CFTR protein correctors and potentiators, 
with proof of clinical efficacy established for at least one compound, the CFTR potentiator 
VX-770. Due to the oral bioavailablity of these new CF therapeutics, CFTR repair is no 
longer restricted to the lungs, as is the case for most DNA- and RNA-based mutation repair 
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techniques, but is feasible in virtually all CF-relevant cell types, including bile ducts, 
intestine, sweat glands and immune cells.  
 Finally, the development of novel techniques to generate almost unlimited numbers of 
epithelial cells and organoids from stem cells in the intestine and from conditionally 
reprogrammed stem cells in the airways, and the introduction of simple, robust and high-
throughput assays to measure CFTR activity in organoids by FIS, has made it possible to 
perform pre-clinical CFTR modulator screens in cells originating from individual CF 
patients. This approach is clearly superior to modulator assays in heterologous mutant CFTR 
expression systems because (i) it allows the detection of modulator responses for individual 
CF patients, irrespective of the mutation, and of possible differences in response to the same 
modulator between CF patients; (2) CFTR correction is assessed in a native cellular and 
genetic background, closely reflecting the in vivo condition; (3) artefacts of CFTR under- or 
overexpression are avoided. Moreover, the option to store cells or organoids from individual 
CF patients in biobanks implies that only a single donation of a small amount of tissue is 
needed to allow repetitive preclinical optimization of treatment with existing CF therapeutics 
or with new drugs emerging from drug development programs. It should be emphasized, 
however, that the value of the new preclinical drug screening tests for predicting the efficacy 
of a CF drug in the clinic still awaits thorough verification by comparisons of in vitro versus 
in vivo drug responses in a large number of CF patients belonging to different mutation 
classes. 
 Patient-specific epithelial organoids also hold promise for regenerative medicine 
approaches to treat CF lung disease (Fig. 3). The feasibility of in vivo epithelial 
transplantation was demonstrated recently in a mouse model showing long-term (>6 months) 
repair of chemically-induced lesions in the colon of immunocompromised recipient mice by 
functional engraftment of colonic organoids expanded in vitro from a single adult colonic 
stem cell [77]. By combining this approach with mutation-specific repair of CFTR in the 
patient’s own tracheal/bronchial  organoids, as has been done successfully in human 
intestinal organoids using the CRISPR/Cas9 genome editing system, stepwise replacement of 
CF epithelium by isogenic, non-immunogenic and non-tumorigenic epithelial transplants may 
perhaps become feasible in the far future.    
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Abstract 
 Transcriptome analysis was performed on the distal small intestine of cystic fibrosis (CF; 
Cftr -/-) mice and littermate controls (Cftr N/N) reared on a conventional (solid) diet. 
Transcriptome data were analyzed using the Ingenuity Pathway Analysis (IPA) software 
application to delineate the impact of CFTR dysfunction on cellular signaling networks. The IPA 
analysis showed that the most strongly affected pathways are involved in antigen presentation, 
and T and B cell maturation/activation, and indicated a bacterial endotoxin-provoked activation 
of the innate and adaptive immune response. IPA indicated that this immune response, through 
activation of the c-Jun N-terminal kinase (JNK) and nuclear factor κB (NFκB) pathways, 
represses signaling via the retinoid X receptor (RXR). Indeed, among the most strongly down-
regulated genes in the CF ileum are the farnesoid X receptor (FXR) targets Nr0b2 (Shp) and 
Fgf15, the pregnane X receptor (PXR) targets Ces2a/b, several members of the cytochrome P450 
family, and many other genes involved in lipid metabolism/transport that are controlled by 
ligand-dependent nuclear receptors that form obligate heterodimers with RXR. In addition, we 
observed dysregulation of genes involved in nutrient and solute uptake, including strong down-
regulation of Cubn (cobalamin/intrinsic factor receptor), Lct (lactase) and Slc28a1 (concentrative 
nucleoside transporter 1), as well as strong up-regulation of the amino acid transporter/CF 
modifier gene Slc6a14. Antibiotic administration reversed most of the CF-typical changes in 
ileal gene expression, attenuated the inflammatory response and largely restored RXR signaling. 
Our data indicate that the gut microbiota has a pervasive, but readily reversible, effect on 
intestinal gene expression in CF mice, and suggest that dysbiosis perturbs intestinal lipid and bile 
acid handling, and nutrient absorption in CF.  
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Introduction 
 The intestinal pathology of cystic fibrosis is characterized by luminal dehydration, 
luminal surface acidification, and accretion of viscous mucus [1]. Mucus accumulation and 
dehydration are thought to play a key role in the development of the CF-typical obstruction of 
the distal small intestine. The abnormally viscous mucus layer that lines the epithelium may also 
provide a niche for bacterial colonization, leading to small intestinal bacterial overgrowth 
(SIBO) [2]. SIBO is relatively common among CF patients and may affect the luminal 
processing and uptake of nutrients (lipids in particular) and bile acids, potentially contributing to 
their malabsorption and to the growth retardation observed in CF. SIBO is likely to markedly 
impact host-microbe interactions, and trigger a local, innate immune response [3]. This is most 
evident from studies on CF mouse models, which report evidence for both SIBO and 
inflammation of the gut wall, which is amenable to antibiotic treatment [4, 5].  
 A limited number of studies have systematically assessed the effect of the CF condition 
on intestinal gene expression, using a DNA microarray approach [4, 6, 7]. Applied to a Cftr null 
mouse model with a severe intestinal phenotype (i.e. a strong predisposition to develop a lethal 
obstruction in early life), these microarray studies have shown that CF is associated with marked 
changes in intestinal gene expression. Some of these changes appear to be directly related to 
SIBO and inflammation, e.g. the up-regulation of genes involved in host-microbe interactions 
[4]. For other differentially regulated genes the link with SIBO and inflammation is less evident. 
For instance, it was shown that antibiotic treatment did not correct the reduction in the 
expression of genes involved in the processing/uptake of macro- and micro-nutrients, although it 
did improve weight gain [5, 7].  
 These studies assessing the CF intestinal transcriptome have yielded important insights 
into the pathophysiology of CF-related intestinal disease. However, one limitation is that they 
were performed on animals reared on a lipid-enriched, low-carbohydrate/protein elemental liquid 
diet (Peptamen), which may have intrinsic effects on the CF gastrointestinal phenotype and the 
gut microbiota [8, 9]. Also, only one of these studies specifically assessed gene expression in the 
distal small intestine, i.e. the region which is most susceptible to obstruction and SIBO, and has a 
key role in bile acid uptake [6]. In the present study, to exclude confounding effects of the 
dietary regimen, we assessed the ileal transcriptome of CF mice reared on a solid diet with a 
standard nutrient formulation. The CF mouse model used by us differs from the one presented in 
previous CF-related transcriptome analyses in that, probably because of secondary genetic and 
environmental factors, it does rarely suffer lethal intestinal obstructions in the adult stage, even 
when maintained on a conventional regimen (i.e. a solid chow and drinking water without added 
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osmolytes). We employed a next-generation sequencing technique, RNAseq, that allows the 
quantification of RNA transcripts with single base-pair resolution, whilst maintaining a high 
dynamic detection range. To minimize variation in gene expression resulting from secondary 
genetic and environmental factors, we used sex (and age) matched littermate couples that, from 
birth onwards, were housed together. Furthermore, recent advancements in the analysis of high-
throughput gene expression data, specifically the application of algorithms that assess causal 
networks that are assimilated based on prior published research, enabled us to identify 
differentially regulated signaling pathways and their upstream modulators [10].  
Methods 
Animal procedures and tissue collection 
 CF mice (Cftrtm1Cam; congenic FVB/n) and littermate controls were housed together in 
individually ventilated cages, in an environmentally controlled facility at the Erasmus MC, 
Rotterdam. Animals were reared on a low fiber diet (C1013; Altromin) and a polyethylene 
glycol/electrolyte drinking solution to prevent intestinal obstruction in early life [11]. In some 
instances, animals were administered drinking water supplemented with ciprofloxacin (0.3 g/L) 
and metronidazole (0.5 g/L) for 15 days [12]. Before tissue collection, animals were kept on 
normal drinking water (or, when applicable, drinking water supplemented with antibiotics) for 
>4 days. This procedure is well tolerated by adult (>12 weeks) CF mice. Intake of food and 
water was monitored during this period, and shown to be comparable between genotypes (not 
shown). Experiments were approved of by the Ethical Committee for Animal Experiments of the 
Erasmus MC. 
RNA Isolation 
 Animals were anaesthetized (ketamine 120 mg/kg, xylazine 20 mg/kg; i.p.), and the 
intestinal tract was collected and flushed with ice-cold saline. Ileal sections (3-5 mm in length) 
were collected at 5-6 cm proximal to the ileocecal valve. Sampling from a CF animal (Cftr -/-) 
and a sex-matched littermate control (Cftr N/N) was performed within a time window of 20 min, 
and between 12:00-14:00h, to control for diurnal variations in gene expression. Tissue was 
homogenized with a rotor-stator homogenizer in Trizol reagent (Qiagen), and total RNA was 
extracted using the Nucleospin RNA kit (Macherey-Nagel). After the integrity of the extracted 
RNA was verified by gel electrophoresis, cDNA was synthesized using the PrimeScript RT 
master mix (Takara Bio).  
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Transcriptome sequencing and pathway analysis 
 Transcriptome sequencing was performed at the Beijing Genomics Institute (BGI). In 
brief, mRNA was isolated from total ileal tissue. The mRNA extracts (200 ng) were fragmented 
and subsequently used for cDNA synthesis. The resulting cDNA library was sequenced using an 
HiSeq 2000 sequencer (TruSeq SBS KIT-HS V3; Illumina). Data were processed with CLC 
genomic workbench 7.5 (CLC Bio), and the sequence reads were mapped to the Genome 
Reference Consortium (GRC) genome data set GRCm38.76, using default parameters. Data 
depict reads per 1000 base pair transcript per million mapped reads (RPKM). 
 For identification of differentially regulated canonical signaling pathways in the ileum of 
CF mice, compared to controls, transcriptome data from 3 couples (2F/1M) were used. For each 
couple and transcript, expression in the Cftr -/- animal was calculated relative to the respective 
control. Identification of differentially regulated signaling pathways was based on those genes 
that, on average, were up- or down-regulated by a factor of ≥2 (see Data analysis). To assess the 
effect of the antibiotic treatment on ileal gene expression, for each genotype, the expression in 
one treated animal was expressed relative to the average expression level in the untreated 
animals, and the analysis was performed on genes that were up- or down-regulated by a factor of 
≥2. 
Data analysis 
 Transcriptome data were analyzed using the Ingenuity® web-based software application 
(Version 1.10; Qiagen). Ingenuity pathway analysis (IPA) and upstream regulator analysis 
(URA) was applied to identify differentially regulated pathways and their upstream modulators, 
as described in detail elsewhere [10]. In brief, to identify differentially regulated pathways, the 
enrichment of the dataset with up- or down-regulated genes comprised within a signal 
transduction network was assessed using Fisher’s exact test (overlap P-value). To assess the 
activation state of a pathway and its upstream regulator, the consistency of the match between 
the observed and the predicted (based on established interactions within a network) expression 
pattern was calculated (activation Z-score). A positive Z-score signifies a regulator in the active 
state, a negative score indicates that its activity is repressed.  
Statistical differences in mean transcript levels were evaluated by the (paired) ratio t-test. Data 
shown are mean ± SE. 
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Results 
Identification of canonical signaling pathways affected by CF 
 We compared the ileal transcriptome of CF mice and wildtype littermates by IPA. This 
identified >100 differentially regulated canonical signaling pathways. The most affected 
canonical pathways (based on the overlap P-value) in the CF ileum are listed below (Figure 1). 
Activation of the innate and adaptive immune response in the CF ileum 
 The IPA indicated a highly significant differential regulation of genes involved in antigen 
presentation, activation of T helper cells, and B cell development (Figure 1; Table S1). This 
points towards the activation of an innate and adaptive immune response, resulting from an 
altered host-microbe (pathogen) interaction in the CF gut (Figure 2A). Among the up-regulated 
genes are those involved in antigen association with MHC molecules and their presentation to T 
cells, and several (co-)receptors and cytokines that stimulate differentiation of naïve CD4+ cells 
into T helper cells (Figure 2B). In contrast, the gene encoding the TGF-β co-receptor ALK7 
(ACVR1C) is down-regulated, which may further promote the immune response [13]. Consistent 
with T helper cell activation, many genes in the B-cell development and iCOS-iCOSL signaling 
in T helper cells pathways were also up-regulated, suggesting an increase in the 
production/recruitment of cells involved in the adaptive immune response (Table S1).  
Figure 1 Differential regulation of canonical signal transduction pathways in the murine CF 
ileum. IPA was used to assess the enrichment of the dataset with up- or down-regulated 
genes that make up predefined signal transduction networks. The top canonical pathways, 
based on overlap P-value, are shown. 
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 The URA suggested that the activation of this inflammatory response is caused by 
exposure to bacterial lipopolysaccharide (LPS) produced by gram-negative bacteria, which, 
Figure 2 A. Antigen presentation to, and activation of, CD4+ T cells. Upon contact with 
microorganisms or their products, antigen-presenting cells produce specific cues that trigger 
differentiation of naïve CD4+ cells into one of several T helper cell subtypes. The MHC complex 
is involved in the processing of antigens and their presentation to the T cell receptor (TCR) 
complex. In conjunction with stimulation of the TCR, specific interleukins are essential for the 
priming of T helper cells. The iCOSL-iCOS (inducible T-cell co-stimulator ligand/receptor) 
interaction contributes to the regulation of activated T cells. CD4+ cell priming is regulated by 
activation of several transcription factors, including Stat1, T-Bet,  Gata3 and Stat5. TGF-β has 
an immune-suppressive action and inhibits differentiation of T cells. B. Transcript levels of 
genes involved in antigen presentation and the Th1 and Th2 activation pathway in the CF 
ileum, relative to a paired Cftr N/N animal. Many of the up-regulated genes encode proteins 
involved in antigen processing or (co-)receptors and ligands that form the immunological 
synapse between antigen-presenting and CD4+ cells. C. The URA indicated that immune 
modulatory receptor ligands, their (co-)receptors, and transcription factors are activated in the 
CF ileum 
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through Toll-like receptor (TLR) stimulation, leads to activation of pro-inflammatory 
transcription factors (interferon regulatory factor, IRF3/7; nuclear factor κB, NFκB; signal 
transducer and activator of transcription, STAT1), and the production of pro-inflammatory 
cytokines (IFNγ, IL-1β, TNFα; Figure 2C).  
 In this context, it is of interest that alkaline phosphatase (Alpi) transcript levels were 
significantly lowered in the ileum of CF mice (407 ± 69 vs. 228 ± 34 RPKM in control and CF 
mice, respectively; P < 0.05, N = 3). Intestinal alkaline phosphatase was shown to have anti-
inflammatory actions, conceivably through catalyzing dephosphorylation of LPS and other 
endotoxins [14]. We also observed that Fut2 transcript levels were significantly higher in CF 
mice than controls (0.3 ± 0.04 vs. 7.4 ± 2.3 RPKM in control and CF mice, respectively; P < 
0.05, N = 3). This fucosyltransferase plays a role in host-microbe interactions and is induced by 
bacterial colonization of the gut [15]. Increased expression of Fut2 has previously been observed 
in CF mice [16].  
LPS represses the activity of ligand-dependent nuclear receptors in the CF ileum 
 The IPA further indicated that the release of LPS and IL-1β inhibits the activity of the 
retinoid X receptors (RXRα/β) in the CF ileum (Figure 1; Table S1). This is in accordance with 
previous studies that have shown that LPS reduces nuclear localization of hepatic RXRα and 
represses induction of its target genes [17, 18]. This repression is thought to be mediated by 
activation of the c-Jun N-terminal kinase (JNK) and NFκB pathways (Figure 3A). RXRs form 
obligate heterodimers with type II ligand-dependent nuclear receptors, including FXR (NR1H4), 
LXR (NR1H2/3), PXR (NR1I2) and PPARα/δ/γ. Indeed, we observed significant down-
regulation of genes involved in the metabolism and transport of fatty acids, bile acids, sterols and 
xenobiotics (Figure 3B; Table S1). Among the most strongly down-regulated genes are the PXR-
induced carboxylesterases Ces2a/b, and the FXR targets Fgf15 and Nr0b2, involved in intestinal 
bile acid transport and hepatic bile acid synthesis. This set also includes members of the ATP 
binding cassette family such as Abca1, Abcb1a, Abcg5, Abcg8, which encode proteins that 
facilitate transport of sterols and xenobiotics to the intestinal lumen [19-21]. Also down-
regulated are genes of the aldehyde hydrogenase and the cytochrome P450 family, involved in 
xenobiotic and lipid metabolism, and the fatty acid binding proteins involved in the transport of 
fatty acids. In line with these data, the URA indicated that the activity of these ligand-dependent 
nuclear receptors is repressed (Figure 3C). 
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CF is associated with down-regulation of genes involved in the absorption of 
monosaccharides, amino acids and B vitamins  
 In view of the reduced expression of genes involved in lipid transport, we also 
investigated whether the transcriptome data show evidence for impaired intestinal translocation 
of other nutrients. We observed a strong reduction in transcript levels of lactase (Lct), a 
disaccharidase ectoenzyme located at the brush border membrane of intestinal epithelial cells 
(Figure 4). 
 Trehalase (Treh) transcript levels were also reduced, albeit to a more moderate extent. In 
contrast, expression of other brush border disaccharidases, i.e. maltase-glucoamylase (Mgam) 
and sucrose-isomaltase (Sis), was similar in CF and control mice. Further, we found that the 
expression of the major monosaccharide transporters located in the brush border membrane, 
Figure 3 LPS/IL-1β-mediated inhibition of RXR. A. LPS, bound to the LPS-binding protein (LBP), 
activates the CD14/TRL4/MD2 receptor complex. This stimulates the production of pro-
inflammatory cytokines (IL-1β, TNFα) by immune cells. Stimulation of intestinal cells by LPS and 
pro-inflammatory cytokines leads to the recruitment of the IKK (inhibitor of NFκB kinase) and 
TAK1 (TGFβ-activated kinase 1) complexes, and activation of NFκB and JNK, which decreases 
RXR transcriptional activity. B. Because RXR dimerizes with type II ligand-dependent nuclear 
receptors, including FXR, LXR, PXR, RAR, CAR and PPAR, this leads to down-regulation of an 
array of genes involved in the metabolism and transport of fatty acids, sterols, bile acids and 
xenobiotics. C. The URA indicated that many ligand-dependent nuclear receptors in the CF ileum 
are in an inactive state. 
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GLUT5 (Slc2a5) and SGLT1 (Slc5a1), was similar in both genotypes. Of the major 
aminopeptidases, only glutamyl aminopeptidase (Enpep) transcript levels showed a moderate 
reduction in the CF ileum, compared to controls, whereas the expression of alanyl 
aminopeptidase (Anpep) was unchanged (Figure 5).  
 The expression of the sodium-dependent neutral amino acid transporter (Slc6a19) was 
modestly reduced in CF mice. No statistically significant difference was observed in the 
expression of the PEPT1 dipeptide transporter (Slc15a1). Intriguingly, we noted strong induction 
of ATB0,+ (Slc6a14), a broad-specificity amino acid transporter, in the CF intestine: whereas 
expression was negligible (<1 RPKM) in ileum of controls, this gene was robustly expressed in 
the ileum of CF mice. 
 The ileum plays a crucial role in the enterohepatic circulation of bile acids and cobalamin 
(vitamin B12). Therefore, we also investigated the expression of plasma membrane proteins 
Figure 5 Transcript level of genes encoding membrane proteins involved in the enzymatic 
release and uptake of oligopeptides and amino acids. *P < 0.05; **P < 0.01; N=3 
Figure 4 Transcript level of genes encoding membrane proteins involved in the enzymatic 
release and uptake of monosaccharides. *P < 0.05; **P < 0.01; N=3. 
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involved in the uptake of this and other water-soluble vitamins, and of the sodium-dependent 
apical bile acid transporter (Slc10a2). We found that transcript levels of Cubn, which encodes 
the cobalamin receptor cubilin, were strongly (>10-fold) reduced in the CF ileum, compared to 
control tissue, whereas the transcript levels of amnionless (Amn), which is also thought to be 
involved in cobalamin uptake, were more moderately reduced (Figure 6). 
 Further, we observed a moderate reduction in the expression of the sodium-dependent 
multivitamin transporter (Slc5a6), principally involved in biotin and panthothenic acid uptake. 
The expression of the pantetheine hydrolase ectoenzyme vanin-1 (Vnn1), a PPARα target 
required for intraluminal production of panthothenic acid from its non-absorbable precursors, 
was also markedly (>3-fold) lower in the CF ileum than in control tissue [22]. The expression of 
ascorbic and folic acid transporters (Slc23a1 and Slc46a1, respectively) and of Slc10a2 was not 
affected.  
Figure 6 Transcript level of genes encoding membrane proteins involved in the uptake of 
vitamins and bile acids. *P < 0.05; N=3. 
Figure 7 Transcript level of genes encoding solute transporters involved in the uptake of 
sodium, chloride, nucleosides, phosphate and sulfate. **P < 0.01; N=3. 
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 Finally, we assessed the expression of some major intestinal solute transporters. These 
facilitate either sodium and chloride uptake via proton (Slc9a3) and bicarbonate (Slc26a3, 
Slc26a6) antiport, respectively, or mediate sulfate/citrate/succinate (Slc13a1/2), nucleoside 
(Slc28a1/2) and phosphate (Slc34a2) uptake via sodium symport. This analysis showed that 
transcript levels of the concentrative nucleoside transporter 1 (CNT1; Slc28a1) were 
significantly (ca. 20-fold) lower in CF than in control tissue (Figure 7). The expression of the 
other genes in this category was not notably affected. 
Effect of antibiotic treatment on intestinal gene expression in CF mice 
 Assuming that increased exposure of the intestinal epithelium to bacterial endotoxins 
does indeed lead to repression of signaling through RXR and other ligand-dependent nuclear 
Figure 8 Effect of antibiotic treatment on the inflammatory response and on ligand-
dependent nuclear receptor activity. A. The URA was used to assess the effect of 
antibiotic treatment on the activation state of inflammation modulators in the CF ileum, 
relative to ileum of control mice. For comparison, the activation state in conventionally 
reared CF mice is included (data as in Figure 2C). Antibiotic treatment reduced the 
activation state of these modulators down to the level observed in (untreated) wildtype 
ileum. B. Activation state of the LPS/IL-1β-mediated inhibition of RXR pathway in CF mice, 
compared to wildtype mice, before and after antibiotic treatment. Antibiotic treatment 
reversed the activation of the LPS/IL-1β-mediated inhibition of RXR pathway. C. Effect of 
antibiotic treatment on the expression of genes involved in the metabolism and transport of 
fatty acids, sterols, bile acids and xenobiotics. Transcript levels are shown relative to Cftr 
N/N mice. Antibiotic treatment reversed the down-regulation of most genes, restoring 
transcript levels closely to those found in Cftr N/N mice 
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receptors, we reasoned that measures to counteract SIBO would restore their activity. To test 
this, we treated animals with an antibiotic regimen that was previously shown to reduce the 
bacterial load in CF whilst increasing community diversity, leading to a convergence of the 
microbiome composition of CF and wildtype mice [12]. The URA was used to assess the effect 
of this regimen on the activation state of key inflammation modulators in the CF ileum. This 
analysis showed that, whereas these modulators were in the activated state in conventionally 
reared CF animals, the antibiotic treatment reduced their activity to (or below) the level observed 
in the ileum of conventionally reared wildtype mice (Figure 8A). This strongly suggests that 
antibiotic treatment effectively reduces exposure to LPS and attenuates the attendant immune 
response to the levels normally observed in the mouse intestine. Consistent with reduced LPS 
exposure and IL-1β production, the repression of RXR activity observed in conventionally reared 
CF mice was lost after antibiotic treatment (Figure 8B), and the expression of most genes 
controlled by RXR heterodimeric nuclear receptors was restored (Figure 8C). 
 We also investigated whether antibiotic treatment could reverse the observed changes in 
the expression of genes involved in the absorption of monosaccharides, amino acids, nucleosides 
and B vitamins. Indeed, antibiotic treatment strongly stimulated expression of Cubn, Lct, 
Slc28a1 and Vnn1 in CF mice, and led to a more moderate induction of Alpi, Slc6a19 and Treh 
(Figure 9). In contrast, Slc6a14 transcript levels were strongly reduced by antibiotic treatment. In 
wildtype mice, antibiotic treatment had comparatively little effect on the expression of these 
genes. Thus, these data show that antibiotic treatment corrects anomalous gene expression in the 
CF ileum. 
Figure 9 Effect of antibiotic treatment on transcript levels of genes encoding brush border 
ectoenzymes, solute transporters or receptors that are differentially regulated in CF mice 
and controls. Data show transcript levels relative to conventionally reared animals 
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Normal expression of villus markers in the CF intestine 
 CF has been associated with enhanced crypt cell proliferation, leading to expansion of the 
crypt compartment [6, 23]. We hypothesized that delayed maturation of the absorptive, columnar 
epithelial cells (enterocytes) may contribute to the observed reduction in transcript levels of 
genes involved in nutrient uptake, as these are typically substantially higher in the upper 
epithelial (villus) compartment than in the crypts. To investigate this, we assessed transcript 
levels of genes which were previously found to be expressed at >60-fold higher levels in the villi 
than in the crypts of mouse ileum [24]. Congruent with our hypothesis, this set of 15 genes 
included Lct and Nr0b2, i.e. genes that are strongly down-regulated in CF ileum. However, none 
of the other transcripts in this set showed a significant reduction in the CF condition, which 
argues against substantial changes in enterocyte maturation (Figure 10). 
 
Discussion 
 It has been proposed that, in CF, intestinal dysbiosis is a key factor in the onset of 
intestinal inflammation and the activation of the immune system [25, 26]. Presently, 
transcriptome analysis showed unequivocal evidence for altered host-microbe interactions and 
the activation of an innate and adaptive immune response in the distal small intestine of a CF 
mouse model, which is triggered by bacterial endotoxins. Gut inflammation was associated with 
a marked overall reduction in the activity of (type II) ligand-dependent nuclear receptors, which 
is predicted to strongly affect fatty acid, sterol, bile acid and xenobiotic metabolism and 
transport. Apart from these marked effects on lipid handling, we noted that CF is associated with 
Figure 10 Transcript level of typical villus markers in CF mice and controls. Transcript levels of 
these genes were previously shown to be >60 fold higher in the villi than in the crypts of mouse 
ileum. 
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reduced expression of a limited set of genes involved in the absorption of other nutrients. Most 
of these changes in gene expression could be corrected by antibiotic treatment, suggesting 
dysbiosis has a pervasive effect on the CF intestinal transcriptome. 
 The IPA indicated that signaling through ligand-dependent nuclear receptors is markedly 
repressed in the CF intestine, as a consequence of LPS/TLR-mediated activation of pro-
inflammatory signaling pathways that lead to repression of RXR. LPS, a component of the outer 
membrane of gram-negative bacteria, triggers the production of pro-inflammatory cytokines by 
macrophages and other immune cells by activation of the LPS core receptor complex (Figure 3) 
[27]. LPS and pro-inflammatory cytokines have been shown to decrease the nuclear levels of 
hepatic RXRα and, consequently, its activity, in a JNK-dependent manner [17]. Down-regulation 
of Alpi and Nr0b2 (encoding the SHP nuclear receptor), may contribute to the inflammatory 
response, as alkaline phosphatase and SHP activity was shown to inhibit LPS/TLR signaling [14, 
28, 29]. Collectively, these data suggest that, in CF, SIBO-provoked enhanced production of 
LPS represses ligand-dependent receptor signaling. 
 The gut microbiota is known to modulate the activity of the bile acid receptor FXR in the 
ileum by intra-luminal conversion of primary bile acids, which limits the level of FXR-
antagonistic species, but may also reduce uptake of the FXR-activating type [30, 31]. Our data 
indicate that dysbiosis, in addition, may repress FXR through its effects on the host immune 
response and RXR activity. RXR heterodimer nuclear receptors play a key role in the 
metabolism of fatty acids, sterols, bile acids and xenobiotics. Altered fatty acid, sterol and bile 
acid transport and metabolism are typical of CF, suggesting that intestinal repression of RXR 
may contribute to the development of CF-related pathologies [32-34]. For instance, a deficiency 
of the intestinal FXR target FGF15, or loss of the receptor for this hormone (FGFR4), was 
shown to enhance fecal excretion of bile acids, and to deplete the gall bladder, respectively [35, 
36]. Similarly, the changes in the expression of genes involved in intestinal lipid physiology we 
present here may play a role in aberrant fatty acid and cholesterol transport and the changes in 
tissue lipid composition observed in CF patients and mouse models [34, 37, 38]. Repression of 
RXR may also contribute to the previously reported loss of intestinal PPARγ activity in CF mice, 
and to the presently observed reduction in Alpi transcripts, as this gene is targeted by the thyroid 
hormone receptor-RXR heterodimer [39-41]. 
 Apart from these wide-ranging effects on the expression of genes involved in lipid 
handling, we also observed discrete changes in the expression of genes involved in the 
absorption of monosaccharides, amino acids, nucleosides and B vitamins. The most significant 
changes were observed in the transcript levels of Cubn, Lct, Slc28a1 (all markedly reduced in CF 
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ileum), and Slc6a14 (strongly increased in CF ileum). Lowered intestinal expression of Cubn and 
Lct has been found in earlier transcriptome analyses on CF mice [4, 6], and lowered intestinal 
lactase, as well as alkaline phosphatase, levels have previously been reported for CF patients 
[42]. We noted that the down-regulation of Cubn and Lct observed in the CF ileum can be 
reversed by antibiotic treatment, suggesting that the CF microbiome also modulates the 
expression of these genes. Consistent with a role of bacterial products, it has been shown that 
LPS-provoked acute endotoxemia reduces Cubn expression in the kidney [43]. Intriguingly, in 
CF mice, cubilin protein levels in the proximal tubules were also reduced, resulting in a mild 
(low molecular weight) proteinuria, but Cubn expression was apparently not affected [44]. Up-
regulation of intestinal Slc6a14 expression has previously been reported for patients suffering 
from ulcerative colitis and for Vibrio cholerae infected subjects, which suggests that the 
regulation of this gene is also linked to host-pathogen interactions and inflammation [45, 46]. In 
line with his notion, we found that antibiotic treatment strongly repressed Slc6a14 expression in 
the CF ileum. Interestingly, genome-wide association studies on CF cohorts have shown that 
single nucleotide polymorphisms at loci near the SLC6A14 gene are associated with meconium 
ileus [47]. Although the functional consequences of this genetic polymorphism are unknown, it 
is conceivable that enhanced SLC6A14-mediated uptake of solutes and stimulation of attendant 
osmotic water transport compounds the CF fluid secretory defect and exacerbates luminal 
dehydration. 
 Expression of genes that encode proteins involved in nutrient processing/uptake is 
particularly high in fully matured enterocytes, located at or near the tips of the villi. Therefore, a 
reduction in the transcript levels of these genes may signal an underlying defect in enterocyte 
maturation [7]. Arguing against such a wide-ranging defect is the observation that the expression 
of many typical villus markers (i.e. genes which are expressed at much higher level in villus than 
in crypt cells) is apparently normal in the CF intestine. Consequently, it is improbable that 
defective cell maturation fully accounts for the observed changes in gene expression. This is also 
indicated by the observation that, although Lct expression is strongly reduced in CF mice, the 
expression of other ectoenzymes located at the brush border of mature enterocytes, like Anpep, 
Mgam and Sis, was not affected. Therefore, if present, this mechanism does appear to affect only 
specific aspects of enterocyte maturation, and it is conceivable that the intestinal micro-
environment provides specific cues which direct cell programming. Our data suggest that the gut 
microbiota is a key determinant of this maturation program. 
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SUPPLEMENTARY DATA 
Table S1: Differentially regulated canonical pathways in the CF ileum. 
 
 
Gene Symbol 
Human 
 
Gene Name 
 
 
Gene Symbol 
Mouse 
 
Expression: 
Fold change 
 
Antigen presentation    
CD74 CD74 molecule Cd74 4.162 
CIITA class II major histocompatibility complex transactivator Ciita 6.042 
HLA-A major histocompatibility complex. class I. A H2-Q7 2.267 
HLA-DMA major histocompatibility complex. class II. DM alpha H2-DMa 5.015 
HLA-DMB major histocompatibility complex. class II. DM beta H2-DMb1 5.267 
HLA-DOA major histocompatibility complex. class II. DO alpha H2-Oa 3.583 
HLA-DOB major histocompatibility complex. class II. DO beta H2-Ob 2.444 
HLA-DQA1 major histocompatibility complex. class II. DQ alpha 1 H2-Aa 3.854 
HLA-DQB1 major histocompatibility complex. class II. DQ beta 1 H2-Ab1 4.405 
HLA-DRA major histocompatibility complex. class II. DR alpha H2-Ea-ps 3.037 
HLA-DRB5 major histocompatibility complex. class II. DR beta 5 H2-Eb1 5.732 
HLA-G major histocompatibility complex. class I. G H2-M3 2.341 
NLRC5 NLR family CARD domain containing 5 Nlrc5 8.639 
PSMB8 proteasome subunit beta 8 Psmb8 3.793 
PSMB9 proteasome subunit beta 9 Psmb9 3.547 
TAP1 transporter 1. ATP binding cassette subfamily B member Tap1 3.858 
    
B cell development   
CD19 CD19 molecule Cd19 14.814 
CD40 CD40 molecule Cd40 4.061 
CD79A CD79a molecule Cd79a 6.106 
CD79B CD79b molecule Cd79b 6.633 
H2-Eb2 histocompatibility 2. class II antigen E beta2 H2-Eb2 3.934 
HLA-A major histocompatibility complex. class I. A H2-Q7 2.267 
HLA-DMA major histocompatibility complex. class II. DM alpha H2-DMa 5.015 
HLA-DMB major histocompatibility complex. class II. DM beta H2-DMb1 5.267 
HLA-DOA major histocompatibility complex. class II. DO alpha H2-Oa 3.583 
HLA-DOB major histocompatibility complex. class II. DO beta H2-Ob 2.444 
HLA-DQA1 major histocompatibility complex. class II. DQ alpha 1 H2-Aa 3.854 
HLA-DQB1 major histocompatibility complex. class II. DQ beta 1 H2-Ab1 4.405 
HLA-DRA major histocompatibility complex. class II. DR alpha H2-Ea-ps 3.037 
HLA-DRB5 major histocompatibility complex. class II. DR beta 5 H2-Eb1 5.732 
Ighg2b immunoglobulin heavy constant gamma 2B Ighg2b 10.012 
IGHM immunoglobulin heavy constant mu Ighm 4.157 
IL7 interleukin 7 Il7 3.374 
SPN sialophorin Spn 2.867 
    
iCOS-iCOSL signaling in Th cells   
CD28 CD28 molecule Cd28 2.315 
CD40 CD40 molecule Cd40 4.061 
CD3D CD3d molecule Cd3d 3.669 
CD3E CD3e molecule Cd3e 2.522 
CD3G CD3g molecule Cd3g 2.457 
FGFR3 fibroblast growth factor receptor 3 Fgfr3 -2.531 
GAB1 GRB2 associated binding protein 1 Gab1 -2.137 
GRAP2 GRB2-related adaptor protein 2 Grap2 2.017 
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H2-Eb2 histocompatibility 2. class II antigen E beta2 H2-Eb2 3.934 
HLA-A major histocompatibility complex. class I. A H2-Q7 2.267 
HLA-DMA major histocompatibility complex. class II. DM alpha H2-DMa 5.015 
HLA-DMB major histocompatibility complex. class II. DM beta H2-DMb1 5.267 
HLA-DOA major histocompatibility complex. class II. DO alpha H2-Oa 3.583 
HLA-DOB major histocompatibility complex. class II. DO beta H2-Ob 2.444 
HLA-DQA1 major histocompatibility complex. class II. DQ alpha 1 H2-Aa 3.854 
HLA-DQB1 major histocompatibility complex. class II. DQ beta 1 H2-Ab1 4.405 
HLA-DRA major histocompatibility complex. class II. DR alpha H2-Ea-ps 3.037 
HLA-DRB5 major histocompatibility complex. class II. DR beta 5 H2-Eb1 5.732 
ICOS inducible T-cell costimulator Icos 5.209 
IL2RB interleukin 2 receptor subunit beta Il2rb 2.533 
IL2RG interleukin 2 receptor subunit gamma Il2rg 2.62 
ITK IL2 inducible T-cell kinase Itk 2.065 
LAT linker for activation of T-cells Lat 3.191 
LCK LCK proto-oncogene. Src family tyrosine kinase Lck 2.496 
LCP2 lymphocyte cytosolic protein 2 Lcp2 2.189 
ZAP70 zeta chain of T-cell receptor associated protein kinase 70 Zap70 3.071 
    
Th1 and Th2 activation   
ACVR1C activin A receptor type 1C Acvr1c -2.559 
CD28 CD28 molecule Cd28 2.315 
CD40 CD40 molecule Cd40 4.061 
CD274 CD274 molecule Cd274 4.73 
CD3D CD3d molecule Cd3d 3.669 
CD3E CD3e molecule Cd3e 2.522 
CD3G CD3g molecule Cd3g 2.457 
CRLF2 cytokine receptor-like factor 2 Crlf2 2.093 
CXCR4 C-X-C motif chemokine receptor 4 Cxcr4 5.114 
FGFR3 fibroblast growth factor receptor 3 Fgfr3 -2.531 
GAB1 GRB2 associated binding protein 1 Gab1 -2.137 
H2-Eb2 histocompatibility 2. class II antigen E beta2 H2-Eb2 3.934 
HLA-A major histocompatibility complex. class I. A H2-Q7 2.267 
HLA-DMA major histocompatibility complex. class II. DM alpha H2-DMa 5.015 
HLA-DMB major histocompatibility complex. class II. DM beta H2-DMb1 5.267 
HLA-DOA major histocompatibility complex. class II. DO alpha H2-Oa 3.583 
HLA-DOB major histocompatibility complex. class II. DO beta H2-Ob 2.444 
HLA-DQA1 major histocompatibility complex. class II. DQ alpha 1 H2-Aa 3.854 
HLA-DQB1 major histocompatibility complex. class II. DQ beta 1 H2-Ab1 4.405 
HLA-DRA major histocompatibility complex. class II. DR alpha H2-Ea-ps 3.037 
HLA-DRB5 major histocompatibility complex. class II. DR beta 5 H2-Eb1 5.732 
ICAM1 intercellular adhesion molecule 1 Icam1 2.056 
ICOS inducible T-cell costimulator Icos 5.209 
IKZF1 IKAROS family zinc finger 1 Ikzf1 2.032 
IL33 interleukin 33 Il33 4.208 
IL1RL1 interleukin 1 receptor like 1 Il1rl1 2.47 
IL27RA interleukin 27 receptor subunit alpha Il27ra 2.5 
IL2RB interleukin 2 receptor subunit beta Il2rb 2.533 
IL2RG interleukin 2 receptor subunit gamma Il2rg 2.62 
IRF1 interferon regulatory factor 1 Irf1 2.329 
JAK3 Janus kinase 3 Jak3 2.106 
KLRD1 killer cell lectin like receptor D1 Klrd1 2.207 
LTA lymphotoxin alpha Lta 6.198 
SOCS1 suppressor of cytokine signaling 1 Socs1 6.08 
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SOCS3 suppressor of cytokine signaling 3 Socs3 3.053 
STAT1 signal transducer and activator of transcription 1 Stat1 3.316 
TNFRSF4 TNF receptor superfamily member 4 Tnfrsf4 2.254 
    
LPS-IL-1 mediated inhibition of RXR function   
ABCA1 ATP binding cassette subfamily A member 1 Abca1 -3.189 
ABCB1 ATP binding cassette subfamily B member 1 Abcb1a -2.904 
ABCC2 ATP binding cassette subfamily C member 2 Abcc2 -2.237 
ABCG5 ATP binding cassette subfamily G member 5 Abcg5 -2.198 
ABCG8 ATP binding cassette subfamily G member 8 Abcg8 -2.677 
ACOX2 acyl-CoA oxidase 2 Acox2 -2.524 
ALDH1A1 aldehyde dehydrogenase 1 family member A1 Aldh1a1 -3.399 
ALDH3A2 aldehyde dehydrogenase 3 family member A2 Aldh3a2 -2.412 
ALDH4A1 aldehyde dehydrogenase 4 family member A1 Aldh4a1 2.137 
CAT catalase Cat -3.622 
CD14 CD14 molecule Cd14 3.364 
CHST3 carbohydrate sulfotransferase 3 Chst3 23.983 
CHST4 carbohydrate sulfotransferase 4 Chst4 3.539 
CHST10 carbohydrate sulfotransferase 10 Chst10 3.18 
CYP2B6 cytochrome P450 family 2 subfamily B member 6 Cyp2b10 -2.566 
CYP2C9 cytochrome P450 family 2 subfamily C member 9 Cyp2c66 -7.949 
CYP3A5 cytochrome P450 family 3 subfamily A member 5 Cyp3a11 -12.095 
CYP4A11 cytochrome P450 family 4 subfamily A member 11 Cyp4a10 -21.224 
FABP1 fatty acid binding protein 1 Fabp1 -3.019 
FABP2 fatty acid binding protein 2 Fabp2 -2.032 
FABP6 fatty acid binding protein 6 Fabp6 -4.583 
FMO2 flavin containing monooxygenase 2 Fmo2 -2.23 
FMO5 flavin containing monooxygenase 5 Fmo5 -2.792 
GAL3ST2 galactose-3-O-sulfotransferase 2 Gal3st2 -2.855 
GSTA5 glutathione S-transferase alpha 5 Gm10639 2.343 
GSTP1 glutathione S-transferase pi 1 Gstp2 2.081 
IL33 interleukin 33 Il33 4.208 
IL1RL1 interleukin 1 receptor like 1 Il1rl1 2.47 
IL1RN interleukin 1 receptor antagonist Il1rn 2.977 
IL4I1 interleukin 4 induced 1 Il4i1 2.834 
NGFR nerve growth factor receptor Ngfr -2.271 
NR0B2 nuclear receptor subfamily 0 group B member 2 Nr0b2 -44.334 
PPARA peroxisome proliferator activated receptor alpha Ppara -3.81 
SMOX spermine oxidase Smox 2.001 
SULT1C2 sulfotransferase family 1C member 2 Sult1c2 -2.988 
TNF tumor necrosis factor Tnf 4.137 
    
FXR/RXR activation   
ABCC2 ATP binding cassette subfamily C member 2 Abcc2 -2.237 
ABCG5 ATP binding cassette subfamily G member 5 Abcg5 -2.198 
ABCG8 ATP binding cassette subfamily G member 8 Abcg8 -2.677 
AGT angiotensinogen Agt -2.902 
APOA4 apolipoprotein A4 Apoa4 -2.237 
BAAT bile acid-CoA:amino acid N-acyltransferase Baat -2.022 
CLU clusterin Clu 3.391 
FABP6 fatty acid binding protein 6 Fabp6 -4.583 
FBP1 fructose-bisphosphatase 1 Fbp1 -3.53 
FGF19 fibroblast growth factor 19 Fgf15 -40.903 
G6PC glucose-6-phosphatase catalytic subunit G6pc -2.944 
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IL33 interleukin 33 Il33 4.208 
IL1RN interleukin 1 receptor antagonist Il1rn 2.977 
MLXIPL MLX interacting protein like Mlxipl -2.124 
NR0B2 nuclear receptor subfamily 0 group B member 2 Nr0b2 -44.334 
PPARA peroxisome proliferator activated receptor alpha Ppara -3.81 
RBP4 retinol binding protein 4 Rbp4 2.111 
SAA1 serum amyloid A1 Saa1 21.654 
SERPINA1 serpin family A member 1 Serpina1b 4.477 
SLC10A2 solute carrier family 10 member 2 Slc10a2 2.29 
TNF tumor necrosis factor Tnf 4.137 
TTR transthyretin Ttr 11.339 
    
LXR/RXR activation   
ABCA1 ATP binding cassette subfamily A member 1 Abca1 -3.189 
ABCG5 ATP binding cassette subfamily G member 5 Abcg5 -2.198 
ABCG8 ATP binding cassette subfamily G member 8 Abcg8 -2.677 
AGT angiotensinogen Agt -2.902 
APOA4 apolipoprotein A4 Apoa4 -2.237 
ARG2 arginase 2 Arg2 -2.303 
CD14 CD14 molecule Cd14 3.364 
CLU clusterin Clu 3.391 
IL33 interleukin 33 Il33 4.208 
IL1RL1 interleukin 1 receptor like 1 Il1rl1 2.47 
IL1RN interleukin 1 receptor antagonist Il1rn 2.977 
LYZ lysozyme Lyz2 2.477 
MLXIPL MLX interacting protein like Mlxipl -2.124 
MYLIP myosin regulatory light chain interacting protein Mylip -2.415 
NGFR nerve growth factor receptor Ngfr -2.271 
NOS2 nitric oxide synthase 2 Nos2 3.976 
RBP4 retinol binding protein 4 Rbp4 2.111 
SAA1 serum amyloid A1 Saa1 21.654 
SERPINA1 serpin family A member 1 Serpina1b 4.477 
TNF tumor necrosis factor Tnf 4.137 
TTR transthyretin Ttr 11.339 
    
PXR/RXR activation   
ABCB1 ATP binding cassette subfamily B member 1 Abcb1a -2.904 
ABCC2 ATP binding cassette subfamily C member 2 Abcc2 -2.237 
ALDH1A1 aldehyde dehydrogenase 1 family member A1 Aldh1a1 -3.399 
Aldh1a7 aldehyde dehydrogenase family 1. subfamily A7 Aldh1a7 -2.73 
ALDH3A2 aldehyde dehydrogenase 3 family member A2 Aldh3a2 -2.412 
CES- Carboxylesterase 2A Ces2a -7.656 
CES- Carboxylesterase 2B Ces2b -9.311 
CYP2B6 cytochrome P450 family 2 subfamily B member 6 Cyp2b10 -2.566 
CYP2C9 cytochrome P450 family 2 subfamily C member 9 Cyp2c66 -7.949 
CYP3A5 cytochrome P450 family 3 subfamily A member 5 Cyp3a11 -12.095 
G6PC glucose-6-phosphatase catalytic subunit G6pc -2.944 
INSR insulin receptor Insr -2.207 
NR0B2 nuclear receptor subfamily 0 group B member 2 Nr0b2 -44.334 
PPARA peroxisome proliferator activated receptor alpha Ppara -3.81 
TNF tumor necrosis factor Tnf 4.137 
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Abstract 
 Guanylin (GN) and uroguanylin (UGN), through activation of guanylyl cyclase C (GCC), 
serve to control intestinal fluid homeostasis. Both peptides are produced in the intestinal 
epithelium, but their cellular origin has not been fully charted. Using quantitative PCR and an 
improved in situ hybridization technique (RNAscope) we have assessed the expression of GN 
(Guca2a), UGN (Guca2b), and GCC (Gucy2c) in mouse intestine. In the crypts of Lieberkühn, 
expression of Guca2a and Guca2b was restricted to cells of secretory lineage, at the crypt’s base, 
and to a region above, previously identified as a common origin of cellular differentiation. In this 
compartment, comparatively uniform levels of Guca2a and Guca2b expression were observed 
throughout the length of the gut. In contrast, Guca2a and Guca2b expression in the villus/surface 
region was more variable, and reflected the distinct, but overlapping expression pattern observed 
previously. Accordingly, in jejunum and ileum, Guca2a and Guca2b were abundantly expressed 
by enterocytes, whereas in colon only Guca2a transcript was found in the surface region. In 
duodenum, only low levels of Guca2b transcript were observed in columnar cells, and Guca2a 
expression was restricted entirely to cells of the secretory lineage. Gucy2c was shown to be 
expressed relatively uniformly along the rostrocaudal and crypt-villus axes, and was also found 
in the duodenal glands. Our study reveals novel aspects of the cellular localization of the GCC 
signaling axis that, apart from its role in the regulation of fluid balance, link it to pH regulation, 
cell cycle control, and host defense.  
 
Key terms: cyclic guanosine monophosphate, enteroendocrine cells, guanylyl cyclase C, 
intestinal fluid transport 
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Introduction 
Signal transduction through the receptor-enzyme guanylyl cyclase C (GCC) serves to control 
intestinal fluid balance. Activation of the luminal, extracellular receptor domain by one of two 
locally produced peptides, guanylin (GN) and uroguanylin (UGN), leads to a surge in cellular 
cGMP levels, which prompts osmotic water transport to the intestinal lumen by protein kinase-
mediated stimulation of anion secretion through the cystic fibrosis transmembrane conductance 
regulator (CFTR) anion channel and inhibition of sodium absorption through the sodium-proton 
exchanger type 3 (NHE3) [1]. This pivotal role of GCC signaling in intestinal fluid balance is 
most poignantly illustrated by gain- and loss-of-function mutations in GUCY2C (encoding 
GCC), which have been shown to cause secretory diarrhea and intestinal obstruction, 
respectively [2-4]. Furthermore, GCC is activated by the (U)GN mimetic heat-stable toxin (STa) 
produced by enterotoxigenic Escherichia coli, a frequent cause of infectious diarrhea.  
 Apart from its role in the regulation of fluid homeostasis, GCC signaling may also 
regulate luminal pH. GCC stimulation strongly enhances duodenal bicarbonate secretion, and 
some data suggest that luminal acid may stimulate UGN release from duodenal enteroendocrine 
cells [5-10]. Evidently, in proximal intestine, such a feedback loop may aid the neutralization of 
the acid load entering from the stomach. In addition, it has become apparent that local 
bicarbonate production is crucial for the proper expansion of the mucins produced by goblet 
cells, and, consequently, the physiochemical properties of the mucus layer covering the 
epithelium along the entire tract [11, 12]. Possibly connected to its effect on mucin unfolding and 
fluid transport, loss of GCC signaling was shown to impair epithelial barrier function, and innate 
host responses to bacterial pathogens [13, 14].  
 Lastly, GCC signaling may modulate the cell cycle in small intestinal and colonic 
epithelium. Mice deficient in either GN, GCC, or the cGMP-dependent protein kinase operating 
downstream of GCC (PRKG2), exhibit enhanced cell proliferation in the crypts, and a reduction 
in the amount of cells of the secretory lineage [15-17]. It has also been suggested that loss of 
GCC signaling predisposes to tumor development [18].  
 The convergence of such apparently disparate physiological processes at the level of 
GCC suggests a strict compartmentalization of signaling routes. In this context, it is of interest 
that various distinct cell types within the intestinal epithelium have been proposed to produce 
GN and UGN. Mostly, these studies indicate production by cells from the secretory 
(granulocytic) lineage. In human small intestine, GN transcript was localized to the Paneth cells, 
whereas in the rat, GN transcript and protein was detected in goblet cells, and UGN transcript 
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was found in enterochromaffin (EC) cells [19-22]. In rat colon, GN was expressed by goblet 
cells, but also by the columnar cells of the surface epithelium, whereas in guinea pig, GN 
immunoreactivity was restricted to EC cells [20, 23, 24]. Finally, in mouse intestine, UGN 
transcript was localized exclusively to the villus, whereas GN transcript was found in both the 
villi and crypts of the small intestine, and in the surface epithelium of colon [25]. These disparate 
results may signify marked differences in the localization, and, perhaps, the physiological role, 
of GN and UGN between species, and different anatomical regions. In addition, they may reflect 
the technical limitations of classical in situ hybridization and immunological methods. 
 Our study aimed to ascertain the expression pattern of GN, UGN, and GCC, using 
quantitative PCR and an improved in situ hybridization technique, which drastically improves 
sensitivity. While our study, in the main, corroborates previously reported patterns of GN, UGN, 
and GCC partitioning along the rostrocaudal axis of the intestine, these technical advances have 
allowed us to chart these patterns in more detail, revealing previously unappreciated differences 
in the expression pattern of duodenum versus jejunum, and the cell lineages involved in the 
production of GN, UGN, and GCC. 
Materials and methods 
Animals  
 Mice (FVB) were maintained in an environmentally controlled facility at the Erasmus 
MC, Rotterdam. All experiments were performed on animals, 8-16 weeks of age, and were 
approved of by the Ethical Committee for Animal Experiments of the Erasmus MC. 
Tissue collection  
 Mice were anaesthetized (ketamine 100 mg/kg, xylazine 20 mg/kg; i.p.), and the 
intestinal tract was collected and flushed with ice-cold saline. All tissue was harvested between 
12:00-14:00h, to control for diurnal variations in gene expression. 
 For assessing the partitioning of transcript along the rostrocaudal axis of the intestinal 
tract, 6 equidistant segments (length: 0.5 cm) of small intestine, and 2 segments of the colon 
were excised. The small intestine was sampled, starting 1 cm caudal to the pyloric sphincter, and 
up to 1 cm proximal to the ileocecal valve. Colon was sampled at 1/3 and 2/3 of its entire length. 
Tissue was flash frozen in liquid nitrogen and stored at -80°C.  
 For RNAscope analysis, and lectin UEA1 (Ulex europeaus agglutinin 1) staining (see 
below), the excised intestine was flushed with ice-cold saline, cut open lengthwise, rolled into a 
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Swiss-roll, and immersed in PBS-buffered formalin (10%) for 24h at 4°C. After fixation, tissue 
was embedded in paraffin, according to established protocols.  
Quantitative Polymerase Chain Reaction (qPCR): 
 Tissue was homogenized with a rotor-stator homogenizer in Trizol reagent (Qiagen), and 
total RNA was extracted using the Nucleospin RNA kit (Macherey-Nagel). After the integrity of 
the extracted RNA was verified by gel electrophoresis, cDNA was synthesized using the 
PrimeScript RT master mix (Takara Bio).  
 Quantitative PCR (primer sequences shown in Table S1) was performed on cDNA, using 
the SYBR Select master mix (Applied Bio System). Median values from assays performed in 
triplicate were used to determine the expression levels of Guca2a, Guca2b and Gucy2c, relative 
to Gapdh. 
In situ hybridization by RNAscope 
 Probes for detection of murine GN, UGN and GCC transcript were purchased from 
Advanced Cell Diagnostics (product code: 427996, 428006, and 436596, respectively). Because, 
other than in conventional in situ hybridization, multiple independent probes have to hybridize to 
the target sequence in tandem in order for signal amplification to occur, RNAscope ensures 
selective amplification of target-specific signals [26]. RNAscope was performed according to the 
instructions of the manufacturer of the probes and the reagent kit (VS Reagent Kit 320600; 
Advanced Cell Diagnostics), on proteinase K (0.1%, 5 min at 37°C) treated paraffin sections (5 
µm). Detection of the ubiquitously expressed gene Ppib (peptidylprolyl isomerase B) served to 
ensure that tissue sections were correctly primed for probe hybridization (Advanced Cell 
Diagnostics, product code: 313919). 
Histochemical detection of lysozyme and fucose-glycoprotein 
 For detection of fucose-glycoprotein producing cells, sections used for RNAscope were 
re-hydrated in PBS, treated with a biotin blocking reagent (Dako), and incubated (1 h, at room 
temparature) with biotinylated lectin UEA1 (Vector Labs). Lectin UEA1 labeled carbohydrate 
moieties were visualized with a streptavidin-conjugated fluorescent probe (Alexa Fluor 594; Life 
Technologies). In negative controls, incubation with lectin UEA1 was omitted. Slides were 
mounted with Prolong Gold Antifade reagent (Life Technologies), and stored at 4°C. 
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Results 
Partitioning of Guca2a, Guca2b, and Gucy2c transcript along the rostrocaudal axis of the 
mouse intestinal tract 
 Quantitative PCR analysis showed that Guca2a transcript levels gradually increased 
along the rostrocaudal axis of the small intestine, and peaked in the proximal colon (Fig. 1a). In 
contrast, Guca2b transcript levels were low in colon. Guca2b levels were also low in the 
duodenum, but rose steeply along the rostrocaudal axis, and peaked in the middle to distal part of 
the small intestine (Fig. 1b). Gucy2c was expressed at much lower (>10-fold) levels than Guca2a 
or Guca2b, and was partitioned more uniformly (Fig. 1c). Distribution of these transcripts was 
similar in male and female mice (not shown).  
 The RNAscope technique was used to visualize Guca2a, Guca2b and Gucy2c transcripts 
in longitudinal sections of mouse intestine. This methodology employs up to 20 pairs of 
oligonucleotide probes per transcript, of which the paired probes need to hybridize in close 
proximity in order for signal amplification to occur. As a consequence, this technique provides a 
strongly improved signal to noise ratio compared with conventional in situ hybridization 
techniques [26]. The distribution pattern that emerged for these transcripts closely matched the 
expression profile assessed by qPCR analysis, i.e. the gradual increase of Guca2a and Guca2b 
expression from duodenum to the distal small intestine, the high expression of Guca2a, but low 
expression of Guca2b, in colon, and the comparatively low expression of Gucy2c (Fig. 2).  
Figure 1 Partitioning of Guca2a (a), Guca2b (b), and Gucy2c (c) transcript along the 
rostrocaudal axis of the mouse intestinal tract. Transcript levels in 6 equidistant sections of 
small intestine, and 2 sections of colon (see diagram) were assessed by qPCR, using 
expression of Gapdh as a reference. Data depict means ± standard error. N=6 
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 This agreement strongly suggests specific hybridization of the probes. In addition, probe 
hybridization was restricted to intestinal epithelial cells, i.e. absent from underlying connective 
and muscle tissue, consistent with the discrete epithelial expression pattern of these genes. Our 
data also corroborate the previously observed high levels of focal Guca2b expression in regions 
of the colonic epithelium that border on lymphoid tissue (Fig. 2b colon section, Fig. 4j) [25]. 
Figure 2 Partitioning of Guca2a (a), Guca2b (b), and Gucy2c (c) transcript in intestinal 
mucosa. Intestinal tissue was paraffin-embedded in a “Swiss roll” configuration and was 
probed by RNAscope. The arrow indicates the transition from gastric to duodenal epithelium. 
P: pancreatic tissue. L: Lymphoid tissue 
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Specificity of the Guca2a probes was further corroborated by RNAscope performed on intestinal 
tissue of Guca2a null mice, in which only sparse punctuate staining was found in the nuclei 
(indicating weak hybridization with DNA), and the cytoplasmic region (indicating weak 
hybridization with truncated Guca2a transcripts; Fig. S1). 
 The observed rostrocaudal distribution patterns of GN, UGN and GCC are congruent 
with those previously reported for rat intestine [27], but differ somewhat from those reported in a 
previous mouse study, in which the levels of Guca2b expression in duodenum and jejunum were 
shown to be similar [25]. However, in this previous study, tissue from the proximal 3 cm of the 
mouse small intestine was pooled to assess duodenal expression, whereas we used a section 
between 1 and 1.5 cm distal to the pylorus. As is apparent from the RNAscope data (Fig. 2b), the 
expression level of Guca2b steeply increases within the first few centimeters of the small 
intestine, indicating that these apparent differences may be due largely to the different sampling 
strategies. Furthermore, it is conceivable that these differences reflect the effect of an 
unidentified environmental factor (i.e. diurnal rhythm, food intake and composition, etc.) on 
duodenal Guca2b expression.  
 We did not detect Guca2a transcript in gastric or in pancreatic epithelia (Fig. 2a, 3), nor 
did we detect expression of Guca2b or Gucy2c in these tissues (Fig. 2b,c). This contrasts with 
previous observations on guinea pig, in which GN immunoreactivity was observed in pyloric EC 
cells [23], and with observations on human and rat pancreatic tissue, in which GN, UGN, and 
GCC transcript and protein were detected [28, 29]. RT-PCR analysis confirmed that, compared 
to the gut, these glandular tissues contain only very low levels of these three transcripts (not 
shown). Such transcripts of low abundance may not be detectable by in situ hybridization, 
particularly in the pancreas, which contains high levels of ribonucleases [30]. However, arguing 
against significant mRNA loss prior to tissue fixation, we could readily detect Ppib transcript, in 
Figure 3 Partitioning of Guca2a and Ppib transcript in the pyloric-duodenal region and in 
pancreas. a,b: Guca2a expression was found in the duodenum (D), in cells at the base of 
the crypts of Lieberkühn, but was not detected in the gastric (G) or the duodenal glands 
(DG), or in the pancreas. c,d: Detection of Ppib transcript in glandular epithelia in the 
pyloric-duodenal region and pancreas. IL: Islet of Langerhans 
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both the stomach and the pancreas (Fig. 3c,d). Therefore, we tentatively conclude that expression 
of the GCC signaling axis is low in mouse-, compared to human pancreas. Interestingly, this 
apparent difference in the pancreatic expression of the GCC signaling axis between these species 
mirrors a previously observed disparity in the regulation of ductal anion and fluid secretion: 
whereas in the human pancreas the GCC signaling axis is thought to control the activity of the 
phosphorylation-regulated CFTR anion channel, anion and fluid secretion in the murine exocrine 
pancreas is principally governed by Ca2+-dependent anion channels, which operate 
independently of the GCC pathway [28, 31]. 
Partitioning of Guca2a and Guca2b transcript along the crypt-villus and crypt-surface axis of 
the mouse small intestine and colon, respectively 
 Along the entire length of the small intestine, high Guca2a transcript levels were found in 
cell clusters at the base of the crypts, and in solitary cells that line the lateral sides of the crypts 
(Fig. 4a-d). In the proximal small intestine, expression in the villus region was restricted to a 
distinct, sparsely distributed cell type (Fig. 4a). Very little expression was found in columnar, 
absorptive villus cells (enterocytes). However, in the proximal jejunum, expression of Guca2a in 
the villus became more prominent, and was found in most columnar cells. Guca2a expression in 
the villus region further increased along the rostrocaudal axis, and distal jejunum and ileum 
showed abundant Guca2a expression in enterocytes (Fig. 4b,c). In colon, Guca2a transcript was 
found along the entire crypt-surface axis, but appeared to be most abundantly expressed by cells 
lining the lateral sides of the crypts, and the surface. Strong expression was also found in cell 
clusters at the base of the crypts (Fig. 4d). Guca2a was also strongly expressed by the follicle-
associated epithelium overlying lymphoid aggregates, in both small and large intestine (Fig. 4e). 
 Like for Guca2a, Guca2b transcript was found in cells at the base and the lateral sides of 
the crypts, along the length of the small intestine (Fig. 4f-h). However, the level of cellular 
expression, and the amount of cells that expressed Guca2b in the crypts, appeared somewhat 
lower than for Guca2a. In the duodenum, Guca2b expression started to emerge at the base of the 
villi, and involved the entire height of the villus in more distal sections of the small intestine 
(Fig. 4f-h). In colon, Guca2b expression was restricted to individual cells, or small clusters of 
cells, in the crypts (Fig. 4i). Although small in number, the level of expression per single cell 
was relatively high, and comparable to the level in Guca2b expressing cells in the crypts of the 
small intestine. As for Guca2a, we observed strong Guca2b expression in the follicle-associated 
epithelium overlying lymphoid tissue, in both small and large intestine (Fig. 2b colon section, 
Fig. 4j). 
Guanylin and uroguanylin localization in mouse intestine 
79 
Partitioning of Gucy2c transcript along the crypt-villus and crypt-surface axis of the mouse 
small intestine and colon, respectively 
 Gucy2c was expressed relatively uniformly, in both the crypt and villus region of the 
epithelium (Fig. 4k-n). As for Guca2a and Guca2b, Gucy2c probe hybridization was restricted to 
intestinal epithelial cells. Expression in these cells was relatively uniform; only at the tip of the 
villi, expression seemed to wane slightly (similar was observed for Guca2a and Guca2b). No 
specific subset of cells was shown to be enriched in (or depleted of) Gucy2c transcript.  
 Further, we found Gucy2c transcripts in the duodenal glands (Fig. 4o). Previously, by 
autoradiographic demonstration of STa specific binding sites in the intestinal mucosa, the 
presence of GCC in the duodenal glands of the North American opossum had been inferred [32]. 
However, similar studies performed on human duodenal mucosa failed to demonstrate specific 
STa binding [33]. Remarkably, the duodenal glands did not contain Guca2a or Guca2b 
transcript, indicating that local GCC activation relies on GN or UGN produced elsewhere. 
Localization of Guca2a and Guca2b in cells of secretory lineage 
 In the small intestine, the Guca2a and Guca2b expressing cells at the base of the crypt 
were found to contain secretory granules and (in part) co-localized with Paneth cells (Fig. 5a,f). 
In contrast, Guca2a or Guca2b expression was not observed in the adjacent stem cells. A 
previous in situ hybridization study suggested that apparent Guca2b localization at the base of 
the crypts was a result of autofluorescence of the Paneth cells [25], but since RNAscope uses an 
enzymatic detection method this cannot have confounded our observations. Moreover our 
detection of Guca2a and Guca2b in Paneth cells is consistent with studies using a fluorescence-
activated cell sorting technique to isolate specific epithelial cell lineages [34, 35]. This showed 
that Guca2a and Guca2b rank in the 90th percentile of most highly expressed genes in murine 
Paneth cells, and that Paneth cells are highly enriched in these transcripts, relative to stem cells 
(NCBI GEO datasets GSE5156 and GSE25109). In addition, these datasets reveal that Gucy2c is 
expressed at near equal levels in Paneth and stem cells, congruent with the relatively uniform 
distribution of Gucy2c transcript in crypt epithelium (Fig. 4k-n).  
 Guca2a and Guca2b transcript were also found in cells at the base of the crypts in colon 
(Fig. 5b,g). These cells appear to occupy the same niche as the Paneth cells of the small intestine, 
suggesting they represent the cKit-positive Paneth-like cells identified previously [36]. In earlier 
studies, only Guca2a transcript had been detected in this compartment, possibly because the low 
sensitivity of conventional in situ hybridization techniques precluded detection of the less 
abundant Guca2b transcripts [25].  
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 Lectin UEA1 staining confirmed that the cells at the base of the crypts, and other 
Guca2a- and Guca2b-positive cells in the crypts and villus region of duodenum were of 
secretory lineage (Fig. 5e). Based on their numbers, localization, and typical shape, these 
Guca2a and Guca2b expressing cells in the villus appear to include brush (tuft) cells (Fig. 5c,h). 
Previously, a murine duodenal enteroendocrine cell type secreting β-endorphin in response to 
acidic or hyperosmotic stimulation was identified [7]. Interestingly, this cell type also contained 
UGN (but, based on immunological detection methods, not GN). In rat, apart from goblet cells, 
some enteroendocrine cell types also seemed to contain immunoreactive GN, although the 
specificity of the signal was questioned by the authors [24]. Collectively, these data strongly 
Figure 4 Localization of Guca2a (a-d), Guca2b (f-i), and Gucy2c (k-n) transcript in 
intestinal epithelium. e: Guca2a expression in follicle-associated epithelium in proximal 
jejunum. j: Guca2b expression in follicle-associated epithelium in colon. o: Gucy2c 
expression in the region of transition from the gastric (G) to duodenal mucosa, with 
duodenal glands (DG) below. L: Lymphoid tissue 
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suggest that distinct brush cell populations co-exist in the murine duodenal epithelium, 
expressing Guca2a or Guca2b.  
 In addition, Guca2a expression was found in a subset of goblet cells in the lower villus 
(Fig. 5d). This suggests that GN may be released concurrently with the mucin containing 
granules produced by goblet cells. No Guca2b was found in goblet cells, but in the duodenum, 
where Guca2b expression is generally low, columnar cells that adjoined goblet cells seemed to 
have relatively (compared to more remote columnar cells) high Guca2b expression, suggesting 
that UGN release from these cells may play a role in goblet cell function (Fig. 5h-j). These 
findings are in line with studies on rat, which detected GN, but not UGN, in a subset of goblet 
cells of the rat small intestine and colon [20, 24]. 
Discussion 
 An improved in situ hybridization technique (RNAscope) has allowed us to reveal novel 
aspects of the localization of the GCC signaling axis in the murine intestinal tract. We 
demonstrate strong expression of Guca2a and Guca2b transcript in cells of secretory lineage, in 
Figure 5 Guca2a and Guca2b expression by cells of the secretory lineage in the 
duodenum and colon. a: Guca2a expression in Paneth cells in duodenum. b: Guca2a 
expression in cells at the base and the neck region of the crypts in colon. c: Guca2a 
expression in a duodenal brush cell. d: Guca2a expression in a duodenal goblet cell. e: 
Co-staining of Guca2a transcript (dark brown) and lectin UEA1-binding fucose-
glycoproteins (bright red) in duodenum. f: Guca2b expression in Paneth cells in 
duodenum. g: Guca2b expression in cells at the base of the crypts in colon. h: Guca2b 
expression in a duodenal brush cell. No Guca2b transcript was observed in goblet cells. 
i,j: Guca2b levels were generally low in columnar cells, but comparatively high in 
columnar cells adjoining goblet cells. B: brush cell; G: goblet cell P: Paneth cell 
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particular Paneth cells located at the base of the crypts and chemosensory brush cells in the 
lower villus. Strikingly, the general pattern of Guca2a and Guca2b expression in this lineage is 
relatively uniform along the entire intestine: even in the proximal part, which was thought to 
produce little GN, we observed prominent Guca2a expression in Paneth and brush cells, whereas 
in colon, which was thought to produce little UGN, robust Guca2b expression was found in 
Paneth-like cells at the base of the crypts.  
 In contrast to this relatively stable expression pattern in the crypts, expression in the 
villus/surface compartment showed more variation between anatomical regions, as expression of 
Guca2a and Guca2b extends to cells from the columnar (absorptive) lineage. It is chiefly the 
expression in this compartment that reiterates the previously reported pattern of GN and UGN 
distribution. i.e. a predominance of UGN in the proximal gut, and of GN in the colon [25, 27]. 
As has been noted before, this pattern is consistent with the observation that GN is a relatively 
(in comparison to UGN) poor GCC ligand at the low pH prevailing in the proximal small 
intestine [25]. Nevertheless, prominent expression of Guca2a is found in the crypts of the 
proximal small intestine, suggesting that the pH in this area may be maintained at more neutral 
values (aided by local bicarbonate secretion). 
 Along the length of the small intestine, Guca2a and Guca2b transcripts were found in 
Paneth cells, or, in case of the colon, in cells which appear to occupy the same position as these. 
Guca2a expression appeared more pronounced than Guca2b, but the localization pattern was 
similar. Previous in situ hybridization studies showed a similar distribution of Guca2a at the base 
of the crypts in jejunum and ileum of mice, although the exact cell types involved could not be 
ascertained [25]. Guca2a and Guca2b expression by murine Paneth cells was also indicated in 
studies that employed cell sorting techniques to isolate epithelial cells representing different 
lineages [34, 35]. Furthermore, GN transcript was localized to human Paneth cells [19].  
 It has been suggested that GN-stimulated fluid secretion emanating from the lower crypt 
may have a cleansing effect that supports the action of the bactericidal products of the Paneth 
cells [19]. In further support of innate immunity, GN and/or UGN release from Paneth cells may 
trigger bicarbonate secretion from neighboring CFTR-containing columnar cells, facilitating 
expansion of condensed mucins, and, consequently, the formation of the protective mucus layer 
covering the epithelium [11, 12]. In accordance with this notion, it has been shown that GCC 
signaling reduces susceptibility to infection by attaching/effacing bacterial pathogens [13]. GN 
stored in goblet cells (and UGN in adjoining columnar cells) may serve a similar role. When 
released together with the mucin granules, a synchronized activation of GCC-dependent 
bicarbonate secretion from adjacent enterocytes (as goblet cells seem to contain little CFTR) 
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may aid the proper expansion of the secreted condensed mucin granules. Consistent with this 
hypothesis, exocytosis from goblet cells is under cholinergic control, and it has been shown that 
cholinergic input also stimulates GN release in rat colon [37, 38]. 
 Apart from producing antibacterial products, Paneth cells also produce various factors 
that modulate stem cell function. It is conceivable that GN and UGN may also contribute to this 
modulation. In mice, it has been shown that GN, PRKG2, or GCC deficiency leads to enhanced 
crypt cell proliferation, and that GCC deficiency reduces goblet and Paneth cell numbers in 
mouse small intestine, whereas PRKG2 deficiency reduces goblet cell numbers in colon [15-17]. 
These results suggest that GCC signaling directs differentiation to a secretory lineage. Indeed, 
PRKG2 has been shown to control the activity of the transcription factor Sox9, which is a key 
determinant of Paneth cell formation [39-41]. Because of their close contact to stem cells and 
their progenitors, the Paneth cells are a likely source of the ligands that control GCC activity in 
this niche. Consistent with this model, both our present data and previous studies (NCBI GEO 
datasets GSE5156 and GSE25109) indicate that Gucy2c expression in the crypts extends to the 
stem cells, whereas Guca2a and Guca2b expression is restricted to cells of the secretory lineage 
[34, 35]. 
 In duodenum, prominent expression of Guca2a and Guca2b in the villi is mostly 
confined to just the few cells of secretory lineage. Apart from Paneth and goblet cells, this 
includes brush cells. UGN, but not GN, has previously been localized to murine brush cells [7]. 
Brush cells are known to monitor the composition of the lumen, and it was shown that this 
particular subset of UGN-containing duodenal brush cells secretes β-endorphin into the lumen 
upon acidic or hypertonic stimulation [7, 42]. We propose that the UGN stored in this cell type 
may also be released upon exposure to these luminal stimuli. In support, an increase in 
bicarbonate secretion was observed in mouse duodenum upon lowering of the luminal pH, which 
may be attributed to endogenous (U)GN release, as GN and UGN are known to strongly 
stimulate duodenal bicarbonate secretion [5, 8, 10]. This assumption is also consistent with the 
observation that (I) luminal hypertonicity stimulates the release of GN and UGN, and inhibits 
NHE3-mediated sodium absorption [43, 44], and (II) enteral salt loading may induce intra-
arterial UGN release from the intestinal mucosa (to stimulate renal natriuresis) [45]. 
Collectively, these data suggest that GN and UGN are released from distinct subsets of brush 
cells upon acidic or hypertonic stimulation, and that their release serves to regulate luminal pH 
and osmolarity. 
 We observed expression of Gucy2c, but not of Guca2a or Guca2b, in the duodenal 
glands.  This GCC pool may be targeted by GN and/or UGN released into the duodenal lumen 
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(although diffusion of peptides into the glands is likely to be opposed by secretory fluid 
movement), and/or by systemic GN and UGN. In support of the latter option, intra-arterial GN or 
UGN has been shown to trigger duodenal bicarbonate secretion [6]. Indeed, systemic UGN has 
been shown to elicit additional GCC-dependent effects, notably in neuro-endocrine tissues [46, 
47]. In further support of such actions in the gut, it was shown that, contra-luminal 
administration of STa to duodenal enteroids provoked GCC-mediated inhibition of Na+,H+ 
antiport activity, strongly suggesting that such oligopeptides are translocated across the 
epithelium, although the presence of GCC at the basolateral aspect of polarized intestinal 
epithelial cells cannot be excluded completely [48]. 
 Distal from the duodenum, prominent Guca2a and Guca2b expression is found in the 
columnar (absorptive) cells of the villus. Strong expression of Guca2a and Guca2b in the villus 
has been observed before in mice, but not in rat or guinea pig [16, 17, 19, 21, 23]. Thus, the 
increase in total expression of Guca2a and Guca2b distal from the duodenum can be mainly 
attributed to expression initiated in enterocytes. This expression pattern is similar to that of the 
transcription factor Cdx2, suggesting that this, or other intestine-specific transcription factors, 
control Guca2a and Guca2b expression in enterocytes [49]. GN and/or UGN released in this 
region is unlikely to enter the crypts, which contain most of the CFTR-mediated anion-secretory 
capacity, and a function in the villus compartment seems indicated. Apart from activating a sub-
pool of CFTR, GN and UGN may limit sodium absorption through NHE3, which is highly 
expressed in mature enterocytes and is inhibited through cGMP-dependent protein 
phosphorylation [48]. Assuming that peptides released at the surface of the villi would diffuse 
more rapidly into the bulk luminal content than those secreted in the crypts, local GCC activity 
and ion transport may simply be controlled by the level to which its ligands are diluted upon 
their release; GCC stimulation would peak at a low level of hydration, when a high concentration 
of its ligands is maintained at the epithelial surface. This may constitute a relatively 
straightforward mechanism to maintain fluid homeostasis, which does not so much rely on a 
stimulus-controlled release of GN and UGN, but on a continual secretion from columnar cells in 
the villus. It is of interest that the combined Guca2a and Guca2b expression in this compartment 
is particularly high in the distal small intestine, a region which appears especially prone to 
dehydration and obstruction caused by GCC deficiency [2]. 
 In the colon, strong Guca2a expression was found in cells positioned at the lateral sides 
of the crypts. At the base of the crypts, expression was markedly lower, and confined to a 
Paneth-like cell type [36]. The distal colon in particular contains high numbers of goblet cells, 
and these also appeared to express Guca2a. As in the small intestine, GN release from goblet 
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cells may play a role in mucin expansion. Guca2b expression was low in colon, but was retained 
in solitary cells in the crypts. Strikingly, high Guca2a and Guca2b expression was found in those 
parts of the epithelium that were in contact with lymphoid tissue. This particular expression 
pattern has been observed before for Guca2b in the ileocecal region of mice [25]. Because the 
follicle-associated epithelium also shows strong expression of genes encoding specific ion 
channels, i.e. Cftr, Clca2, Kcnj15 and Kcna1 [50], and we also found weak expression of Gucy2c 
in this region, it is conceivable that GN and UGN regulate ion transport across the follicle-
associated epithelium through autocrine signaling. 
 In summary, the present study charts Guca2a, Guca2b, and Gucy2c expression along the 
entire murine intestinal tract. Whereas Gucy2c expression is relatively uniform along the 
rostrocaudal and crypt-villus axes, strong regional differences exist in the expression of its 
ligands. These differences mostly reflect varying levels of expression in the upper regions of the 
epithelium. Gucy2c expression was found in the duodenal glands, suggesting it serves a role in 
UGN/GN-dependent duodenal bicarbonate secretion. Further, we show distinct expression of 
Guca2a and Guca2b in Paneth cells and brush cells, suggesting that GN and UGN play a role in 
chemoreception, stem cell proliferation, and host defense. 
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Supplementary 
Table 1 Sequence of the primers used for qPCR.  
Protein Gene Forward primer Reverse Primer 
GN Guca2a GATCCTGCAGAGGCTAGAGG AAGGCAAGCGATGTCACTCT 
UGN Guca2b AGGAGATGTCCAATCCCCAG ACAGTTCACATTCGTCGGTGG 
GCC Gucy2c TGTGAACGCGACTTTCATCTAC GCAGCCCATCTTATGATCTCTTG 
GAPDH Gapdh TTCCAGTATGACTCCACTCACGG TGAAGACACCAGTAGACTCCACGAC 
 
. 
 
 
 
 
 
 
 
 
Figure Supplementary 1 (S1). RNAscope analysis of Guca2a transcript in jejunal tissue of 
normal (a) and Guca2a null (b) mice. In control mice, Guca2a staining matched the pattern 
shown in Figure 3, but in Guca2a null mice, only sparse punctuate staining was found in the 
nuclei (indicating hybridization with DNA), and cytoplasmic region (indicating weak 
hybridization with truncated Guca2a transcripts) 
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Abstract 
 Cystic fibrosis (CF) related gastrointestinal disease is characterized by dehydration of the 
epithelial surfaces, a reduction in the luminal surface pH, and mucus plugging, often culminating 
in impaction of the distal small intestine contents and bacterial overgrowth (SIBO). We 
hypothesized that this pathology affects the production of the luminocrine peptides guanylin 
(GN) and uroguanylin (UGN), which, through activation of the guanylyl cyclase C (GCC), 
control intestinal fluid homeostasis. To address this question, we investigated gene and protein 
expression of GN, UGN and GCC in intestinal tissue of CF (Cftr null) and wildtype mice reared 
on a conventional diet or after oral antibiotic treatment. We found that expression of GN, UGN 
and GCC was markedly reduced in the distal small intestine of CF mice, compared to tissue of 
wildtype mice. Corresponding with low GN and UGN transcript levels, the level of the secreted 
peptide precursors were also reduced in the CF ileum. Expression of GN and UGN was restored 
in primary organoids cultures of CF intestinal epithelium, suggesting that the down-regulation of 
the GCC signaling axis results from secondary disease manifestations. Indeed, intestinal 
dysbiosis was indicated by a marked induction of genes involved in host-microbe interactions, 
and antibiotic treatment restored GN and UGN transcript levels to those observed in wildtype 
mice. We conclude that CF-related changes in the gut microbiota suppress signaling through the 
pro-secretory (U)GN-GCC signaling axis, suggesting that impaired GCC signaling may 
contribute to luminal dehydration and acidification in CF. 
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Introduction 
 Dehydration of the epithelial surfaces, mucus plugging, and obstruction of the distal 
small intestine are hallmarks of cystic fibrosis (CF) related gastrointestinal disease. This 
pathology is caused by loss-of-function mutations in the gene encoding the CF transmembrane 
conductance regulator (CFTR) anion channel. CFTR mediates chloride and bicarbonate transport 
to the intestinal lumen and the biliary and exocrine pancreatic ducts. Both a reduction in the 
resultant osmotic water transport and a decrease in surface pH, which is a critical determinant of 
the physiochemical properties of the mucus layer lining the luminal surfaces, are thought to 
contribute to the gastrointestinal phenotype [1]. In turn, anomalous mucus production and 
luminal dehydration lead to impaired pancreatic enzyme delivery, malabsorption and intestinal 
obstruction. Combined, these factors may elicit distinct alterations in the gut microbiota 
(dysbiosis). 
 In the intestine, CFTR operates downstream of several intricately interwoven signaling 
pathways that control intestinal fluid balance and acid-base homeostasis [2]. One of these 
pathways is controlled by the release of 2 luminocrine factors, the cysteine-rich peptides 
guanylin (GN) and uroguanylin (UGN), by the intestinal epithelium. These peptides control the 
activity of the receptor-enzyme guanylyl cyclase C (GCC), which is located on the luminal 
membrane of epithelial cells throughout the length of the gut [3-5]. GCC stimulation increases 
cellular cyclic guanosine monophosphate (cGMP) levels, which prompts protein kinase mediated 
phosphorylation/activation of CFTR, and, consequently, chloride and bicarbonate secretion. 
Concurrent phosphorylation/inhibition of the sodium-proton exchanger type 3 (NHE3) leads to 
luminal retention of sodium, which is thought to contribute significantly to the pro-secretory 
effect of cGMP- and cyclic AMP-linked (neuro-)endocrine pathways [2]. The importance of the 
GCC signaling axis for intestinal fluid homeostasis is underlined by the fact that loss-of-function 
mutations in GCC lead to a CF-like phenotype, i.e. a predisposition to develop obstruction of the 
distal small intestine [6]. 
 Apart from regulating intestinal fluid homeostasis, the GCC signaling axis may also play 
a role in host-microbe interactions and the innate immune response to pathogens. This 
involvement may, in part, reflect the role of GCC in luminal pH regulation. Acid-stimulated 
GCC activation was shown to trigger strong CFTR-dependent bicarbonate secretion [7, 8]. This 
luminal alkalization was shown to be crucial for proper unfolding of condensed mucins, and the 
CF-typical changes in the physiochemical properties of the mucus layer are thought to precipitate 
mucus plugging and bacterial colonization of the small intestine [1, 9]. In addition, it is probable 
that GCC signaling has further roles in the regulation of innate immunity: GN and UGN are 
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highly expressed in Paneth cells, and, by stimulating local fluid secretion, may oppose microbial 
invasion of the crypts of Lieberkühn [5, 10]. This fluid movement may also aid the dispersion of 
the anti-microbial products produced by Paneth cells. Consistent with such a role, it was shown 
that loss of GCC activity compromises the epithelial barrier and the innate host response to 
pathogens in mice [11, 12].  
 GN and UGN are expressed by several different epithelial cell types of the secretory 
lineage, including some enteroendocrine types [5, 13]. This suggests that their production and 
release may be controlled through a chemosensory mechanism, i.e. by luminal input. Indeed, it 
was shown that luminal hyperosmotic fluid triggers the expression of GN and UGN in mouse 
small intestine, whereas intake of a high-fat diet was shown to suppress UGN and GN expression 
in the gut [14-16]. Of interest, inflammation of the gut wall is associated with down-regulation of 
the GCC signaling axis, suggesting that local chemo-/cytokine production affects (U)GN 
production and GCC signaling [17-19].  
 Considering the potential effect of luminal salinity, pH, inflammation, and the gut 
microbiota on GN and UGN production, we hypothesized that the CF condition may alter GN 
and UGN expression. An increase in either GN or UGN production, resulting from a decrease in 
luminal pH and the low hydration level of the luminal surface, would enhance GCC signaling, 
and counteract the CF fluid secretory defect, principally by reducing sodium uptake through 
NHE3. In contrast, dysbiosis and inflammation may attenuate GCC activity and promote further 
luminal dehydration. To test these different scenarios, we assessed the expression of GN, UGN, 
and GCC along the intestinal tract of CF mice and littermate controls. 
Materials and methods 
Animals  
 CF mice (Cftrtm1Cam; FVB) and littermate controls were maintained in an environmentally 
controlled facility at the Erasmus MC, Rotterdam. Animals were reared on a low fiber diet 
(C1013; Altromin) and a polyethylene glycol/electrolyte drinking solution to prevent intestinal 
obstruction [20]. All experiments were performed on animals >12 weeks of age, and were 
approved of by the Ethical Committee for Animal Experiments of the Erasmus MC. 
Tissue collection  
 Prior to tissue collection, animals were weaned of the osmotic laxative and kept on 
normal drinking water for >4 days. Animals were anaesthetized (ketamine 100 mg/kg, xylazine 
20 mg/kg; i.p.), and the intestinal tract was collected and flushed with ice-cold saline. Sampling 
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from a CF mouse and a sex-matched littermate control was performed within a time window of 
20 min, and between 12:00-14:00h, to control for diurnal variations in gene expression. 
 For assessing the partitioning of transcript along the rostrocaudal axis of the intestinal 
tract, segments (length: 0.5 cm) were excised from small intestine and the colon. The small 
intestine was sampled 1 cm caudal to the pyloric sphincter (duodenum), half-length (jejunum) 
and at 6 and 1 cm proximal to the ileocecal valve (ileum). Colon was sampled at 1/3 of its entire 
length. Tissue was flash frozen in liquid nitrogen and stored at -80°C.  
Organoid culture 
 Organoids were derived from mouse ileum, and cultured in serum-free medium 
containing epidermal growth factor, noggin, and R-spondin, as described in detail elsewhere 
[21].  
Quantitative Polymerase Chain Reaction (qPCR) and transcriptome sequencing 
 Tissue and organoids were homogenized with a rotor-stator homogenizer in Trizol 
reagent (Qiagen), and total RNA was extracted using the Nucleospin kit (Macherey-Nagel). 
After the integrity of the extracted RNA was verified by gel electrophoresis, cDNA was 
synthesized using the PrimeScript RT master mix (Takara Bio).  
 Quantitative PCR (primer sequences in Table S1) was performed on cDNA, using the 
SYBR Select master mix (Applied Bio System). Median values from assays performed in 
triplicate were used to determine the expression levels of Guca2a (GN), Guca2b (UGN) and 
Gucy2c (GCC), relative to Gapdh. To correct for regional differences in gene expression in the 
distal small intestine, mean values of the relative expression levels at the 2 ileal sampling 
locations are presented.  
 Transcriptome sequencing was performed at the Beijing Genomics Institute (BGI). In 
brief, mRNA was isolated from total tissue or organoid RNA extracts (200 ng), fragmented, and, 
subsequently used for cDNA synthesis. The resulting cDNA library was sequenced using an 
HiSeq 2000 sequencer (TruSeq SBS KIT-HS V3; Illumina). Data analysis was performed using 
CLC genomic workbench 7.5 (CLC Bio), and the sequence reads were mapped to the Genome 
Reference Consortium (GRC) genome data set GRCm38.76, using default parameters. Data 
depict reads per 1000 base pair transcript per million mapped reads (RPKM). Data are available 
through the NCBI-GEO record GSE92991. 
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Western Analysis 
 Epithelial cell lysates were prepared from 6 cm sections of the distal ileum. The segment 
was cut open lengthwise and cut in to sections of circa 5 mm in length. Sections were 
extensively washed in ice-cold phosphate buffered saline (PBS), supplemented with a protease 
inhibitor cocktail (Roche), and subsequently incubated with EDTA (2.5 mmol/L) in 20 mL PBS 
(4°C), on a bench-top roller to dissociate the epithelial cell layer. After 30 min, dissociation was 
completed by brief, vigorous shaking, and crypt/villus fragments and single cells were filtered 
through a cell strainer (70 µm) to remove tissue debris. Subsequently, the filtered epithelial 
fraction was collected by centrifugation (300x g, 5 min) and lysed by brief sonication in ice-
cooled lysis buffer, NaCl (150 mmol/L), Tris/HCl pH 7.6 (25 mmol/L), Triton X100 (1%), 
sodium deoxycholate (1%), SDS (0.1%), NaF (5 mmol/L), Na3VO4 (3 mmol/L), supplemented 
with protease inhibitor cocktail. Lysates were subjected to SDS-PAGE, and proteins were 
transferred to nitrocellulose membrane. GN and UGN prohormone was detected by Western 
analysis, using the previously characterized antisera #2538 and #6910, respectively [22, 23]. 
Detection of β-actin served as loading control (SC47778; Santa Cruz).  
Statistical Analysis 
 The statistical significance of differences between mean expression levels of Guca2a, 
Guca2b and Gucy2c in CF and wildtype tissue was analyzed by one-way Anova followed by 
Bonferroni’s multiple comparison test on selected pairs of data sets (Graphpad Prism 5, 
Graphpad Software). The statistical significance of differences between transcript levels was 
analyzed using the (paired) ratio t-test. 
Results 
Reduced expression of Guca2a, Guca2b and Gucy2c in the CF intestine  
 We assessed expression of Guca2a, Guca2b and Gucy2c along the rostrocaudal axis of 
the intestinal tract, in CF mice (Cftr -/-) and littermate controls (Cftr N/N). We noted that, in the 
distal small intestine, expression of all 3 genes was >2-fold lower in CF mice than in control 
littermates (Figure 1). In contrast, expression in other parts of the intestinal tract was comparable 
between CF mice and controls, except that Guca2b expression was also moderately lowered in 
the jejunum of CF mice (Figure 1). The rostrocaudal distribution pattern of Guca2a, Guca2b and 
Gucy2c observed, matches with previous reports on the partitioning of these transcripts in rat and 
mouse intestine [4, 5, 24, 25]. Our transcriptome analysis showed that Guca2a and Guca2b rank 
among the most highly expressed genes in mouse ileum, and confirmed that their transcript 
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levels are markedly lower in CF mice, compared to controls (not shown). The levels of Gucy2c 
transcript were considerably lower than of its ligands, and peaked in the distal part of the 
intestinal tract (Figure 1c). 
 To assess whether such marked reductions in transcript levels translate to lowered protein 
levels, we quantified the levels of the secreted precursors of GN and UGN in intestinal epithelial 
cells by Western analysis. This analysis showed that the levels of pro-GN and pro-UGN present 
in ileal tissue of CF mice were markedly lower than in the corresponding samples of littermate 
controls (Figure 2).  
 Previously, we have shown that, in the distal small intestine, Guca2a and Guca2b are 
expressed by Paneth cells and other cells of the secretory lineage, and by mature columnar cells 
in the upper (villus) regions of the epithelium [5]. Because CF was shown to affect both 
proliferation and apoptosis in the intestinal epithelium, we considered that CF may lead to a 
Figure 1 Expression of Guca2a (A), Guca2b (B), and Gucy2c (C) in the small intestine and colon 
of CF mice (Cftr -/-) and littermate controls (Cftr N/N) was assessed by qPCR. N=5-6. Values 
depict mean ± standard error. ** P < 0.01; *** P < 0.001 
 
Figure 2 GN and UGN prohormone level in the distal small intestine of CF mice and controls. 
Western analysis of pro-GN and pro-UGN was performed on epithelial cell lysates prepared 
from ileum of CF animals (-/-) and sex-matched littermate controls (N/N). For quantitation, 
signal intensity was normalized against the β-actin signal of the same sample. The bar graph 
shows protein abundance in Cftr -/- animals relative, to controls. N = 4. * P < 0.05 
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relative reduction in specific GN or UGN producing cell types [26, 27]. However, we have 
previously assessed transcript levels of typical villus markers (i.e. genes which are highly 
expressed in the villi, relative to the crypts) and found no evidence for delayed cell maturation in 
the CF ileum (Chapter 3). Further, transcriptome analysis showed that the expression of 
transcription factors that direct differentiation to the secretory (granulocytic) lineage (Atoh1, 
Klf4, Sox9 and Spdef), or of typical enteroendocrine cell markers (Chga, Lyz1) was not reduced 
in the CF ileum, which argues against a specific reduction in GN and/or UGN producing cells of 
the secretory lineage (Figure 3) [28, 29]. Consistent with these findings, we found that goblet 
cell numbers were normal or even slightly increased in the CF ileum, compared to control tissue 
(Figure S1). 
 Next, we asked whether these apparent changes in the expression of Guca2a, Guca2b and 
Gucy2c are intrinsic to loss of CFTR anion channel function, or may be caused by secondary 
disease manifestations (e.g. inflammation, dysbiosis). We reasoned that if it is an epithelial-
autonomous defect, it should be preserved in primary cultures of CF intestinal epithelial cells. 
Therefore, we obtained organoid cultures from ileal stem cells, to determine transcript levels of 
Guca2a, Guca2b and Gucy2c in intestinal epithelial cells in the absence of confounding 
environmental factors. A paired comparison of CF and control organoids (obtained from 
littermates) showed that the differences in gene expression between genotypes observed in native 
tissue were lost in cultured epithelial cells (Figure 4). 
Antibiotic treatment corrects Guca2a and Guca2b expression in the CF intestine 
 Because differences in expression of the GCC signaling axis between CF and control 
ileum are lost in organoid cultures, we hypothesized that changes in the intestinal environment 
secondary to loss of CFTR function, and absent under cell culture conditions, prompt Guca2a 
and Guca2b down-regulation. One such factor may be inflammation of the gut wall, which 
Figure 3. Transcript levels of 
selected genes in the distal small 
intestine of CF mice and controls 
that are specifically expressed in 
cells of the secretory lineage (Atoh1, 
Klf4, Sox9, Spdef), enterochromaffin 
cells (Chga), and Paneth cells 
(Lyz1). N = 3. 
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previously has been shown to lead to down-regulation of GN and UGN in the setting of 
inflammatory bowel disease (IBD) [18, 19]. In CF, inflammation of the gut wall is thought to 
result from small intestinal bacterial overgrowth (SIBO), and aberrant Paneth/goblet cell 
function and mucus production/unfolding [1, 30, 31]. Indeed, transcriptome analysis clearly 
indicated the activation of an (innate) immune response in the CF ileum, as many genes involved 
in host-pathogen interactions were up-regulated, including those encoding the lipopolysaccharide 
co-receptor CD14, and the antimicrobial peptides muclin (Dmbt1),  REG3β/γ and RELM-β 
(Retnlb; Figure 5). 
 To investigate whether dysbiosis is involved in the down-regulation of the GCC signaling 
axis, we treated CF mice with antibiotics. The antibiotic regimen applied has previously been 
shown not to fully eradicate the microbiota but to reduce bacterial overgrowth and increase 
community diversity in CF mice [32]. We found that this mild regimen increased the expression 
of both Guca2a and Guca2b in the CF ileum, up to the level observed in antibiotic-treated 
control mice, in which antibiotics did not increase Guca2a or Guca2b expression (Figure 6). 
Figure 4. Transcript 
levels of selected genes 
involved in host-pathogen 
interactions in the distal 
small intestine of CF mice 
and controls. * P < 0.05; 
** P < 0.01; N = 3. 
Figure 5. Transcript numbers of 
Guca2a, Guca2b, and Gucy2c in 
organoids derived from ileum of CF 
(Cftr -/-) and wildtype (Cftr N/N) 
mice.  
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Discussion 
 GN and UGN are highly abundant intestinal luminocrine factors that control intestinal 
fluid transport by stimulating epithelial salt and fluid secretion. The key finding of our study is 
that the expression of both of these peptides is markedly reduced in the CF intestine, in particular  
in the distal small intestine. We surmise that diminished production of GN and UGN, by 
reducing GCC activity and cGMP production, may contribute to the dehydration and 
acidification of the CF intestine.  
 It has been shown previously that the dissolution of secretory granules produced by 
Paneth cells is impaired in CF mice [31]. This was associated with a concurrent downregulation 
of genes encoding some of the antimicrobial peptides produced by this cell type, and it was 
proposed that impaired post-exocytotic processing of secretory granules might exert feedback 
control on gene expression [31]. Because this cell lineage is an important source of GN and 
UGN, it is conceivable that the reduction in Guca2a and Guca2b transcript levels shown here 
are, similarly, caused by defects in the process of exocytosis, and feedback control on gene 
expression [5]. For goblet cells (a source of GN in mice), defects in the release and processing of 
secretory granules have been attributed to impaired regulation of the pH of the secretory granules 
and their luminal environment, which appears to link these defects directly to loss of CFTR 
activity [30]. However, we observed that Guca2a and Guca2b down-regulation was resolved in 
cultured epithelial cells, which argues against an intrinsic cellular defect. Instead, this suggests 
that changes in the intestinal environment secondary to loss of CFTR function, and lost in 
organoid cultures, prompt down-regulation of GCC signaling.  
Figure 6. Effect of antibiotic treatment on expression of Guca2a and Guca2b in the ileum of CF 
mice and controls. Two-way ANOVA indicated a statistically significant interaction between 
antibiotic treatment and Cftr genotype for Guca2a and Guca2b, expression, implying that loss 
of CFTR affects the response to antibiotic treatment. ** P < 0.01; N = 4-6 
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 Indeed, the observation that antibiotic treatment normalized Guca2a and Guca2b 
expression in CF mice suggests that CF-related changes in the gut microbiota play a role in the 
repression of these genes. Congruently, it was shown that colonization of the gut by a gram-
negative pathogen, Citrobacter rodentium, markedly represses Guca2a expression in mouse 
colon [11]. Conversely, this study also showed that GCC deficiency aggravates the deleterious 
effects of C. rodentium infection on the intestinal epithelium, implying a role of the GCC 
signaling axis in the innate immune response to enteric pathogens. Consistent with such a role, 
we found that acute exposure of intestinal epithelium to lipopolysaccharide (ex vivo), a product 
of gram-negative bacteria, moderately induced Guca2a and Guca2b (unpublished data). Thus, 
these results suggest that the initial response to bacterial pathogens is an activation of GCC 
signaling, but that prolonged colonization, possibly through the attendant inflammatory response, 
leads to attenuation of GCC signaling. That chronic inflammation may down-regulate the GCC 
signaling axis is also suggested by the observation that, in patients suffering from IBD, 
expression of GN and UGN is generally low [18, 19]. 
 Reduced GCC signaling in CF intestine may have several consequences for CF 
pathology. Foremost, loss of GCC/cGMP-dependent NHE3 inhibition may enhance sodium and 
water uptake, and reduce the extracellular pH [33]. Furthermore, it has been shown that some 
UGN-dependent bicarbonate secretion persists in Cftr null mice [34]. This UGN-dependent, 
CFTR-independent bicarbonate secretion will be reduced by low GCC stimulation, and this may 
further contribute to the deregulation of luminal pH in CF. These effects are expected to 
aggravate the mucus inspissation and dehydration of the luminal surface that typifies CF. They 
may also contribute to the dysbiosis that is common in CF, as GCC is a key component of the 
host defense response triggered by enteric pathogens [11]. In this context, it is of interest that 
down-regulation of the GCC signaling axis is most evident in the distal small intestine, which 
seems especially predisposed to develop obstruction and SIBO.  
 Secondly, GCC signaling, through activation of the cGMP-dependent protein kinase 
PRKG2, modulates cell cycle progression in intestinal epithelium [3, 35]. Mice deficient in GN, 
GCC or PRKG2 show signs of enhanced proliferation, and subtle changes in the cellular 
composition of the epithelium [36-38]. Consistent with impaired GCC signaling, the intestinal 
epithelium of CF mice also displays enhanced cell proliferation and/or a reduced rate of 
apoptosis [26, 27].  
 In summary, our data suggest that CF may be associated with impaired GCC signaling 
resulting from reduced intestinal GN and UGN production. Impaired GCC signaling may 
contribute to the intestinal manifestations of CF, like luminal dehydration and acidification. 
Impaired GCC signaling in CF mice 
103 
Because the GCC receptor, except for distal small intestine, is normally expressed in the CF 
intestine, GCC signaling may be enhanced by (oral) supplementation with exogenous ligands 
[39]. Such treatment may compensate for the shortage of endogenous ligand, repress sodium 
absorption and partly restore the intestinal fluid balance. In addition, it may have a beneficial 
effect on mucin unfolding and the gut microbiota.  
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Supplementary data 
Supplementary materials and methods 
Histochemical detection of goblet cells 
 Paraffin sections (5µm) were stained (30 min) with Alcian blue solution (1% Alcian blue 
8GX in 3% acetic acid solution, pH 2.5), washed in water, and subsequently counterstained (5 
min) with nuclear fast red solution (0.1% nuclear fast red, 5% aluminum sulfate). After rinsing in 
water, sections were mounted in Pertex mounting medium (Histolab Products AB), and stored at 
room temperature. 
 
Table S1  
Sequence of the primers used for qPCR.  
Genes Accession Forward primer Reverse Primer 
Guca2a NM008190.1 GATCCTGCAGAGGCTAGAGG AAGGCAAGCGATGTCACTCT 
Guca2b NM008191.2 AGGAGATGTCCAATCCCCAG ACAGTTCACATTCGTCGGTGG 
Gucy2c NM001127318.1 TGTGAACGCGACTTTCATCTAC GCAGCCCATCTTATGATCTCTTG 
Gapdh NM008084.3 TTCCAGTATGACTCCACTCACGG TGAAGACACCAGTAGACTCCACGAC 
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Supplementary results 
Figure S1. Detection of goblet cells in mouse ileum. Representative tissue sections of a 
CF animal (Cftr -/-) and littermate control (Cftr N/N) were stained with Alcian blue to 
identify the mucopolysaccharide containing goblet cells (blue staining). (original 
magnification: 20x) 
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Summary 
 Bile acid (BA) metabolism is regulated by the BA-activated farnesoid X receptor (FXR), 
which controls hepatic BA synthesis and cell proliferation via the intestinal hormone fibroblast 
growth factor 19 (FGF19). Because cystic fibrosis (CF) is associated with anomalous BA 
handling and biliary cirrhosis, we investigated FXR signaling in CF. We found that ileal Fgf15 
(the murine FGF19 ortholog) expression was markedly lower in CF (Cftr null) mice than in 
controls, although luminal BA composition, and expression and localization of the apical 
sodium-dependent BA transporter were not affected. Ex vivo, BAs induced Fgf15 up to normal 
levels in the CF ileum, but suppression was reinstated when tissue was exposed to bacterial 
lipopolysaccharide (LPS). Transcriptome sequencing and pathway analysis revealed a marked 
activation of the innate and adaptive immune responses in the CF intestine, and indicated LPS-
provoked inhibition of signaling through FXR’s obligate heterodimeric partner, the retinoid X 
receptor (RXR). Antibiotic treatment reversed the up-regulation of inflammatory markers, and 
restored intestinal FXR/RXR-signaling. Loss of intestinal FXR/RXR activity was associated 
with a markedly blunted hepatic trophic response to oral BA supplementation, and with impaired 
repression of Cyp7a1, the gene encoding the rate-limiting enzyme in BA synthesis. We conclude 
that, in CF mice, the gut microbiota suppresses intestinal RXR activity, and, consequently, FXR-
dependent hepatic cell proliferation and feedback control of BA synthesis.  
 
KEYWORDS  Bile acids and salts; Gut microbiota; Fibroblast Growth Factors; 
Receptors, Cytoplasmic and Nuclear  
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Introduction 
 Bile acids (BAs) are amphiphilic molecules synthesized from cholesterol in the liver. 
Upon release into the proximal small intestine, BAs aid the absorption of dietary lipids, after 
which they are reabsorbed, mainly through active uptake in the distal ileum via the apical 
sodium-dependent BA transporter (ASBT; encoded by SLC10A2) [1]. Although very little of the 
load entering the intestine escapes re-uptake, small amounts of BA pass through the colon and 
are excreted in the feces. Fecal loss is compensated for by de novo synthesis, which is regulated 
through a finely tuned homeostatic control mechanism, to maintain a near constant body BA 
pool. One of the key elements of this control mechanism is the activation of the farnesoid X 
receptor (FXR) in ileal epithelial cells by reclaimed BAs [2, 3]. Intestinal FXR activation 
induces the expression of an array of genes involved in BA transport and metabolism. Most 
importantly, BA reabsorption triggers the production and release of fibroblast growth factor 19 
(FGF19). This hormone, through activation of its hepatic receptor (FGFR4), represses expression 
of CYP7A1, the gene encoding the cholesterol 7α-hydroxylase that catalyzes the rate-limiting 
step in cholic acid (CA) synthesis [4]. The importance of this feedback loop is underlined by the 
observation that in FGF15 (the murine FGF19 ortholog) deficient mice, hepatic BA synthesis 
and intestinal delivery are stimulated to a level that exceeds the capacity for reabsorption, 
resulting in enhanced fecal excretion [5]. In addition, FGF15/19 has trophic effects in the liver, 
which are crucial for liver regeneration after injury [6, 7]. Through its effects on hepatic BA 
synthesis and cell proliferation, FGF15/19 signaling may prevent cholestasis-induced liver 
damage [8].  
 Cystic fibrosis (CF), an autosomal, recessive disease caused by mutations in the CF 
transmembrane conductance regulator (CFTR) gene, is characterized by focal biliary cirrhosis, 
which in a subgroup of patients (circa 30%) progresses to a clinically significant, advanced stage 
of CF-related liver disease (CFLD) [9]. Principally, this cholangiopathy is thought to be caused 
by obstruction of the intrahepatic bile ducts by mucoid secretions and accumulation of 
hydrophobic BAs, but other factors, like exposure to gut-derived endotoxins, may also contribute 
[9-11]. Bile of CF patients shows a relative increase in CA levels and a decrease in the levels of 
secondary BAs, which is indicative of enhanced de novo synthesis [12]. This is also implied by 
the observation that the body BA pool size of CF patients is normal to large, despite the fact that 
in many, fecal BA excretion is abnormally high [12]. Fecal BA wasting, high biliary CA levels, 
and a mild cholangiopathy are also observed in most CF mouse models [13-15]. These 
observations suggest that, perhaps because of interrupted enterohepatic cycling of BAs, the 
FXR/FGF19 signaling pathway is suppressed in CF. Indeed, strongly reduced ileal Asbt and 
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Fgf15 expression, indicative of reduced BA uptake and FXR activation, was reported for one CF 
mouse model [16]. In this instance, low FXR/FGF15 signaling was attributed to defective 
gallbladder emptying, which severely limited intestinal delivery of BAs. Further, more 
circumstantial, evidence for attenuated FXR/FGF15 signaling in CF is provided by one of our 
previous studies, in which it was shown that dietary CA supplementation, which is known to 
induce hepatocyte proliferation through an FXR/FGF15-dependent pathway, triggers a markedly 
blunted response in CF mice [6, 7, 17]. Assuming that the virtual absence of this response in our 
CF mice is indeed linked to a low intestinal FGF15 production, our data imply that enhanced 
intestinal delivery of BAs (as per diet) does not fully correct FXR/FGF15 signaling. This led us 
to speculate that, apart from defective gallbladder emptying, other factors may contribute to 
impaired FXR/FGF15 signaling.  
 In recent years it has become apparent that the gut microbiota, through modulation of 
intestinal FXR signaling, is a key regulator of BA metabolism. In mice, intra-luminal microbial 
BA conversion appears to be a key determinant of BA uptake and FXR activity, as both 
eradication of the microflora and colonization of the gut by probiotics were shown to markedly 
repress Fgf15 induction [18-20]. Further, it was shown that bacterial endotoxins, by activation of 
the nuclear factor κB (NFκB) pathway, repress hepatic FXR signaling, and that FGF15 
production is reduced in inflamed intestinal tissue [21-23]. Because murine CF models display 
distinct quantitative and qualitative changes in the gut microbiota (dysbiosis) and inflammation 
of the gut wall [24-26], it is conceivable that BA biotransformation or exposure to endotoxins 
leads to a loss of FXR-dependent feedback control of hepatic BA synthesis.  
 Presently, we have investigated the role of the gut microbiota in intestinal FXR signaling 
in CF mice. We show that intestinal FXR signaling is markedly attenuated in CF mice, despite 
normal luminal BA levels, and that repression of FXR signaling persists upon supra-
physiological BA dosage, but that constraining bacterial colonization by antibiotic treatment 
reduces the expression of inflammation markers and normalizes Fgf15 expression and BA 
synthesis. 
Results 
Intestinal FXR signaling is impaired in CF mice  
 The expression of FXR targets Fgf15 and Shp (Nr0b2) was markedly lower in the ileum 
of CF mice as compared to littermate controls, whereas expression of Fxr (Nr1h4) itself was 
similar between genotypes (Figure 1A). Congruent with low intestinal FGF15 production, 
hepatic expression of Cyp7a1 was enhanced in CF mice.  
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 We hypothesized that a shortage of activating ligands may have attenuated FXR 
signaling, possibly as a result of reduced ASBT-mediated BA uptake. Therefore, we assessed the 
expression and localization of ASBT. In the distal ileum, the mRNA level of Asbt (Slc10a2) was 
similar in CF mice and controls (Figure 1B). A high ASBT protein abundance was detected in 
ileal brush border membrane preparations of CF mice and controls (Figure 1C). By 
immunohistochemistry, ASBT was localized at the apical plasma membrane of enterocytes in the 
villi, and this pattern was unaffected by CFTR deficiency (Figure 1D). When ileal tissue sheets 
of CF mice and controls were exposed to TC, Fgf15 was induced to a similar extent in both 
groups (Figure 1E). These findings argue against a primary defect in cellular BA uptake.  
Figure 1 FXR activity, ASBT localization, and TC-dependent gene induction in the CF ileum. A. 
Expression of Fxr and its target genes, Fgf15 and Shp, in the ileum, and of Cyp7a1 in the liver of CF 
mice (Cftr -/-) and controls (Cftr N/N). Data represent expression in a CF animal relative to an age/sex-
matched littermate control. aA (paired) ratio t test indicated that Fgf15 (p = 0.005) and Shp (p = 0.006) 
expression were significantly reduced in CF mice, relative to controls, whereas expression of Cyp7a1 
was increased (p = 0.002). Fxr expression was not affected.  n = 5-8. B. Expression of Asbt in ileum of 
CF mice (Cftr -/-) and controls (Cftr N/N). C. ASBT protein was detected in brush border membranes 
prepared from CF (-/-) and control (N/N) ileum. Both the monomeric (46 kDa) and dimeric form were 
detected. Numerals to the left of the blot refer to the molecular mass (kDa) of protein standards. D. 
Immunohistochemical detection of ASBT. ASBT was localized at the apical aspect of epithelial cells of 
the villi in CF mice (Cftr -/-) and controls (Cftr N/N). E. Induction of gene expression by TC in ileal 
tissue sections of CF mice (Cftr -/-) and controls (Cftr N/N). bTwo-way ANOVA indicated that TC 
treatment significantly enhanced Fgf15 expression (p = 0.01), independent of genotype. n = 3-5. 
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CFTR deficiency affects the composition, but not the size, of the luminal BA pool 
 Because, ex vivo, FXR could be fully activated by exogenous BAs, we hypothesized that, 
in vivo, FXR activation may be curtailed by a low luminal BA level, as was suggested previously 
[16]. Therefore, we assessed the levels of the major BAs in the small intestinal lumen and in 
gastrointestinal tissues. This analysis showed that the BA content of the small intestinal lumen 
was similar in CF mice and controls (Figure 2A). The total amount of BA contained in the 4 
compartments analyzed (representing most of the total pool) was also similar between genotypes. 
However, the composition of the luminal BA pool was changed by CFTR deficiency: β-MCA 
levels were markedly lower, whereas CA levels were higher than in control mice (Figure 2B). 
We have previously observed that hepatic CA synthesis is enhanced in CF mice, leading to a 
similar shift in the biliary β-MCA/CA ratio [15]. Low ileal Fgf15 expression, enhanced hepatic 
BA synthesis, and low biliary β-MCA/CA ratios have been linked to enhanced intra-luminal 
conversion (deconjugation, dehydroxylation) of BAs upon gut microbiota modulation by 
probiotic bacterial strains [20]. Because CF mice display a distinct dysbiosis [24], it is 
conceivable that the reduced β-MCA/CA ratio observed in CF mice, similarly, results from 
enhanced BA biotransformation, interrupted enterohepatic cycling and increased de novo 
synthesis. However, arguing against enhanced intraluminal biotransformation, the level of the 
secondary BA deoxycholic acid (DCA) in the small intestinal lumen was similar in CF mice and 
controls (Figure 2B). Therefore, whereas the luminal BA composition in CF mice is indicative of 
enhanced hepatic BA synthesis, in line with attenuated FXR/FGF15 signaling, it does not 
provide evidence for reduced intestinal BA delivery or enhanced BA biotransformation. 
Figure 2 Partitioning of BAs in gastrointestinal tissues and composition of the luminal BA 
pool. A. BA content, normalized to body mass, of the small intestinal lumen and 
gastrointestinal tissues in CF mice (Cftr -/-) and controls (Cftr N/N). The total levels 
shown are a summation of the 4 separate compartments analyzed. B. The relative 
contribution of the major BAs to the luminal pool. *p < 0.05, **p < 0.01, n = 4. 
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Antibiotic treatment corrects FXR signaling in CF mice 
 In view of the tentative role of the gut microbiota in the regulation of FXR activity in CF 
mice, we assessed the effect of antibiotic treatment on FXR signaling. Previously, it was shown 
that complete eradication of the microflora strongly reduces Fgf15 expression, as the gut 
microbiota appears to control the level of the FXR antagonist tauro-β-MCA [18]. Therefore we 
applied an antibiotic regimen that was previously shown not to fully eradicate the microflora, but 
to reduce small intestinal bacterial overgrowth, and increase bacterial community diversity in CF 
mice [25]. We found that, in CF mice, Fgf15 and Shp expression were markedly enhanced by 
this particular regimen, up to the level observed in control animals, in which antibiotic treatment 
did not induce Fgf15 or Shp (Figure 3A). In fact, antibiotic treatment appeared to moderately 
reduce the expression of Fgf15 in controls, which may indicate that even this mild regimen leads 
to increased tauro-β-MCA levels and suppression of FXR activity. If present, this antagonistic 
action of tauro-β-MCA is apparently offset by a dominant FXR stimulatory effect in CF mice. 
Concomitant with induction of Fgf15, hepatic expression of Cyp7a1 was reduced in CF mice 
(Figure 3B). These results strongly suggest that a CF-related dysbiosis, that is lost or reduced 
after antibiotic treatment, impairs intestinal FXR signaling. 
 
Figure 3 The effect of antibiotic treatment on intestinal and hepatic gene expression. A. The 
effect of antibiotic treatment on ileal Fgf15 and Shp expression in CF mice (Cftr -/-) and 
littermate controls  (Cftr N/N). aTwo-way ANOVA indicated a statistically significant interaction 
between antibiotic treatment and Cftr genotype for Fgf15 expression (p = 0.03), implying that 
loss of CFTR affects the response to antibiotic treatment. n = 4-6. B. The effect of antibiotic 
treatment on hepatic Cyp7a1 expression. bAntibiotic treatment reduced Cyp7a1 expression (p 
= 0.02). n = 3-8. 
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Bacterial LPS abrogates FXR-dependent Fgf15 induction 
 We considered that, apart from through its effect on BA biotransformation and uptake, 
the CF microbiota may reduce FXR activity via other mechanisms. Previously, it was shown that 
the activity of the retinoid X receptor (RXR) in the liver is attenuated by specific cytokines that 
are produced upon exposure to bacterial LPS [27-29]. As FXR forms an obligate heterodimer 
with RXR, we hypothesized that LPS may also impair intestinal FXR/RXR function. To test this 
hypothesis, we assessed the effect of LPS on Fgf15 induction by the synthetic FXR agonist 
GW4064. These experiments showed that LPS exposure completely abrogated GW4064-
dependent Fgf15 expression in the ileum (Figure 4). These results are consistent with a previous 
study showing that pro-inflammatory cytokines (IL-1β, TNFα) suppress FXR activity in mouse 
ileum through an NFκB-dependent route [30], and indicate that the gut microbiota may suppress 
FXR/RXR signaling by triggering an endotoxin-provoked inflammatory response. 
The ileal CF transcriptome reveals impaired RXR function  
 To assess whether bacterial endotoxins also suppress FXR/RXR activity in the CF 
intestine, in vivo, we performed transcriptome sequencing, followed by Ingenuity® Pathway 
Analysis (IPA), to identify canonical signaling pathways that were differentially regulated in CF 
ileum, compared to control tissue. Our model predicts that Toll-like receptor (TLR)-mediated 
activation of the NFκB and cJun-N-terminal kinase (JNK) pathways not only attenuates FXR 
signaling, but also signaling through other RXR binding partners [27-29, 31]. Because RXR 
forms obligate heterodimers with most lipid-sensing nuclear receptors, loss of its function is 
expected to impinge on the transcriptional regulation of many genes involved in BA and lipid 
metabolism. 
 Firstly, the IPA confirmed that FXR signaling was impaired in CF mice, as many 
differentially regulated FXR target genes were identified, including Fgf15 and Shp (Figure 5A, 
Figure 4 Bacterial LPS inhibits FXR-
dependent Fgf15 induction in mouse 
ileum. Induction of Fgf15 expression 
by GW4064 in the presence or 
absence of LPS. Data depict the 
level of gene expression relative to 
the level of expression in the 
absence of GW4064. **p < 0.01, n = 
4. 
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Table S2). Further, it provided compelling evidence for the activation of an immune response in 
the CF intestine, as exemplified by the up-regulation of many genes involved in antigen 
presentation (Figure 5A, Table S2). In fact, many of the most strongly up-regulated genes in the 
CF ileum are involved in host-microbe interactions and host defense, including NFκB-inducible 
chemokines and acute phase proteins, the alarmin IL-33, and the fucosyltransferase 2, which is 
induced by bacterial colonization of the gut, and was previously shown to increase mucin 
fucosylation in CF mice (Figure 5B) [32-34]. In line with the up-regulation of these immune 
response markers, upstream regulator analysis (URA) indicated strong activation of LPS- and 
cytokine-mediated, NFκB-dependent pro-inflammatory signaling in the CF ileum (Figure 5C).  
 Importantly, URA also indicated a concomitant marked inactivation of RXR heterodimer 
nuclear receptors, and many genes involved in lipid metabolism and transport appear to be 
dysregulated in the CF ileum (Figure 5C, Table S2). Of interest, this set includes the peroxisome 
proliferator activated nuclear receptor γ (PPARγ), which inactivation has previously been linked 
to CF intestinal disease (Figure 5C, Figure S1) [35]. The IPA suggests that repression of RXR is 
triggered by exposure to LPS and pro-inflammatory cytokines (Figure 5D). These data imply 
that CF is associated with an overall reduction in RXR-dependent signaling, which extends to 
nuclear receptors that are activated by ligands other than (conjugated) BAs. However, the 
expression of these receptors was unaffected, except for Ppara (Figure S2). 
 To substantiate the role of the CF-related dysbiosis in the pathogenesis of impaired 
FXR/RXR signaling, we performed transcriptome sequencing and IPA/URA on tissue from mice 
that were treated with antibiotics. As already indicated by our analysis of Fgf15 and Shp 
expression, antibiotic treatment enhanced FXR signaling in CF mice (Figure 6A, Table S3). 
Further, antibiotic treatment suppressed the inflammatory response in the CF intestine, as 
exemplified by the down-regulation of genes involved in antigen presentation (Figure 6A, Table 
S3), host-microbe interactions, and host defense (Figure 6B). As expected, antibiotic treatment 
also affected the innate and adaptive immune response in control mice, but its effect on gene 
expression was generally more moderate than in the CF mice (Figure 6B). In CF mice, 
repression/reversal of the immune response after antibiotic treatment was also evident from the 
URA, showing inactivation of LPS- and cytokine-mediated, NFκB-dependent pro-inflammatory 
signaling, whereas signaling through RXR heterodimer nuclear receptors was restored (Figure 
6C). Accordingly, IPA indicated that antibiotic treatment alleviates the repression of RXR 
function, imposed by LPS and pro-inflammatory cytokines (Figure 6D, Table S3). These results 
suggest that a CF-related dysbiosis represses RXR function, and, consequently, FXR signaling. 
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 In a murine colitis model, it was shown that glucuronic acid conjugation of BAs is 
enhanced in inflamed tissue and that this prevents FXR activation [22]. An up-regulation of 
UDP-glucuronosyltransferase encoding genes was shown to be the crucial step in this 
mechanism. To assess the role of glucuronic acid conjugation in the CF-related FXR signaling 
Figure 5 Differentially regulated signal transduction pathways in the ileum of CF mice and 
controls. A. The ileal transcriptome of CF mice and controls was compared by IPA. 
Regulation of canonical pathways involving FXR/RXR function and antigen presentation 
were significantly affected by CF. B. Expression of genes involved in host-microbe 
interactions and host defense in the ileum of CF mice (Cftr -/-) and controls (Cftr N/N), 
assessed by transcriptome sequencing. Data depict reads per 1000 base pair transcript 
per million mapped reads (RPKM). *p < 0.05, **p < 0.01, n = 3. Ccl8: chemokine C-C motif 
ligand 8, Cxcl9: chemokine C-X-C motif ligand 9, Duoxa1/2: dual oxidase maturation factor 
A1/A2, Fut2: fucosyltransferase 2, Il33: Interleukin 33, Ltf: lactotransferrin, Saa1/3: serum 
amyloid A1/A3, Ubd: ubiquitin D (FAT10). C. URA based on ileal gene expression in CF 
mice, relative to controls. D. IPA indicates that repression of RXR in the CF ileum is 
triggered by LPS and IL-1β. Numerals in the pie charts refer to the number of genes 
represented by each segment. Numerals in parentheses are –log(overlap p-value). 
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defect, we determined the level of UDP-glucuronosyltransferase-encoding transcripts in CF mice 
and controls. We found that none of the UDP-glucuronosyltransferases identified were up-
regulated, suggesting that glucuronic acid conjugation of BAs is not enhanced in the CF intestine 
(Figure S3). 
 
Figure 6 Effect of antibiotic treatment on differentially regulated signal 
transduction pathways in the ileum of CF mice. A. The ileal transcriptome of 
antibiotic-treated and conventionally reared CF mice was compared by IPA. 
Regulation of canonical pathways involving FXR/RXR function, and antigen 
presentation were significantly affected by antibiotic treatment. B. Effect of antibiotic 
treatment on the expression of genes involved in host-microbe interactions and host 
defense in CF mice (Cftr -/-) and controls (Cftr N/N), as assessed by transcriptome 
sequencing. Data denote fold change relative to the expression in conventionally 
reared animals. $Not detected in antibiotic treated tissue. C. URA based on ileal gene 
expression in antibiotic treated, relative to conventionally reared CF mice. D. IPA 
indicates that antibiotic treatment alleviates repression of RXR function in the CF 
ileum. Numerals in the pie charts refer to the number of genes represented by each 
segment. Numerals in parentheses are –log(overlap p-value). 
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Impaired intestinal FXR signaling reduces BA-dependent hepatic cell proliferation  
 FGF15-dependent hepatic cell proliferation was shown to promote liver regeneration 
after injury, and it was proposed that this intestine-liver signaling axis also drives homeotrophic 
liver growth/repair [6, 7, 36]. It was shown that, through activation of this axis, dietary CA 
supplementation increases liver mass [36]. 
 To investigate whether impaired FXR/RXR signaling in the CF intestine affects this 
intestine-liver signaling axis, we assessed the effect of dietary CA supplementation on liver 
mass, and intestinal and hepatic expression of FXR target genes. We found that CA 
supplementation induced Fgf15, and enhanced production of FGF15 protein in both genotypes, 
but that this effect was markedly more pronounced in control than in CF mice (Figures 7A, 7B). 
In control mice, the strong stimulation of FGF15 production elicited by CA supplementation was 
associated with a marked increase in liver mass (Figure 7C). In contrast, in CF mice, this trophic 
response was lost completely. In accord with the low FGF15 production observed in CF mice, 
Cyp7a1 expression was much less effectively suppressed in CA fed CF mice than in controls 
(Figure 7D). However, the regulation of genes that are controlled (predominantly) through 
hepatic FXR was not affected: CA supplementation suppressed Cyp8b1 expression, and induced 
hepatic Shp, to a similar extent in CF mice and controls (Figure 4D) [2, 5, 37].  
 These results demonstrate that dietary CA supplementation fails to correct FXR signaling 
in the ileum, but leads to apparently normal activation of hepatic FXR. The loss of intestinal 
FXR activity markedly reduced the trophic effect of BAs on the CF liver, and impaired the 
feedback regulation exerted on hepatic BA synthesis. Because the CA dose used in these 
experiments was >100-fold in excess of the estimated daily amount entering the intestine through 
biliary secretion and is predicted to saturate the capacity for intra-luminal conversion and 
absorption [38], these data further argue against the notion that biotransformation limits BA 
uptake and FXR activity in CF mice. 
Discussion 
 This study shows that signaling through the BA-activated nuclear receptor FXR is 
markedly impaired in the distal small intestine of CF mice. Impaired intestinal FXR signaling 
compromised FGF15-dependent regulation of hepatic cell proliferation and BA synthesis. This 
defect was associated with an up-regulation of genes involved in the innate and adaptive immune 
response, and suppression of RXR signaling. Antibiotic treatment attenuated the immune 
response, and restored FXR and RXR activity in the CF ileum. Conversely, LPS treatment of 
non-CF ileum elicited a CF-like phenotype, i.e. strong repression of FXR-dependent Fgf15 
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induction. These data suggest that a CF-related inflammatory response suppresses signaling 
through these nuclear receptors. 
 It has been proposed that bacterial modification (deconjugation, dehydroxylation) of 
intraluminal BAs may reduce their uptake via ASBT and, consequently, FXR activity [20]. 
Because CF is associated with small intestinal bacterial overgrowth [24], this model accounts for 
the fact that FXR signaling is impaired in CF mice. Indeed, we observed that suppression of 
bacterial growth (by antibiotic treatment) enhanced FXR signaling, specifically in CF mice, 
Figure 7 The effect of dietary BA supplementation on FXR signaling. CF mice (Cftr -/-) and 
controls (Cftr N/N) were fed a CA-enriched or a conventional diet. A. Induction of intestinal 
Fgf15. aTwo-way ANOVA indicated a significant interaction between CA intake and Cftr 
genotype for the effect on Fgf15 expression (p = 0.0001), implying that loss of CFTR 
affects the response to dietary CA supplementation. Control data as shown in Figure 3. n = 
3-6. B. FGF15 protein was below detection levels in jejunal and ileal tissue of mice fed a 
control diet. CA feeding increased FGF15 levels in both CF mice and controls, but this 
effect was more pronounced in controls. Numerals to the left of the blot refer to the 
molecular mass (kDa) of protein standards. The bar diagram depicts the intensity of the 
fluorescent signal of the FGF15 band relative to the β-actin signal of the same sample. *p < 
0.05, n = 3. C. Effect of CA supplementation on liver mass. bTwo-way ANOVA indicated a 
statistically significant interaction between CA feeding and Cftr genotype for the effect on 
liver mass (p = 0.004), implying that loss of CFTR affects the response to dietary CA 
supplementation. n = 3-6. D. Effect of dietary BA supplementation on hepatic gene 
expression. cTwo-way ANOVA indicated that CA feeding suppressed hepatic Cyp7a1 (p = 
0.001) and Cyp8b1 (p = 0.0001) expression, but enhanced expression of Shp (p = 0.003). 
             
Impaired intestinal FXR signaling in CF mice 
123 
indicating that the CF microbiota does play a role in the down-regulation of FXR signaling. 
Because much of the microflora will be lost upon tissue isolation, this model also accounts for 
the observation that TC exposure triggered normal levels of Fgf15 induction in tissue explants. 
 However, not all our results are consistent with the above model, suggesting that other 
factors play a more decisive role. Key to this notion was the observation that dietary CA 
supplementation induced some hepatic FXR target genes to a similar extent in CF mice and 
controls, which seems incongruent with low BA absorption, whereas the intestinal FXR 
signaling defect persisted. In fact, the dosage used in these experiments was projected to result in 
luminal BA levels well in excess of those occurring naturally, and it seems implausible that, 
under these conditions, microbial biotransformation could have such an overriding effect on BA 
uptake and intestinal FXR activity. Furthermore, the IPA showed that signaling through other 
RXR heterodimer forming nuclear receptors, that are activated by ligands other than BAs and are 
unlikely to be strongly affected by a purported reduction in BA uptake, was also down-regulated. 
This led us to consider that a common mechanism, unrelated to BA biotransformation, underlies 
the suppression of FXR and other ligand-dependent nuclear receptors in the CF ileum.  
 The acute activation of NFκB and JNK in response to bacterial LPS or pro-inflammatory 
cytokines plays a central role in the defense against pathogens. NFκB induces the transcription of 
an array of genes involved in the inflammatory response, and also modulates the activity of 
several nuclear receptors; its p65 subunit was shown to interact directly with RXR, to prevent 
binding of the PXR/RXR heterodimer to DNA regulatory sequences [29]. Activation of JNK was 
shown to induce phosphorylation of RXR, and reduce its nuclear localization [27, 28, 31]. 
Consistent with this role of NFκB and JNK in RXR repression, LPS treatment inhibited the 
activity of the RXR heterodimers of FXR and PXR in hepatocytes [21, 29, 39], and it was 
observed that TNFα and IL-1β, cytokines that trigger the canonical NFκB pathway, repress 
intestinal FXR/RXR activity [30]. In line with these data, we show here that LPS strongly 
repressed FXR-dependent Fgf15 induction in non-diseased ileum, essentially mimicking the 
repression of FXR/RXR activity found in vivo in the CF intestine. These data indicate that a 
bacterial endotoxin-induced inflammatory response may impair FXR/RXR function in the gut. 
This notion is supported by the IPA, which revealed a marked activation of the innate and 
adaptive immune response, coinciding with impaired FXR and RXR signaling. The IPA 
indicated that repression of RXR is triggered by LPS and pro-inflammatory cytokines, leading to 
recruitment of TAK1 (TGFβ-activated kinase 1) and IKK (inhibitor of nuclear factor-κB kinase) 
complexes and subsequent activation of NFκB and JNK. Further, the IPA showed that antibiotic 
treatment ameliorated the inflammatory response, and restored FXR/RXR function in the CF 
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ileum. Therefore, we propose that local inflammation of the gut wall, most plausibly though 
activation of the NFκB and/or JNK pathways, suppresses RXR activity in the CF ileum, leading 
to a concomitant inhibition of FXR activity.  
 In mice, both complete FGF15 deficiency and suppression of FGF15 production by 
microbiota modification were shown to markedly enhance the fecal excretion of BAs [5, 20]. 
Our current findings indicate that the fecal BA wasting observed in CF mice may, similarly, 
result from low FGF15 production and impaired feedback regulation of BA synthesis (Figure 
S4). Consistent with this model, some studies have shown that biliary BA secretion is enhanced 
in CF mice [14, 15].  Because it does not imply an epithelial transport defect, this model also 
accounts for the fact that a correlation between enhanced excretion and reduced uptake of BAs 
has proved difficult to establish, in CF mice as well as in patients [40, 41]. It may also explain 
why the presentation of fecal BA wasting is quite variable between patients, as any factor that 
affects the gut microbiota and the host immune response (e.g. diet, antibiotic use, intestinal 
obstruction) may act to modulate FXR signaling and BA handling. The same probably holds true 
for CF mouse models. For instance, liquid diets or oral laxatives, often applied to prevent 
luminal dehydration and intestinal obstruction in CF mice, were shown to strongly affect the 
intestinal bacterial load [42]. Therefore, it is important to note that the animals used at present 
were reared on a solid diet and were withheld laxative several days before experimentation. 
 This model for the pathogenesis of CF-related fecal BA wasting shows distinct 
similarities to the one proposed for idiopathic BA malabsorption (chronic BA diarrhea). As for 
CF, anomalous BA handling in this syndrome was initially attributed to impaired reabsorption of 
BAs, although evidence for a primary defect in epithelial translocation proved elusive (reviewed 
by Hofmann, Mangelsdorf [43]). More recently, it has been linked to abnormally low plasma 
FGF19 levels, causing impaired feedback regulation of BA synthesis, enhanced intestinal BA 
delivery, saturation of ASBT, and increased spillage of BAs to the colon [44]. Upon entering the 
colon, BAs provoke secretory diarrhea via a CFTR-dependent mechanism (perhaps ironically, 
implying CF patients would not be afflicted). Whether in idiopathic BA malabsorption low 
plasma FGF19 levels are linked to changes in the gut microbiota, or even reduced intestinal FXR 
activity, has, however, not been established.  
 Although not the focus of the present investigation, we surmise that an intestinal FXR 
signaling defect may also be of consequence for the pathophysiology of CFLD. Firstly, by 
enhancing BA synthesis and reducing the capacity for homeostatic liver regeneration, repression 
of intestinal FXR/FGF19 signaling may contribute to the progression of the cholangiopathy 
typical of CF [8]. Secondly, impaired intestinal FXR signaling may enhance exposure of the 
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liver to endotoxins, as it was shown that FXR deficiency, in conjunction with dysbiosis, 
compromises epithelial barrier function [45]. Congruent with this scenario, it was shown that a 
chemically induced colitis exacerbates liver disease in CF mice, and a pathogenic role of gut-
derived bacterial products was indicated [11]. Indeed, although focal biliary cirrhosis is thought 
to result primarily from the loss of local CFTR activity, it is also apparent that some 
gastrointestinal manifestations of CF, like pancreatic insufficiency and a history of meconium 
ileus, seem to predispose to the development of CFLD [10, 46, 47]. It is conceivable that such 
manifestations impact the gut microbiota and host-microbe interactions, potentially leading to 
inflammation of the gut wall and repression of FXR. Collectively, these data imply that intestinal 
inflammation and FXR dysfunction may contribute to the pathogenesis of biliary cirrhosis, 
suggesting that therapeutic interventions aimed at restoring FXR signaling may slow the 
progression of CFLD. 
Experimental procedures 
Animal procedures and tissue collection 
 CF mice (Cftrtm1Cam; congenic FVB/n) and littermate controls were maintained in 
individually ventilated cages in an environmentally controlled facility at the Erasmus MC. 
Animals were reared on a low fiber diet (C1013; Altromin) and a polyethylene glycol/electrolyte 
dinking solution to prevent intestinal obstruction in early life [48]. In some instances, before 
further experimentation, animals were administered either a diet supplemented with CA (0.5%), 
or drinking water supplemented with ciprofloxacin (0.3 g/L) and metronidazole (0.5 g/L) for 15 
days [25]. Intake of food and water was monitored during this period, and shown to be 
comparable between genotypes (not shown).  
 Before tissue collection, animals (13-22 weeks) were kept on normal drinking water (or, 
when applicable, drinking water supplemented with antibiotics) for >4 days, which is well 
tolerated by adult CF mice. Animals were anaesthetized (ketamine 120 mg/kg, xylazine 20 
mg/kg; i.p.), and the intestinal tract and liver were collected, and flushed or rinsed, respectively, 
with ice-cold saline. Sampling from a CF animal and a sex-matched littermate control was 
performed within a time window of 20 min, and between 12:00-14:00h, to control for diurnal 
variations in gene expression. Experiments were approved by the Independent Committee on 
Ethical Use of Experimental Animals, Rotterdam, according to national guidelines (120-
0402/0501/0503/0902; 141-1204/1208/1210). 
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Intestinal and hepatic gene expression  
 For gene expression studies, two ileal sections (3-5 mm in length) were collected, at 0.5-
1.5 and 5-6 cm proximal to the ileocecal valve. Liver tissue was sampled from the right lobe. 
Tissue homogenization, RNA extraction, and quantitative PCR (primer sequences shown in 
Table S1) was performed as described elsewhere [49]. Median values of assays performed in 
triplicate were used to determine gene expression levels, relative to Gapdh. To correct for 
regional differences in gene expression in the distal small intestine, mean values of the relative 
expression levels at the 2 sampling locations are presented. 
Ex vivo FXR-dependent induction of intestinal gene expression 
 For assessing BA-dependent induction of gene expression, 2 contiguous sections of the 
small intestine were collected, 3-5 cm proximal to the ileocecal valve. Mucosal tissue sheets 
were mounted in Ussing chambers and bathed in modified Meyler solution, gassed with 95% O2-
5% CO2, at 37°C, as described previously [40]. After a 40 min equilibration period, the solution 
bathing the luminal side of one tissue sheet was supplemented with TC (0.25 mmol/L), while the 
other section served as vehicle (water) control. After 1h, tissue was collected and processed for 
RNA extraction (see above). For assessing the effect of bacterial LPS on FXR-dependent gene 
induction, ileal tissue sections were incubated for 18h with the FXR agonist GW4064 (1 
µmol/L), in the presence or absence of LPS (Salmonella enterica; 10 µg/mL), in Dulbecco 
Modified Eagle’s Medium, supplemented with fetal calf serum (10%), penicillin (50 U/mL), and 
streptomycin (0.005%), at 37°C, in 5% CO2. Gene expression was assessed as outlined above.  
Transcriptome sequencing 
 Transcriptome sequencing was performed at the Beijing Genomics Institute. In brief, 
mRNA was isolated from total tissue RNA extracts (200 ng), fragmented, and, subsequently 
used for cDNA synthesis. The resulting cDNA library was sequenced using an HiSeq 2000 
sequencer (TruSeq SBS KIT-HS V3; Illumina). Data were processed using CLC genomic 
workbench 7.5 (CLC Bio), and the sequence reads were mapped to the Genome Reference 
Consortium (GRC) genome data set GRCm38.76, using default parameters.  
Detection of ASBT and FGF15 by Western analysis 
 For ASBT detection, brush border membrane fractions were prepared from the distal 8 
cm of the small intestine, as described in detail elsewhere [50]. For FGF15 detection, ileal tissue 
was excised 2-5 cm proximal to the ileocecal valve, and epithelial cells were gently scraped of 
the underlying connective tissue layers, using a glass cover slip. Cell and brush border 
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membrane preparations were lysed by brief sonication (3 15s bursts) in ice-cooled NaCl (150 
mmol/L), Tris/HCl pH 7.6 (25 mmol/L), Triton X100 (1%), sodium deoxycholate (1%), sodium 
dodecylsulphate (0.1%), NaF (5 mmol/L), Na3VO4 (3 mmol/L), supplemented with a protease 
inhibitor cocktail. The resulting lysates were subjected to SDS-PAGE, and proteins were 
transferred to nitrocellulose membrane. ASBT was detected using a polyclonal antibody directed 
against hamster ASBT [51]. FGF15 was detected using a polyclonal antibody directed against an 
epitope of mouse origin (SC27177; Santa Cruz). A fluorescent dye-labeled secondary antibody 
and the Odyssey infrared imaging system (Application software 3, Licor Biosciences) were used 
for quantification of the FGF15 signal. Detection of β-actin served as loading control (SC47778; 
Santa Cruz). 
Immunohistochemistry 
 Paraformaldehyde-fixed, paraffin-embedded tissue sections (5 µm) of the distal small 
intestine (excised 2-4 cm proximal to the ileocecal valve), were probed with ASBT antibody (see 
above), followed by an anti-rabbit IgG horseradish peroxidase-conjugated secondary antibody. 
Immune complexes were visualized by incubation with 3,3-diaminobenzidine 
tetrahydrochloride, and sections were counterstained with hematoxylin.  
Analysis of BA in luminal eluates and gastrointestinal tissues 
 Tissue was collected from anesthetized animals, as outlined above. To collect its 
contents, the intestinal lumen was rinsed with 10 mL ice-cold phosphate buffered saline. The 
intestine was subsequently divided in a proximal section (2/3 of the entire length) and a distal 
section. Tissue samples and eluates were weighed and the former were homogenized in ice-cold 
phosphate buffered saline. After samples were saponified in NaOH (1 mol/L; in methanol), BAs 
were extracted on Sep-Pak C18 cartridges (Mallinckrodt Baker). BAs were analyzed as 
unconjugated, methyl ester-trimethylsilyl ether derivatives, by capillary gas chromatography 
[52]. 
Data analysis 
 The statistical significance of differences between mean levels of gene expression, 
FGF15 abundance and tissue BAs in CF and wildtype mice were analyzed by Student’s t test (2 
sided). The effect of BA and antibiotic treatment on gene expression in CF mice and controls 
was analyzed by 2-way ANOVA (Graphpad Prism 5, Graphpad Software). Data shown are 
means ± SE.  
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 Transcriptome data were analyzed using the Ingenuity® software application (Version 
1.10; Qiagen). IPA/URA was applied to identify differentially regulated pathways and their 
upstream modulators, as described in detail elsewhere [53]. For identification of canonical 
signaling pathways that were differentially regulated in the ileum of CF mice, compared to 
controls, transcriptome data from 3 sex-matched (2F/1M) littermate couples were used. For each 
couple and transcript, expression in the Cftr -/- animal was calculated relative to the respective 
Cftr N/N control. Identification of differentially regulated signaling pathways was based on those 
genes that, on average, were up- or down-regulated by a factor of ≥2. To assess the effect of the 
antibiotic treatment on ileal gene expression, for each genotype, the expression in one treated 
animal was expressed relative to the average expression level in the untreated animals, and the 
analysis was performed on genes that were up- or down-regulated by a factor of ≥2. To identify 
differentially regulated pathways, the enrichment of the dataset with up- or down-regulated 
genes comprised within a signal transduction network was assessed (overlap p-value). To assess 
the activation state of a pathway and its upstream regulator, the consistency of the match 
between the observed and the predicted (based on established interactions within a network) 
expression pattern was calculated (activation z-score). A positive z-score signifies a regulator in 
the active state, a negative score indicates that its activity is repressed.  
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Table S1 – Related to Experimental procedures.  
Primer sequences 
Protein Gene Forward primer Reverse Primer 
ASBT Slc10a2 GGAACTGGCTCCAATATCCTG GTTCCCGAGTCAACCCACAT 
FXR Nr1h4 CATCAAGGACAGAGAGGCGG TCAGCGTGGTGATGGTTGAA 
FGF15 Fgf15 GTCCCTATGTCTCCAACTGCTTCCT TTCCTCCCTGAAGGTACAGTCTTCC 
SHP Nr0b2 CGAATCCTCCTCATGGCCTC TCCCATGATAGGGCGGAAGA 
CYP7A1 Cyp7a1 ACTCTCTGAAGCCATGATGCAA AGCGTTAGATATCCGGCTTCAA 
CYP8B1 Cyp8b1 TTGCAAATGCTGCCTCAACC TAACAGTCGCACACATGGCT 
GAPDH Gapdh TTCCAGTATGACTCCACTCACGG TGAAGACACCAGTAGACTCCACGAC 
 
 
Table S2 – Related to Figure 5.  
Differentially regulated signal transduction pathways in ileum of CF mice and controls. Gene 
expression in Cftr null mice is depicted relative to the expression in wildtype mice. 
 
LPS-IL1-RXR 
 
Symbol Entrez Gene Name 
Gene Symbol - 
mouse (Entrez 
Gene) 
Expr Fold 
Change 
ABCA1 ATP binding cassette subfamily A member 1 Abca1 -3.189 
ABCB1 ATP binding cassette subfamily B member 1 Abcb1a -2.904 
ABCB9 ATP binding cassette subfamily B member 9 --   
ABCC2 ATP binding cassette subfamily C member 2 Abcc2 -2.237 
ABCC3 ATP binding cassette subfamily C member 3 --   
ABCG1 ATP binding cassette subfamily G member 1 --   
ABCG5 ATP binding cassette subfamily G member 5 Abcg5 -2.198 
ABCG8 ATP binding cassette subfamily G member 8 Abcg8 -2.677 
ACOX1 acyl-CoA oxidase 1 Acox1 -1.771 
ACOX2 acyl-CoA oxidase 2 Acox2 -2.524 
ACOX3 acyl-CoA oxidase 3, pristanoyl --   
ACSL1 acyl-CoA synthetase long-chain family member 1 Acsl1 -1.406 
ACSL3 acyl-CoA synthetase long-chain family member 3 --   
ACSL4 acyl-CoA synthetase long-chain family member 4 --   
ACSL5 acyl-CoA synthetase long-chain family member 5 --   
ALAS1 5'-aminolevulinate synthase 1 --   
ALDH16A1 aldehyde dehydrogenase 16 family member A1 --   
ALDH18A1 aldehyde dehydrogenase 18 family member A1 --   
ALDH1A1 aldehyde dehydrogenase 1 family member A1 Aldh1a1 -3.399 
ALDH1A2 aldehyde dehydrogenase 1 family member A2 Aldh1a2 -1.867 
ALDH1A3 aldehyde dehydrogenase 1 family member A3 --   
ALDH1B1 aldehyde dehydrogenase 1 family member B1 --   
ALDH1L1 aldehyde dehydrogenase 1 family member L1 --   
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ALDH3A2 aldehyde dehydrogenase 3 family member A2 Aldh3a2 -2.412 
ALDH3B1 aldehyde dehydrogenase 3 family member B1 --   
ALDH4A1 aldehyde dehydrogenase 4 family member A1 Aldh4a1 2.137 
ALDH5A1 aldehyde dehydrogenase 5 family member A1 --   
ALDH6A1 aldehyde dehydrogenase 6 family member A1 --   
ALDH7A1 aldehyde dehydrogenase 7 family member A1 --   
ALDH9A1 aldehyde dehydrogenase 9 family member A1 --   
APOC2 apolipoprotein C2 Apoc2 1.983 
APOE apolipoprotein E Apoe -1.182 
CAT catalase Cat -3.622 
CD14 CD14 molecule Cd14 3.364 
CHST1 carbohydrate sulfotransferase 1 --   
CHST3 carbohydrate sulfotransferase 3 Chst3 23.983 
CHST4 carbohydrate sulfotransferase 4 Chst4 3.539 
CHST10 carbohydrate sulfotransferase 10 Chst10 3.180 
CHST11 carbohydrate sulfotransferase 11 --   
CHST12 carbohydrate sulfotransferase 12 --   
CPT2 carnitine palmitoyltransferase 2 --   
CPT1A carnitine palmitoyltransferase 1A --   
CYP2B6 cytochrome P450 family 2 subfamily B member 6 Cyp2b10 -2.566 
CYP2C9 cytochrome P450 family 2 subfamily C member 9 Cyp2c66 -7.949 
CYP3A5 cytochrome P450 family 3 subfamily A member 5 Cyp3a11 -12.095 
CYP3A7 cytochrome P450 family 3 subfamily A member 7 --   
CYP4A11 cytochrome P450 family 4 subfamily A member 11 Cyp4a10 -21.224 
ECSIT ECSIT signalling integrator --   
FABP1 fatty acid binding protein 1 Fabp1 -3.019 
FABP2 fatty acid binding protein 2 Fabp2 -2.032 
FABP4 fatty acid binding protein 4 Fabp4 1.571 
FABP5 fatty acid binding protein 5 --   
FABP6 fatty acid binding protein 6 Fabp6 -4.583 
FMO1 flavin containing monooxygenase 1 Fmo1 -1.677 
FMO2 flavin containing monooxygenase 2 Fmo2 -2.230 
FMO4 flavin containing monooxygenase 4 --   
FMO5 flavin containing monooxygenase 5 Fmo5 -2.792 
GAL3ST2 galactose-3-O-sulfotransferase 2 Gal3st2 -2.855 
GSTA3 glutathione S-transferase alpha 3 --   
GSTA5 glutathione S-transferase alpha 5 Gm10639 2.343 
GSTK1 glutathione S-transferase kappa 1 --   
GSTM1 glutathione S-transferase mu 1 --   
GSTM2 glutathione S-transferase mu 2 --   
Gstm3 glutathione S-transferase, mu 3 --   
GSTM3 glutathione S-transferase mu 3 --   
GSTM4 glutathione S-transferase mu 4 --   
GSTM5 glutathione S-transferase mu 5 --   
GSTO1 glutathione S-transferase omega 1 --   
GSTP1 glutathione S-transferase pi 1 Gstp2 2.081 
GSTT2/GSTT2B glutathione S-transferase theta 2 (gene/pseudogene) --   
HMGCS1 3-hydroxy-3-methylglutaryl-CoA synthase 1 --   
HMGCS2 3-hydroxy-3-methylglutaryl-CoA synthase 2 --   
HS2ST1 heparan sulfate 2-O-sulfotransferase 1 --   
HS3ST1 heparan sulfate-glucosamine 3-sulfotransferase 1 --   
HS6ST1 heparan sulfate 6-O-sulfotransferase 1 --   
IL18 interleukin 18 Il18 1.276 
IL33 interleukin 33 Il33 4.208 
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IL1R1 interleukin 1 receptor type 1 Il1r1 1.133 
IL1RL1 interleukin 1 receptor like 1 Il1rl1 2.470 
IL1RN interleukin 1 receptor antagonist Il1rn 2.977 
IL4I1 interleukin 4 induced 1 Il4i1 2.834 
IRAK1 interleukin 1 receptor associated kinase 1 Irak1 1.142 
JUN Jun proto-oncogene, AP-1 transcription factor subunit Jun -1.164 
LY96 lymphocyte antigen 96 --   
MAOA monoamine oxidase A --   
MAOB monoamine oxidase B Maob -1.885 
MAP2K4 mitogen-activated protein kinase kinase 4 --   
MAP2K7 mitogen-activated protein kinase kinase 7 --   
MAP3K1 mitogen-activated protein kinase kinase kinase 1 --   
MAPK8 mitogen-activated protein kinase 8 Mapk8 1.116 
MAPK9 mitogen-activated protein kinase 9 Mapk9 -1.088 
MGMT O-6-methylguanine-DNA methyltransferase --   
MGST1 microsomal glutathione S-transferase 1 --   
MGST2 microsomal glutathione S-transferase 2 --   
MGST3 microsomal glutathione S-transferase 3 --   
MYD88 myeloid differentiation primary response 88 Myd88 1.492 
NCOA1 nuclear receptor coactivator 1 Ncoa1 1.035 
NDST1 N-deacetylase and N-sulfotransferase 1 Ndst1 -1.163 
NDST2 N-deacetylase and N-sulfotransferase 2 --   
NGFR nerve growth factor receptor Ngfr -2.271 
NR0B2 nuclear receptor subfamily 0 group B member 2 Nr0b2 -44.334 
NR1H2 nuclear receptor subfamily 1 group H member 2 Nr1h2 -1.021 
NR1H3 nuclear receptor subfamily 1 group H member 3 Nr1h3 -1.166 
NR1H4 nuclear receptor subfamily 1 group H member 4 Nr1h4 1.053 
NR1I2 nuclear receptor subfamily 1 group I member 2 Nr1i2 -1.334 
NR1I3 nuclear receptor subfamily 1 group I member 3 Nr1i3 -1.165 
NR5A2 nuclear receptor subfamily 5 group A member 2 Nr5a2 -1.211 
PAPSS2 3'-phosphoadenosine 5'-phosphosulfate synthase 2 --   
PLTP phospholipid transfer protein --   
PPARA peroxisome proliferator activated receptor alpha Ppara -3.810 
PPARGC1A PPARG coactivator 1 alpha Ppargc1a -1.557 
PPARGC1B PPARG coactivator 1 beta Ppargc1b 1.133 
RARA retinoic acid receptor alpha Rara -1.346 
RXRA retinoid X receptor alpha Rxra -1.436 
SCARB1 scavenger receptor class B member 1 Scarb1 -1.157 
SLC27A1 solute carrier family 27 member 1 --   
SLC27A2 solute carrier family 27 member 2 --   
SLC27A4 solute carrier family 27 member 4 --   
SMOX spermine oxidase Smox 2.001 
SOD3 superoxide dismutase 3, extracellular --   
SREBF1 sterol regulatory element binding transcription factor 1 Srebf1 -1.596 
SULT1B1 sulfotransferase family 1B member 1 --   
SULT1C2 sulfotransferase family 1C member 2 Sult1c2 -2.988 
Sult1d1 sulfotransferase family 1D, member 1 --   
SULT2B1 sulfotransferase family 2B member 1 --   
TNF tumor necrosis factor Tnf 4.137 
TNFRSF11B TNF receptor superfamily member 11b --   
TNFRSF1A TNF receptor superfamily member 1A Tnfrsf1a 1.051 
TNFRSF1B TNF receptor superfamily member 1B Tnfrsf1b 1.775 
TRAF2 TNF receptor associated factor 2 --   
TRAF6 TNF receptor associated factor 6 Traf6 -1.069 
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XPO1 exportin 1 Xpo1 1.200 
FXR-RXR 
 
Symbol Entrez Gene Name 
GenBank/Gene 
Symbol - mouse 
(Entrez Gene) 
Exp Fold 
Change 
ABCC2 ATP binding cassette subfamily C member 2 Abcc2 -2.237 
ABCG5 ATP binding cassette subfamily G member 5 Abcg5 -2.198 
ABCG8 ATP binding cassette subfamily G member 8 Abcg8 -2.677 
AGT angiotensinogen Agt -2.902 
AKT1 AKT serine/threonine kinase 1 Akt1 1.149 
AKT2 AKT serine/threonine kinase 2 --   
AKT3 AKT serine/threonine kinase 3 --   
ALB albumin Alb 285.441 
APOA1 apolipoprotein A1 Apoa1 -1.490 
APOA4 apolipoprotein A4 Apoa4 -2.237 
APOB apolipoprotein B --   
APOC2 apolipoprotein C2 Apoc2 1.983 
APOE apolipoprotein E Apoe -1.182 
BAAT bile acid-CoA:amino acid N-acyltransferase Baat -2.022 
C3 complement C3 C3 1.307 
C4A/C4B complement C4B (Chido blood group) --   
CLU clusterin Clu 3.391 
CREBBP CREB binding protein Crebbp -1.507 
CYP27A1 cytochrome P450 family 27 subfamily A member 1 Cyp27a1 -1.494 
FABP6 fatty acid binding protein 6 Fabp6 -4.583 
FASN fatty acid synthase --   
FBP1 fructose-bisphosphatase 1 Fbp1 -3.530 
FGF19 fibroblast growth factor 19 Fgf15 -40.903 
FGFR4 fibroblast growth factor receptor 4 --   
FOXA1 forkhead box A1 Foxa1 -1.147 
FOXA2 forkhead box A2 Foxa2 -1.275 
FOXA3 forkhead box A3 Foxa3 1.234 
FOXO1 forkhead box O1 Foxo1 -1.196 
G6PC glucose-6-phosphatase catalytic subunit G6pc -2.944 
G6PC3 glucose-6-phosphatase catalytic subunit 3 --   
HNF1A HNF1 homeobox A Hnf1a -1.318 
HNF4A hepatocyte nuclear factor 4 alpha Hnf4a -1.060 
IL18 interleukin 18 Il18 1.276 
IL33 interleukin 33 Il33 4.208 
IL1RN interleukin 1 receptor antagonist Il1rn 2.977 
LPL lipoprotein lipase Lpl -1.100 
MAP2K4 mitogen-activated protein kinase kinase 4 --   
MAPK8 mitogen-activated protein kinase 8 Mapk8 1.116 
MAPK9 mitogen-activated protein kinase 9 Mapk9 -1.088 
MAPK12 mitogen-activated protein kinase 12 --   
MLXIPL MLX interacting protein like Mlxipl -2.124 
MTTP microsomal triglyceride transfer protein Mttp -1.226 
NR0B2 nuclear receptor subfamily 0 group B member 2 Nr0b2 -44.334 
NR1H3 nuclear receptor subfamily 1 group H member 3 Nr1h3 -1.166 
NR1H4 nuclear receptor subfamily 1 group H member 4 Nr1h4 1.053 
NR1I2 nuclear receptor subfamily 1 group I member 2 Nr1i2 -1.334 
NR5A2 nuclear receptor subfamily 5 group A member 2 Nr5a2 -1.211 
PCK2 phosphoenolpyruvate carboxykinase 2, mitochondrial --   
PCYOX1 prenylcysteine oxidase 1 --   
PKLR pyruvate kinase, liver and RBC --   
PLTP phospholipid transfer protein --   
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PON3 paraoxonase 3 --   
PPARA peroxisome proliferator activated receptor alpha Ppara -3.810 
PPARG peroxisome proliferator activated receptor gamma Pparg 1.321 
PPARGC1A PPARG coactivator 1 alpha Ppargc1a -1.557 
RARA retinoic acid receptor alpha Rara -1.346 
RBP4 retinol binding protein 4 Rbp4 2.111 
RXRA retinoid X receptor alpha Rxra -1.436 
SAA1 serum amyloid A1 Saa1 21.654 
SCARB1 scavenger receptor class B member 1 Scarb1 -1.157 
SDC1 syndecan 1 --   
SERPINA1 serpin family A member 1 Serpina1b 4.477 
SERPINF1 serpin family F member 1 --   
SLC10A2 solute carrier family 10 member 2 Slc10a2 2.290 
SLC4A2 solute carrier family 4 member 2 --   
SLC51A solute carrier family 51 alpha subunit Slc51a -1.869 
SLC51B solute carrier family 51 beta subunit Slc51b -1.421 
SREBF1 sterol regulatory element binding transcription factor 1 Srebf1 -1.596 
TF transferrin --   
TNF tumor necrosis factor Tnf 4.137 
TTR transthyretin Ttr 11.339 
Antigen 
presentation 
Symbol Entrez Gene Name 
Gene Symbol - 
mouse (Entrez 
Gene) 
Expr Fold 
Change 
B2M beta-2-microglobulin B2m 1.443 
CALR calreticulin --   
CANX calnexin --   
CD74 CD74 molecule Cd74 4.162 
CIITA class II major histocompatibility complex transactivator Ciita 6.042 
HLA-A major histocompatibility complex, class I, A H2-Q7 2.267 
HLA-DMA major histocompatibility complex, class II, DM alpha H2-DMa 5.015 
HLA-DMB major histocompatibility complex, class II, DM beta H2-DMb1 5.267 
HLA-DOA major histocompatibility complex, class II, DO alpha H2-Oa 3.583 
HLA-DOB major histocompatibility complex, class II, DO beta H2-Ob 2.444 
HLA-DQA1 major histocompatibility complex, class II, DQ alpha 1 H2-Aa 3.854 
HLA-DQB1 major histocompatibility complex, class II, DQ beta 1 H2-Ab1 4.405 
HLA-DRA major histocompatibility complex, class II, DR alpha H2-Ea-ps 3.037 
HLA-DRB5 major histocompatibility complex, class II, DR beta 5 H2-Eb1 5.732 
HLA-E major histocompatibility complex, class I, E --   
HLA-F major histocompatibility complex, class I, F --   
HLA-G major histocompatibility complex, class I, G H2-M3 2.341 
MR1 major histocompatibility complex, class I-related --   
NLRC5 NLR family CARD domain containing 5 Nlrc5 8.639 
PDIA3 protein disulfide isomerase family A member 3 --   
PSMB5 proteasome subunit beta 5 --   
PSMB6 proteasome subunit beta 6 --   
PSMB8 proteasome subunit beta 8 Psmb8 3.793 
PSMB9 proteasome subunit beta 9 Psmb9 3.547 
TAP1 transporter 1, ATP binding cassette subfamily B member Tap1 3.858 
TAP2 transporter 2, ATP binding cassette subfamily B member --   
TAPBP TAP binding protein Tapbp -1.004 
    
 
 
   Impaired intestinal FXR signaling in CF mice 
137 
Figure S1 – Related to Figure 5C 
. 
 
Figure S2 – Related to Figure 5C 
 
 
 
  
Expression of PPARγ target genes in 
the ileum of CF mice and controls. 
Transcript levels of genes that were 
previously analyzed to signal 
inactivation of PPARγ (Harmon et 
al. 2010). Data depict reads per 1000 
base pair transcript per million reads 
mapped (RPKM). N=3. *p < 0.05 
Expression of ligand-dependent 
nuclear receptors in ileum of CF 
mice and controls. Data depict reads 
per 1000 base pair transcript per 
million reads mapped (RPKM). N=3. 
*p < 0.05 
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Table S3 – Related to Figure 6.   
Effect of antibiotic treatment on differentially regulated signal transduction pathways in ileum of CF 
mice. Gene expression after antibiotic treatment is depicted relative to the expression in non-treated animals. 
ABX 
LPS-IL1-RXR  
Symbol Entrez Gene Name 
GenBank/Gene 
Symbol - mouse 
(Entrez Gene) 
Exp Fold 
Change 
ABCA1 ATP binding cassette subfamily A member 1 Abca1 4.616 
ABCB1 ATP binding cassette subfamily B member 1 --   
ABCB9 ATP binding cassette subfamily B member 9 --   
ABCC2 ATP binding cassette subfamily C member 2 Abcc2 3.355 
ABCC3 ATP binding cassette subfamily C member 3 --   
ABCG1 ATP binding cassette subfamily G member 1 --   
ABCG5 ATP binding cassette subfamily G member 5 Abcg5 2.124 
ABCG8 ATP binding cassette subfamily G member 8 Abcg8 3.701 
ACOX1 acyl-CoA oxidase 1 Acox1 2.680 
ACOX2 acyl-CoA oxidase 2 Acox2 3.783 
ACOX3 acyl-CoA oxidase 3. pristanoyl --   
ACSL1 acyl-CoA synthetase long-chain family member 1 --   
ACSL3 acyl-CoA synthetase long-chain family member 3 Acsl3 2.497 
ACSL4 acyl-CoA synthetase long-chain family member 4 --   
ACSL5 acyl-CoA synthetase long-chain family member 5 --   
ALAS1 5'-aminolevulinate synthase 1 --   
ALDH16A1 aldehyde dehydrogenase 16 family member A1 --   
ALDH18A1 aldehyde dehydrogenase 18 family member A1 --   
ALDH1A1 aldehyde dehydrogenase 1 family member A1 Aldh1a1 6.046 
ALDH1A2 aldehyde dehydrogenase 1 family member A2 Aldh1a2 -1.101 
ALDH1A3 aldehyde dehydrogenase 1 family member A3 Aldh1a3 2.093 
ALDH1B1 aldehyde dehydrogenase 1 family member B1 --   
ALDH1L1 aldehyde dehydrogenase 1 family member L1 --   
ALDH3A2 aldehyde dehydrogenase 3 family member A2 Aldh3a2 4.558 
ALDH3B1 aldehyde dehydrogenase 3 family member B1 --   
ALDH4A1 aldehyde dehydrogenase 4 family member A1 --   
ALDH5A1 aldehyde dehydrogenase 5 family member A1 --   
ALDH6A1 aldehyde dehydrogenase 6 family member A1 --   
ALDH7A1 aldehyde dehydrogenase 7 family member A1 --   
ALDH9A1 aldehyde dehydrogenase 9 family member A1 --   
APOC2 apolipoprotein C2 Apoc2 2.349 
APOE apolipoprotein E Apoe 1.635 
CAT catalase Cat 5.660 
CD14 CD14 molecule Cd14 -2.802 
CHST1 carbohydrate sulfotransferase 1 --   
CHST3 carbohydrate sulfotransferase 3 Chst3 2.121 
CHST4 carbohydrate sulfotransferase 4 Chst4 -5.964 
CHST10 carbohydrate sulfotransferase 10 --   
CHST11 carbohydrate sulfotransferase 11 --   
CHST12 carbohydrate sulfotransferase 12 Chst12 -2.049 
CPT2 carnitine palmitoyltransferase 2 --   
CPT1A carnitine palmitoyltransferase 1A --   
CYP2B6 cytochrome P450 family 2 subfamily B member 6 Cyp2b10 4.225 
CYP2C9 cytochrome P450 family 2 subfamily C member 9 Cyp2c66 17.276 
CYP3A5 cytochrome P450 family 3 subfamily A member 5 Cyp3a11 34.386 
CYP3A7 cytochrome P450 family 3 subfamily A member 7 Cyp3a13 2.157 
CYP4A11 cytochrome P450 family 4 subfamily A member 11 Cyp4a10 181.115 
ECSIT ECSIT signalling integrator Ecsit -2.006 
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FABP1 fatty acid binding protein 1 Fabp1 10.414 
FABP2 fatty acid binding protein 2 Fabp2 3.059 
FABP4 fatty acid binding protein 4 Fabp4 -1.097 
FABP5 fatty acid binding protein 5 Fabp5 -2.215 
FABP6 fatty acid binding protein 6 Fabp6 -2.991 
FMO1 flavin containing monooxygenase 1 --   
FMO2 flavin containing monooxygenase 2 Fmo2 2.962 
FMO4 flavin containing monooxygenase 4 --   
FMO5 flavin containing monooxygenase 5 Fmo5 3.531 
GAL3ST2 galactose-3-O-sulfotransferase 2 Gal3st2 3.431 
GSTA3 glutathione S-transferase alpha 3 Gsta3 6.051 
GSTA5 glutathione S-transferase alpha 5 Gsta1 3.756 
GSTK1 glutathione S-transferase kappa 1 --   
GSTM1 glutathione S-transferase mu 1 --   
GSTM2 glutathione S-transferase mu 2 --   
Gstm3 glutathione S-transferase. mu 3 Gstm3 2.386 
GSTM3 glutathione S-transferase mu 3 Gstm5 -2.083 
GSTM4 glutathione S-transferase mu 4 --   
GSTM5 glutathione S-transferase mu 5 Gstm1 4.264 
GSTO1 glutathione S-transferase omega 1 --   
GSTP1 glutathione S-transferase pi 1 Gstp2 -3.510 
GSTT2/GSTT2B glutathione S-transferase theta 2 (gene/pseudogene) --   
HMGCS1 3-hydroxy-3-methylglutaryl-CoA synthase 1 Hmgcs1 -2.326 
HMGCS2 3-hydroxy-3-methylglutaryl-CoA synthase 2 Hmgcs2 11.330 
HS2ST1 heparan sulfate 2-O-sulfotransferase 1 --   
HS3ST1 heparan sulfate-glucosamine 3-sulfotransferase 1 Hs3st1 -2.785 
HS6ST1 heparan sulfate 6-O-sulfotransferase 1 --   
IL18 interleukin 18 Il18 -1.853 
IL33 interleukin 33 Il33 -3.934 
IL1R1 interleukin 1 receptor type 1 --   
IL1RL1 interleukin 1 receptor like 1 Il1rl1 -5.512 
IL1RN interleukin 1 receptor antagonist Il1rn -2.753 
IL4I1 interleukin 4 induced 1 --   
IRAK1 interleukin 1 receptor associated kinase 1 --   
JUN Jun proto-oncogene. AP-1 transcription factor subunit Jun 1.342 
LY96 lymphocyte antigen 96 --   
MAOA monoamine oxidase A Maoa 2.014 
MAOB monoamine oxidase B Maob 2.385 
MAP2K4 mitogen-activated protein kinase kinase 4 Map2k4 -1.300 
MAP2K7 mitogen-activated protein kinase kinase 7 --   
MAP3K1 mitogen-activated protein kinase kinase kinase 1 Map3k1 1.204 
MAPK8 mitogen-activated protein kinase 8 Mapk8 -1.073 
MAPK9 mitogen-activated protein kinase 9 Mapk9 -1.165 
MGMT O-6-methylguanine-DNA methyltransferase --   
MGST1 microsomal glutathione S-transferase 1 --   
MGST2 microsomal glutathione S-transferase 2 --   
MGST3 microsomal glutathione S-transferase 3 --   
MYD88 myeloid differentiation primary response 88 Myd88 -2.574 
NCOA1 nuclear receptor coactivator 1 Ncoa1 -1.325 
NDST1 N-deacetylase and N-sulfotransferase 1 --   
NDST2 N-deacetylase and N-sulfotransferase 2 --   
NGFR nerve growth factor receptor Ngfr 1.886 
NR0B2 nuclear receptor subfamily 0 group B member 2 Nr0b2 7.028 
NR1H2 nuclear receptor subfamily 1 group H member 2 Nr1h2 1.018 
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NR1H3 nuclear receptor subfamily 1 group H member 3 Nr1h3 1.138 
NR1H4 nuclear receptor subfamily 1 group H member 4 Nr1h4 -1.393 
NR1I2 nuclear receptor subfamily 1 group I member 2 Nr1i2 1.749 
NR1I3 nuclear receptor subfamily 1 group I member 3 Nr1i3 3.386 
NR5A2 nuclear receptor subfamily 5 group A member 2 Nr5a2 -1.201 
PAPSS2 3'-phosphoadenosine 5'-phosphosulfate synthase 2 --   
PLTP phospholipid transfer protein --   
PPARA peroxisome proliferator activated receptor alpha Ppara 4.844 
PPARGC1A PPARG coactivator 1 alpha Ppargc1a 1.675 
PPARGC1B PPARG coactivator 1 beta Ppargc1b -2.336 
RARA retinoic acid receptor alpha Rara -1.031 
RXRA retinoid X receptor alpha Rxra 1.222 
SCARB1 scavenger receptor class B member 1 Scarb1 1.110 
SLC27A1 solute carrier family 27 member 1 --   
SLC27A2 solute carrier family 27 member 2 Slc27a2 7.577 
SLC27A4 solute carrier family 27 member 4 --   
SMOX spermine oxidase Smox -2.796 
SOD3 superoxide dismutase 3. extracellular --   
SREBF1 sterol regulatory element binding transcription factor 1 Srebf1 2.048 
SULT1B1 sulfotransferase family 1B member 1 --   
SULT1C2 sulfotransferase family 1C member 2 --   
Sult1d1 sulfotransferase family 1D. member 1 Sult1d1 3.399 
SULT2B1 sulfotransferase family 2B member 1 --   
TNF tumor necrosis factor Tnf -2.332 
TNFRSF11B TNF receptor superfamily member 11b --   
TNFRSF1A TNF receptor superfamily member 1A Tnfrsf1a 1.105 
TNFRSF1B TNF receptor superfamily member 1B --   
TRAF2 TNF receptor associated factor 2 Traf2 -1.139 
TRAF6 TNF receptor associated factor 6 --   
XPO1 exportin 1 --   
ABX 
FXR-RXR 
Symbol Entrez Gene Name 
Gene Symbol - 
mouse (Entrez 
Gene) 
Expr Fold 
Change 
ABCC2 ATP binding cassette subfamily C member 2 Abcc2 3.355 
ABCG5 ATP binding cassette subfamily G member 5 Abcg5 2.124 
ABCG8 ATP binding cassette subfamily G member 8 Abcg8 3.701 
AGT angiotensinogen Agt 1.113 
AKT1 AKT serine/threonine kinase 1 Akt1 -1.128 
AKT2 AKT serine/threonine kinase 2 --   
AKT3 AKT serine/threonine kinase 3 --   
ALB albumin Alb 8.857 
APOA1 apolipoprotein A1 Apoa1 1.608 
APOA4 apolipoprotein A4 Apoa4 7.796 
APOB apolipoprotein B Apob 3.440 
APOC2 apolipoprotein C2 Apoc2 2.349 
APOE apolipoprotein E Apoe 1.635 
BAAT bile acid-CoA:amino acid N-acyltransferase --   
C3 complement C3 --   
C4A/C4B complement C4B (Chido blood group) --   
CLU clusterin Clu 2.124 
CREBBP CREB binding protein Crebbp -1.068 
CYP27A1 cytochrome P450 family 27 subfamily A member 1 Cyp27a1 4.105 
FABP6 fatty acid binding protein 6 Fabp6 -2.991 
FASN fatty acid synthase --   
FBP1 fructose-bisphosphatase 1 Fbp1 2.632 
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FGF19 fibroblast growth factor 19 Fgf15 54.014 
FGFR4 fibroblast growth factor receptor 4 Fgfr4 -1.319 
FOXA1 forkhead box A1 Foxa1 -1.184 
FOXA2 forkhead box A2 Foxa2 -1.481 
FOXA3 forkhead box A3 Foxa3 -1.696 
FOXO1 forkhead box O1 Foxo1 1.446 
G6PC glucose-6-phosphatase catalytic subunit G6pc 5.422 
G6PC3 glucose-6-phosphatase catalytic subunit 3 --   
HNF1A HNF1 homeobox A Hnf1a 1.011 
HNF4A hepatocyte nuclear factor 4 alpha Hnf4a 1.037 
IL18 interleukin 18 Il18 -1.853 
IL33 interleukin 33 Il33 -3.934 
IL1RN interleukin 1 receptor antagonist Il1rn -2.753 
LPL lipoprotein lipase Lpl -1.638 
MAP2K4 mitogen-activated protein kinase kinase 4 Map2k4 -1.300 
MAPK8 mitogen-activated protein kinase 8 Mapk8 -1.073 
MAPK9 mitogen-activated protein kinase 9 Mapk9 -1.165 
MAPK12 mitogen-activated protein kinase 12 Mapk12 1.248 
MLXIPL MLX interacting protein like Mlxipl 2.314 
MTTP microsomal triglyceride transfer protein Mttp 1.985 
NR0B2 nuclear receptor subfamily 0 group B member 2 Nr0b2 7.028 
NR1H3 nuclear receptor subfamily 1 group H member 3 Nr1h3 1.138 
NR1H4 nuclear receptor subfamily 1 group H member 4 Nr1h4 -1.393 
NR1I2 nuclear receptor subfamily 1 group I member 2 Nr1i2 1.749 
NR5A2 nuclear receptor subfamily 5 group A member 2 Nr5a2 -1.201 
PCK2 phosphoenolpyruvate carboxykinase 2. mitochondrial --   
PCYOX1 prenylcysteine oxidase 1 --   
PKLR pyruvate kinase. liver and RBC --   
PLTP phospholipid transfer protein --   
PON3 paraoxonase 3 --   
PPARA peroxisome proliferator activated receptor alpha Ppara 4.844 
PPARG peroxisome proliferator activated receptor gamma Pparg -1.331 
PPARGC1A PPARG coactivator 1 alpha Ppargc1a 1.675 
RARA retinoic acid receptor alpha Rara -1.031 
RBP4 retinol binding protein 4 --   
RXRA retinoid X receptor alpha Rxra 1.222 
SAA1 serum amyloid A1 Saa1 -152.960 
SCARB1 scavenger receptor class B member 1 Scarb1 1.110 
SDC1 syndecan 1 --   
SERPINA1 serpin family A member 1 Serpina1b 5.082 
SERPINF1 serpin family F member 1 --   
SLC10A2 solute carrier family 10 member 2 Slc10a2 -13.666 
SLC4A2 solute carrier family 4 member 2 --   
SLC51A solute carrier family 51 alpha subunit Slc51a -1.753 
SLC51B solute carrier family 51 beta subunit --   
SREBF1 sterol regulatory element binding transcription factor 1 Srebf1 2.048 
TF transferrin Trf 2.432 
TNF tumor necrosis factor Tnf -2.332 
TTR transthyretin --   
ABX 
Antigen 
presentation 
Symbol Entrez Gene Name 
Gene Symbol - 
mouse (Entrez 
Gene) 
Expr Fold 
Change 
B2M beta-2-microglobulin B2m -1.642 
CALR calreticulin --   
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CANX calnexin --   
CD74 CD74 molecule Cd74 -3.127 
CIITA class II major histocompatibility complex transactivator Ciita -3.153 
HLA-A major histocompatibility complex. class I. A H2-Q1 2.735 
HLA-DMA major histocompatibility complex. class II. DM alpha H2-DMa -3.570 
HLA-DMB major histocompatibility complex. class II. DM beta H2-DMb1 -3.932 
HLA-DOA major histocompatibility complex. class II. DO alpha --   
HLA-DOB major histocompatibility complex. class II. DO beta --   
HLA-DQA1 major histocompatibility complex. class II. DQ alpha 1 H2-Aa -2.418 
HLA-DQB1 major histocompatibility complex. class II. DQ beta 1 H2-Ab1 -3.070 
HLA-DRA major histocompatibility complex. class II. DR alpha --   
HLA-DRB5 major histocompatibility complex. class II. DR beta 5 H2-Eb1 -3.064 
HLA-E major histocompatibility complex. class I. E H2-T23 -2.179 
HLA-F major histocompatibility complex. class I. F Gm11127 -2.413 
HLA-G major histocompatibility complex. class I. G --   
MR1 major histocompatibility complex. class I-related --   
NLRC5 NLR family CARD domain containing 5 Nlrc5 -3.498 
PDIA3 protein disulfide isomerase family A member 3 --   
PSMB5 proteasome subunit beta 5 --   
PSMB6 proteasome subunit beta 6 --   
PSMB8 proteasome subunit beta 8 Psmb8 -2.825 
PSMB9 proteasome subunit beta 9 Psmb9 -4.378 
TAP1 transporter 1. ATP binding cassette subfamily B member Tap1 -4.269 
TAP2 transporter 2. ATP binding cassette subfamily B member --   
TAPBP TAP binding protein Tapbp -1.159 
 
 
Figure S3 – Related to Figure 5. 
 
 
  
Expression of UDP glucuronosyltransferases in 
ileum of CF mice and controls.  Data depict 
reads per 1000 base pair transcript per million 
reads mapped (RPKM). N=3. 
   Impaired intestinal FXR signaling in CF mice 
143 
Figure S4 – Related to Discussion (Graphical abstract) 
 
 
 
Impaired feedback regulation of hepatic BA synthesis in CF. BAs are synthesized in 
hepatocytes and secreted across the canalicular membrane by the bile salt export pump 
(BSEP). BAs that enter the intestine through biliary secretion are reabsorbed in the distal small 
intestine via ASBT. In intestinal cells, BAs activate the nuclear receptor FXR. Activated FXR 
dimerizes with its heterodimer binding partner RXR to induce several genes involved in BA 
metabolism, including FGF19. FGF19, via activation of its hepatic receptor (FGFR4), 
represses expression of the gene encoding the rate-limiting enzyme in hepatic BA synthesis, 
CYP7A1. In addition, FGF19 has trophic actions in the liver and supports liver regeneration 
after injury. BAs are exported from intestinal cells via OSTα/β, after which they are shuttled 
back to the liver. In CF, a dysbiosis triggers inflammation of the gut wall, leading to post-
translational modification and inactivation of RXR. The attendant reduction in FXR activity 
leads to reduced FGF19 induction/production. Low portal FGF19 levels increase hepatic 
CYP7A1 expression, leading to enhanced BA synthesis and biliary secretion. When intestinal 
BA delivery exceeds the capacity for re-uptake, fecal excretion increases. Low FGF19 
production will also decrease hepatocyte proliferation and reduce the capacity for homeostatic 
liver regeneration. 
 144 
 
145 
 
Chapter 7 
Summary and future perspectives 
 
 146 
Chapter 7 
147 
 
Summary 
 The primary disease-causing consequences of CFTR dysfunction are dehydration and 
acidification of the luminal surface of CFTR-expressing epithelia. Combined, these factors 
lead to accretion of viscous mucus and inspissation of the contents of exocrine pancreatic and 
biliary ducts, and the gut lumen [1, 2]. Exocrine pancreatic dysfunction, the resultant 
maldigestion, and mucus plugging, precipitate bacterial colonization of the upper intestinal 
tract, i.e. small intestinal bacterial overgrowth (SIBO), which may further nutrient 
malabsorption [1, 3, 4]. Although nowadays rarely fatal, these gastrointestinal complication 
of CF are a significant cause of morbidity and distress among patients. Abdominal pain and 
discomfort affects many CF patients throughout their lives, and has a strong bearing on the 
perceived quality of life [1-5].  
 In addition, principally because of its impact on nutritional status, CF-related 
gastrointestinal disease is an important determinant of disease progression and prognosis, and 
its clinical management remains one of the mainstays of patient care.  Mainly due to such 
careful clinical management, the life expectancy of CF patients has increased dramatically 
over the past few decades [6, 7]. As treatment of CF lung disease becomes more effective and 
the life expectancy of CF patients increases, the non-pulmonary complication of CF, such as 
distal intestinal obstructive syndrome (DIOS) and CF-related liver disease (CFLD), are 
expected to become a prominent cause of morbidity and mortality in CF patients [8, 9]. 
Therefore, there remains an unmet need for effective treatment of the pulmonary as well as 
the non-pulmonary (gastrointestinal) complications of CF. Recently developed therapies 
directed at correcting the basic molecular defect in CFTR anion channel function may in 
future meet this need (Chapter 2) [10]. Ever expanding knowledge of the molecular structure 
of CFTR has made it possible to model the impact of the most common disease-causing 
mutation on the structure and the function of CFTR. A sub-division in mutation classes, 
based on these structural and functional consequences, provides a rationale for the 
development of CFTR-targeted drug therapies. This development is aided by improved 
diagnostic tools which are used to monitor the efficacy of novel CFTR-targeted 
pharmacotherapies. 
 However, currently, these novel therapies are still incompletely developed and only 
effective in correcting the activity of specific CFTR mutants, which makes them applicable to
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only a subset of patients [10]. Moreover, the currently (July 2017) approved drugs are 
prohibitively expensive, which further limits their application in a wider group of patients, 
especially in less affluent nations [11]. Therefore, a search for cost-effective, so-called 
mutation-agnostic therapies, which rely on improving symptomatic treatment and/or on 
alternative strategies to correct the luminal dehydration/acidification defect, is still warranted. 
 One such strategy entails the modulation of other ion transport mechanisms, of which 
the  (in)activation may counteract the phenotypic consequences of CFTR dysfunction. Most 
work in this area has centered on the (hyper)activation of alternative anion channels in the 
apical plasma membrane of airway epithelia cells, including Ca2+-activated Cl- channels [12] 
and the CFTR-associated SLC26A9 [13]. However, these channels are expressed at only low 
levels in the gut, or their subcellular localization precludes a role in anion secretion [14, 15] . 
Therefore, as the options for increasing anion secretion in the CF intestine appear to be 
limited, we surmise that improving luminal hydration by reducing Na+-coupled water 
absorption may have more therapeutic potential. For instance inhibition of apically located 
Na+ channels (i.e. ENaC) or Na+/H+ exchangers, in particular NHE3, the major nutrient-
independent absorptive transporter of Na+ in the intestine, is a potentially viable approach to 
prevent epithelial dehydration in the absence of CFTR function [16].  
 To further improve care and management of CF patients, a thorough understanding of 
the pathophysiological mechanisms that spring from the primary dehydration/acidification 
defect is crucial. As the gastrointestinal pathophysiology results from an intricate interplay 
between the combined effects of pancreatic, biliary and intestinal CFTR dysfunction, the 
causality of, and relation between, separate disease phenomena can be difficult to fathom. For 
instance, CF-related SIBO will impact host-microbe interactions, which, in turn may have 
profound effects on many physiological processes within and outside of the intestinal tract 
[17, 18]. To gain more insight in this complex pathophysiology, we applied transcriptome 
analysis to systematically chart the changes in gene expression resulting from loss of CFTR 
function in the distal small (Chapter 3). This allowed us to identify cellular signal 
transduction routes that are dysregulated in CF and may, therefore, be considered therapeutic 
targets. One of the striking findings of this  analysis was that the CF condition  has a wide-
ranging impact on gene expression, and affects an array of cellular function. The analysis 
provided clear evidence for intestinal dysbiosis, leading up to an altered host-microorganism 
interaction and inflammation of the gut wall. In turn, this leads to repression of ligand-
dependent nuclear receptor signaling, dysregulation of genes involved in intestinal lipid, 
sterol, bile acid, and xenobiotic metabolism and in nutrient and solute absorption [19, 20].
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 In Chapter 4 and 5, we focused on the therapeutic potential of a class of endogenous 
inhibitors of NHE3, the peptides guanylin and uroguanylin, which have the unique ability to 
activate a readily accessible luminal surface receptor in the intestine, the guanylyl cyclase C 
(GCC). Activation of GCC by orally administered (uro)guanylin (mimetic) peptides is 
predicted to result in retention of salt and water in the intestinal lumen by blockade of NHE3-
mediated Na+ absorption. In addition, in the subset of patients with residual CFTR activity, it 
may stimulate low levels of chloride/bicarbonate secretion. 
 Firstly, we charted the cellular origin of these two luminocrine peptides using an 
improved in situ hybridization technique, RNAscope (Chapter 4). The expression patterns of 
uroguanylin and guanylin were distinct, although there also was considerable overlap in some 
regions. Both guanylin and uroguanylin transcripts were found in cells of the secretory 
lineage, as well as in columnar absorptive cells (enterocytes).  Guanylin and uroguanylin 
were expressed by the Paneth cells that neighbor the intestinal stem cells in the crypts of 
Lieberkühn, suggesting a role in host defense and, possibly, cell cycle control. Expression in 
the brush cells in the duodenal villi suggests that these peptides are involved in the regulation 
of duodenal bicarbonate secretion and luminal pH. GCC transcript was found in epithelial 
cells along the entire rostrocaudal axis of the intestines. In addition, GCC transcript was 
found in the duodenal (Brunner) glands. These results suggest that (uro)guanylin (mimetic 
peptides) may have an additional beneficial action on the CF gut: by triggering CFTR-
independent HCO3- release from GCC-containing columnar cells, they may promote the 
expansion of the condensed mucins and their detachment from goblet cells, and restore the 
protective mucus layer covering the epithelium. 
 Next, we demonstrated that, in line with the transcriptome data, the production of 
guanylin and uroguanylin is reduced in CF mice (Chapter 5). This repression of the 
(uro)guanylin/GCC signaling axis appears to result from SIBO and inflammation of the gut 
wall, as antibiotic treatment could correct this defect. Reduced GCC activity may exacerbate 
the fluid secretory defect in CF, and contribute to luminal dehydration and acidification by 
relieving the repression imposed by cGMP signaling on NHE3 activity. Because of the role 
of GCC signaling in host defense, lowered (uro)guanylin production may also contribute to 
intestinal dysbiosis in CF. [21, 22]. 
 The transcriptome analysis indicated that the SIBO found in CF mice is associated 
with repression of ligand-dependent nuclear receptor signaling. Consistent with this analysis, 
we observed that intestinal farnesoid X receptor (FXR) signaling in CF mice was markedly 
impaired, and FXR targets such as Fgf15 and Nr0b2 (Shp) rank among the most down-
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regulated genes in the CF intestine (Chapter 6). Antibiotic treatment corrected FXR 
signaling suggesting that a CF-related inflammatory response suppresses FXR activity. 
Repression of FXR signaling enhanced de novo bile acid (BA) synthesis, which may 
culminate in enhanced fecal bile acid excretion, as is present in Cftr and Fgf15 null mice and 
in CF patients [1, 23, 24]. Because intestinal FXR activity appears to be crucial for intestinal 
barrier function and checks the development of certain cholangiopathies, it is conceivable 
that the loss of its activity in CF plays a role in the etiology of CFLD [25-28]. These results 
suggest that therapies aimed at restoring FXR function may improve lipid metabolism in CF 
and slow the development in CFLD. FXR targeted therapy may also improve hepatic glucose 
and energy metabolism in CF patients [29, 30]. 
Future perspective 
 The presently prioritized CF therapies are the CFTR-targeted, personalized therapies 
which are mostly based on mutation-specific small molecule drugs [10].  
 However, because of the large number of disease-causing mutations in CF 
(http://www.genet.sickkids.on.ca/app) and their complex effects on CFTR expression and 
function [31], there remains an interest in therapies that do not rely mainly or solely on 
restoration of CFTR function, but aim to restore intestinal fluid balance by modulating the 
activity of other principal intestinal ion transport mechanisms. Our study provides a rationale 
for targeting the intestinal (uro)guanylin/GCC signaling axis to counteract the CF-typical 
fluid secretory defect. A similar approach may also be used to treat other complications of CF 
intestinal disease, including SIBO, gut wall inflammation and DIOS.  
 The intestinal microbiome is crucial for maintaining health and intestinal dysbiosis 
has been associated with local gastroenterologic disorders, as well as disease of other organs 
[32]. To what extent SIBO contributes to the general CF pathology is still unclear, but it has 
been reported that both intestinal dysbiosis and inflammation are associated with poor 
nutritional status in patient [33-35]. Our data indicate that dysbiosis and inflammation have a 
marked effect on intestinal gene expression, and repress the GCC- and ligand-dependent 
nuclear receptor signaling. Our finding that bacterial lipopolysaccharide (LPS) appears to be 
a key trigger of the CF-typical immune response suggests that gram-negative bacteria 
contribute to SIBO. Therapies aimed at reducing colonization of the gut by gram-negative 
bacteria may attenuate the host immune response and reduce the deleterious effect of gut wall 
inflammation  [36-39]. Because prolonged use of antibiotics is undesirable (e.g. because of 
potential side effects and development of antibiotics resistance), one possible direction that 
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may be pursued is the application of probiotics to favor proliferation of bacterial species that 
repress inflammation (Lactobacillus murinis) and epithelial damage (Lactobacillus 
plantaram) [40-47]. 
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Samenvatting 
 Cystic fibrosis (CF; taaislijmziekte) is een erfelijke ziekte die wordt veroorzaakt door 
mutaties in het CF gen. Dit leidt tot verlies van functie van het CFTR eiwit, dat een belangrijke rol 
speelt in het transport van zouten en water over de slijmvliezen van (onder andere) de luchtwegen 
en het darmstelsel. CF wordt gekenmerkt door uitdroging van deze slijmvliezen en de ophoping van 
viskeus (taai) slijm in deze orgaansystemen. Als gevolg hiervan is de spijsvertering verstoord en is 
de capaciteit voor de opname van voeding verminderd. De combinatie van deze factoren leidt onder 
meer tot een groeiachterstand bij kinderen, vet-diarree en darmverstoppingen. Deze gastro-
intestinale complicaties, alhoewel zelden direct levensbedreigend, zijn zeer belastend voor de 
patiënt en beïnvloeden het algehele ziekteverloop en de levensverwachting. Om deze redenen is de 
behandeling van deze gastro-intestinale complicaties een belangrijk onderdeel van de zorg voor 
patiënten. Mede door dit beleid is de levensverwachting van CF patiënten over de laatste decennia 
aanzienlijk toegenomen. Desalniettemin blijft er behoefte aan meer effectieve behandelmethoden. 
De nieuwe medicijnen die op dit ogenblik worden ontwikkeld om het basis-defect in de functie van 
het CFTR eiwit te corrigeren zullen mogelijk in de toekomst in deze behoefte kunnen voorzien. 
Deze ontwikkelingen zijn het onderwerp van hoofdstuk 2 van dit proefschrift. Tot het zo ver is 
blijft er echter behoefte aan andere, betaalbare, behandelmethoden die toepasbaar zijn in een brede 
groep CF patiënten.  
 Om verder inzicht te krijgen in hoe de verschillende gastro-intestinale complicaties van CF 
zich ontwikkelen vanuit het primaire defect in CFTR functie, is in hoofdstuk 3 onderzocht wat het 
effect is van het verlies van CFTR activiteit op de expressie van genen in het laatste deel van de 
dunne darm. Deze zogenaamde transcriptoom-analyse toont aan dat CF een breed scala van 
processen in het darmslijmvlies beïnvloedt. De analyse geeft eenduidig bewijs voor de 
aanwezigheid van bacteriële overgroei en ontsteking van de darmwand, die vervolgens leidt tot een 
verstoorde regulatie van de opname en verwerking van vetten en andere essentiële voedingsstoffen. 
De studie laat verder zien dat een gerichte bestrijding van de bacteriële overgroei deze defecten 
grotendeels herstelt. 
 Een nieuwe aanpak ter bestrijding van zulke gastro-intestinale CF complicaties die in dit 
proefschrift wordt verkend is gericht op het verminderen/voorkomen van de CF-kenmerkende 
uitdroging van de darmslijmvliezen. Deze aanpak heeft niet tot doel de CFTR functie te verbeteren, 
maar probeert de zout- en waterbalans in de darm te herstellen door de absorptie van zouten en 
water uit de darm te verminderen. Het is al langer bekend dat de darm twee hormonen produceert, 
guanyline en uroguayline, die netto transport van zouten en water naar het darmlumen stimuleren 
door activering van een receptor op het darmslijmvlies. Met het oog op de mogelijke toepassing van 
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(uro)guanyline-achtige receptor-activators in de behandeling van CF patiënten, werd deze 
hormonale route verder onderzocht in de hoofdstukken 4 en 5. 
 Allereerst werd onderzocht in welke celtypen guanyline en uroguanyline worden 
aangemaakt en welke celtypen van het darmslijmvlies de receptor produceren en dus gevoelig zijn 
voor (uro)guanyline stimulatie (hoofdstuk 4). Uit dit onderzoek bleek dat de beide hormonen 
slechts in bepaalde celtypen en op specifieke locaties in het darmkanaal worden aangetroffen, 
terwijl de receptor over de gehele lengte van de dunne en dikke darm, en ook in duodenale klieren, 
aanwezig is. Dit wijst er op dat stimulatie van deze receptor door een oraal toegediende activator 
over de gehele lengte van de darm een gunstig effect op de vochtbalans zal hebben. Omdat deze 
receptor ook betrokken is bij de neutralisatie van het maagzuur in het bovenste deel van de dunne 
darm, zou stimulatie ook een gunstig effect op de zuur-base balans en de daarmee samenhangende 
viscositeit van de slijmlaag kunnen hebben. In hoofdstuk 5 wordt bovendien aangetoond dat de 
productie van guanyline en uroguanyline is verlaagd in CF. Dat suggereert dat een verminderde 
stimulering van de (uro)guanyline receptor bijdraagt aan de CF-typische uitdroging van het 
darmslijmvlies, en dat dit defect kan worden gecompenseerd door toediening van stoffen die de 
werking van (uro)guanyline imiteren.  
 Uit de transcriptoom analyse (hoofdstuk 3) was gebleken dat de opname en verwerking van 
lipiden is verstoord in CF. In hoofdstuk 6 is dit verder onderzocht en werd aangetoond dat 
bacteriële overgroei en het onstekingsproces de activiteit van de galzout-receptor FXR onderdrukt. 
Deze remming van FXR in de darm leidt tot een verhoogde synthese van galzouten in de lever. 
Mogelijk draagt dit bij aan de verhoogde fecale excretie van galzouten, kenmerkend voor CF, en 
aan de ontwikkeling van CF-gerelateerde leverziekte.   
 De ontwikkeling van nieuwe CF therapieën is nu sterk gericht op het identificeren van 
stoffen die via een directe interactie de functie van het defecte CFTR eiwit verbeteren. Dit leidt 
doorgaans tot de ontdekking van stoffen die enkel het effect van specifieke mutaties corrigeren en 
daarom niet in alle patiënten toepasbaar zijn. Mede omdat het aantal verschillende CF-
veroorzakende mutaties zo hoog is, blijft er behoefte aan middelen die niet gericht zijn op de 
correctie van een specifieke defect in de structuur van het CFTR eiwit en daardoor breed inzetbaar 
zijn binnen de populatie van CF patiënten. Het in dit proefschrift beschreven onderzoek biedt 
aanknopingspunten voor de ontwikkeling van dergelijke therapieën. Deze zijn gericht op het 
verbeteren van de vochtbalans in de darm en het voorkomen van de complicaties die, direct of 
indirect, voortvloeien uit het verlies van CFTR activiteit.  
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